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Cervical cancer is an important cause of death in women worldwide. An estimated 
number of 370,000 - 470,000 new cases occur per year, and 230,000 women die of 
cervical cancer per year.1•3 It is the second to third most common cancer in women with 
large incidence differences between developed countries with cervical cancer screening 
programs and less developed countries. The cumulative l ifetime risk for a woman to 
develop cervical cancer varies from 0.4% in Israel to 5.3% in Colombia.4 Infection with 
high-risk human papillomavirus (HPV) has been identified as the main causative factor 
in cervical carcinogenesis.5 The prevalence of high-risk HPV infection is much more 
common than the prevalence of cervical cancer, indicating that although HPV infection 
is a necessary cause, it is not a sufficient cause for ful l  cervical carcinogenesis. 
Additional factors, both viral and host-cell-related factors are required. 
THE EPITHELIAL SURFACE OF THE UTERINE CERVIX 
The uterine cervix is covered with non-keratinizing squamous epithelium mainly at the 
ecto-cervix and glandular columnar epithelium at the endo-cervix. The border between 
the two different epithelial cell types is called the squamo-columnar junction (SCJ). 
Metaplastic transformation in the SCJ starts from puberty onwards and columnar 
epithelium is replaced by squamous epithelium, shifting the original SCJ towards the 
ecto-cervix, forming a neo-SCJ. The area between the original and neo-SCJ is called the 
transformation zone. It is assumed that the transformation zone is most susceptible to 
oncogenic influences due to the local high cell-turnover.6 
CERVICAL INTRAEPITHELIAL NEOPLASIA: CLASSIFICATION AND SCREENING 
Richart suggested in the late 1 960's that cervical cancer develops from non-invasive 
cervical cancer precursor lesions, called cervical intraepithelial neoplasia (CIN). 7  CIN 
lesions have been subdivided according to the severity of dysplasia. CIN I describes 
mild dysplasia, restricted to the basal one-third of the epithelium, CIN II describes 
moderate dysplasia, restricted to the basal two-third of the epithelium and CIN I l l  
describes severe dysplasia, dysplasia in the full thickness of the squamous cervical 
epithelium.8 The risk of developing cervical cancer has been estimated to rise with 
increasing severity of the CIN lesion. Approximately 1 %  of patients with CIN I and 5-
45% of the CIN I I/I I I lesions will progress to cervical cancer when the CIN lesion is left 
untreated. It is estimated that the progression from CIN to cervical cancer generally 
takes 1 0-1 5 yearsY0 
Papanicolaou and Traut were among the first to demonstrate that morphologic review of 
exfol iated cells could be used to detect carcinoma in situ and invasive cancer of the 
cervix.11 Based on the assumption that treatment of precancerous lesions would prevent 
the development of cervical cancer and that early detection of cervical cancer would 
positively influence survival, many countries started to organize nation-wide screening 
programs. Nowadays cytomorphological examination of cervical smears is the most 
widely applied screening-method for cervical cancer and its precursors. The observed 
decline in the number of cervical cancer related deaths in the last decades has generally 
been attributed to the implementation of such screening programs.12•13 Cervical smears 
are classified according to a modified Papanicolaou system (CISOE-A) or the Bethesda 
classification system.  In table 1 an overview is given of the different nomenclatures used 
to describe cervical cytological and histological abnormalities of the squamous 
epithelium. 
Table 1: Cytolomorphological and histolmorphological nomenclature 
Dysplasia CIN 
Normal Normal 
Benign atypia Inflammatory atypia 
Atypical cells Squamous atypia 
Mild dysplasia* CIN I 
Moderate dysplasia CIN II 
Severe dysplasia CIN Ill 
Carcinoma in situ CIN Ill 
(microinvasive) cancer (microinvasive) cancer 
CIN Cervical intraepithelial neoplasia 
Sll Squamous intraepithelial lesion 
Bethesda 
Within normal limits 
















*The term 'dysplasia' is used for a histological diagnosis. In cytological revteWS the term dysplasia IS replaced by 
the term 'dyskaryosis'. 
TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA 
Although the exact indications for referral differ between countries, in general women 
with abnormal cytology reports wil l be referred to a gynecologist for colposcopic 
examination. CIN lesions and cervical cancer can be visualized after acetic whitening 
and diagnozed by histological examination of colposcopy-directed biopsies of suspect 
areas of the uterine cervix. Because no markers exist that identify those CIN lesions 
that wil l  progress, clinicians have felt compelled to treat at least all CIN II/III lesions. A 
large part of al l  women treated for CIN would never actual ly have developed cervical 
cancer. 10'12 Treatment options for CIN are: large loop excision of the transformation 
zone (LLETZ), laser evaporation, cryocoagulation, cone biopsy or hysterectomy 
depending on the preference and expertise of the attending gynecologist. In general, 
LLETZ is preferred because it can be performed in an outpatient setting, the tissue 
removed can be histo-morphologically reviewed and a LLETZ seems to have no effect 
on menstruation or fertility.14 With LLETZ a cure rate of more than 90% can be 
achieved.14 
STAGING AND TREATMENT OF CERVICAL CANCER 
The main histologic types of cervical cancer are squamous cell carcinoma and 
adenocarcinoma. Over 80% of all cervical cancers are of squamous cell type. Clinical 
staging of cervical cancer occurs by the FIGO criteria for which, during a pelvic 
examination under general anaesthesia, tumour-size and involvement of the vagina and 








prognostic parameter and therefore determines the choice of treatment modal ity to a 
great extent. Stage lA, microinvasive cancer, can be treated by LLETZ or exconisation to 
maintain fertility or by simple hysterectomy. Stages 181 , 182 and IIA are considered 
early stages for which radical hysterectomy (combined with adjuvant radiotherapy 
when indicated) and primary radiotherapy are equally effective treatments.16·17 Most 
gynecologic oncologists prefer radical hysterectomy with pelvic lymphadenectomy for 
their relative young and healthy low-risk early stage patients because of the shorter 
treatment course, opportunity for ovarian preservation, and presumed better post· 
treatment vaginal function.18 It is generally accepted to treat patients with lymph node 
metastases, positive resection margins or parametrial involvement with adjuvant 
radiotherapy. 18 19 Patients with stage 1 18-IV disease are usually treated with primary 
radiotherapy in combination with chemotherapy because of the increase in survival 
(1 5%) compared to the treatment with radiotherapy alone.20·23 The five year relative 
survival rates for cervical cancer patients vary from approximately 80% for patients 
with localized disease to 55% for those with lymph node metastases. 14 Survival rates 
for patients with more advanced disease at diagnosis are considerably worse.2 5  
OUTLINE O F  THIS THESIS 
Important drawbacks of morphology based cervical cancer screening are high numbers 
of false positives and false negatives.26•28 Therefore objective methods based on 
molecular changes in cervical cancer might improve the current screening approach. In 
Chapter 2 data on cervical cancer epidemiology, etiology and the current cervical 
cancer screening approach are summarized. Available data on new molecular based 
approaches for screening are reviewed in more detail and the potential of these 
approaches to replace or augment current Pap-smear screening is discussed. 
Apart from the high false positive and false negative rates another drawback of cervical 
cancer screening is the referral of patients with abnormal cervical cytology reports who 
would never had developed cervical cancer. 10• 12 These unnecessary referrals cause 
unfavorable effects such as high anxiety levels, overtreatment and reduced cost­
effectiveness of cervical cancer screening programs.29"31 Chapter 3 describes whether 
HPV, hTERT, hTR DNA detection or telomerase activity assessment in cervical scrapings 
can identify those patients that harboured CIN II or CIN I l l  within a group of patients 
with borderline, mild or moderate dyskaryosis. 
Although the overal l  mortality of cervical cancer has been markedly reduced by the 
widespread availabi lity of effective cytologic screening programs, survival by stage did 
not change significantly untill radiotherapy with concurrent chemotherapy was 
introduced for primary and adjuvant therapy.2532 Even if we are not able to influence 
survival we can improve patient care by reducing treatment related morbidity. In 
Chapter 4 it was therefore studied whether the known squamous cell cervical cancer 
serum tumor marker, serum SCC-ag, could be used to identify a group of patients that 
might preferably be treated with primary radiotherapy in stead of primary radical 
hysterectomy in order to reduce morbidity associated with double modal ity treatment. 
The development of diagnostic tools starts with knowled ge of cervical carcinogenesis. 
After Zur Hausen in 1 973 suggested that viral oncogenesis was involved in the 
development of cervical cancer our understanding of HPV mediated carcinogenesis has 
grown.33 35 Para l lel with this increasing understanding thousands of studies have 
provided insi ght in the epidemiology of HPV. Although HPV infection is an initiating 
event for cervical carcinogenesis, other factors need to be involved, because the 
prevalence of h igh -risk HPV infection is much more common than the prevalence of 
cervical cancer. Knowledge of these factors is l imited and we therefore explored the 
role of possible infectious (co)factors in cervical carcinogenesis and reported the results 
of three epidemiologic studies. In Chapter 5 the prevalence of. risk factors for, and the 
impact on histologic changes of bacterial vaginosis was studied in patients with 
cytological abnormalities of the uterine cervix. Chapter 6 describes an explorative 
study on the possible association between the presence of Chlamydia trachomatis 
antibodies and the severity of neoplastic lesions in patients with cervical dyskaryosis. 
Chapter 7 describes the last and most important infectious factor studied, HPV. In a 
previous study using the GPS/6 primers based HPV PCR we observed that the 
prevalence of HPV rises with increasing histological severity of neoplasia, more 
cigarettes smoked per day and h igher lifetime number of sexual partners in patients 
with cervical dyskaryosis. 36 Some years after that initial epidemiologic study the highly 
sensitive SPF1 0 primers and lnno-LiPA (line probe assay) HPV prototype research assay 
became available for the detection and typing  of HPV. Using the SPF1 0-LiPA system, the 
stored cervical scrapings of the earlier described study population were re-analyzed. 
Knowledge of the role of infectious cofactors only reflects a small part of our increasing 
understanding of carcinogenesis in general .  Partly due to the development of new 
technologies, scientific achievements have been made to unravel the molecular 
pathogenesis of cervical cancer. In Chapter 8 and 9 translational research on two 
topics that have been subject of major interest in the last decade is described. It has 
become increasingly clear that not only mutations occur during cancer development, 
but epi genetic mutations such as silencing of tumor suppressor- or other cancer­
associated genes by methylation of CpG islands, are common features of cancer tissues 
as wel l .  Hypermethylation of tumor suppressor genes also occurs frequently in cervical 
cancer. Although these aberrant methylation patterns represent excel lent targets for 
novel diagnostic approaches, it was unknown whether a cervical scraping could reflect 
the hypermethylation status of the underlying  epithelium. It was therefore unclear 
whether quantitative hypermethylation specific PCR (QMSP) on cervical scrapings could 
be used as a future screening method augmenting the current approach. In Chapter 8 
the use of QMSP on cervical scrapings was explored by analyzing  cervical scrapings and 
paired fresh frozen cervical tissue samples obtained from cervical cancer patients and 
controls by QMSP for the genes APC, DAPK, MGMT and GSTP1 . 
Programmed cell death, or apoptosis, is a genetically controlled mechanism that plays 
an important role in the regulation of cellular homeostasis.37 Many triggers can lead to 
apoptosis induction, including  binding of apoptosis-inducing 'death l igands' such as Fas 
l igand (Fasl) and TNF-related apoptosis-inducing l igand (TRAIL) to their cognate cell-
l4 
surface death receptors, Fas and DR4/DRS, respectively.38 The Fas death receptor­
mediated apoptosis pathway has been most extensively investi gated. Since cross­
l inking of Fas by anti-Fas antibodies resulted in apoptosis in certain hematopoietic 
mal ignancies394' the Fas-mediated apoptosis pathway attracted a lot of attention as a 
possible target for application for cancer treatment.3943 Expression of Fas and TRAIL 
receptors have been reported in many normal (epithelial) cells and neoplastic cells.42•44•47 
Increasing imbalance between prol iferation and apoptosis is thought to be important in 
cervical carcinogenesis. Downregu lation of Fas expression is observed in CIN 1 1/1 1 1  
lesions.48 I n  cervical cancer DR4 and DRS downregulation did not occur.49 No  data were 
available on the expression of TRAIL and its death receptors in different grades of CIN 
lesions. The aim of the study, described in Chapter 9, was to examine the role of FasL 
and TRAIL and their death receptors in the increasing  imbalance between proliferation 
and apoptosis. 
Finally the results of our studies are summarized and some perspectives for future 
studies are discussed. 
REFERENCES 
Pisani P, Parkin OM,  Ferlay J .  E stimates of the worldwide mortality from eighteen 
major cancers in 1 985. Implications for prevention and projections of future 
burden. l nt J Cancer 1 993;55 :891 -903. 
2 Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer 
Invest 2002;20:1 080-1 085. 
3 Parkin OM, P isani P, Ferlay J. Estimates of the worldwide incidence of 25 major 
cancers in 1 990. lnt J Cancer 1 999;80: 827-841 . 
4 l sacson C, Kessi s TO, Hedrick L, et al. Both cell proliferation and apoptosi s 
increase with lesion grade in cervical neoplasia but do not correlate with human 
papillomavirus type. Cancer Res 1 996;56:669-674. 
5 Munoz N, Bosch FX, de Sanjose S, et al .  Epidemiologic cla ssification of human 
papillomavirus types associated with cervical cancer. N Engl J Med 
2003;348:51 8-527. 
6 Ferenczy A, Wri ght TC. Anatomy and h istology of the cervix. In: Kurman RJ, 
editor. Blaustein's pathology of the female genital tract. New York: Springer­
Verla g  1 994:1 85-201 . 
7 Richart RM. A theory of cervical carcinogenesi s. Obstet Gynecol Surv 
1 969;24:874-879. 
8 Kurman RJ, Norris HJ, Wilkinson E. Tumors of the cervix, vagina, and vulva; 
Tumors of the cervix. In: Rosai J, editor. Atlas  of tumor pathology. Washington, 
D.C.: Armed Forces Institute of Pathology 1 992:37-1 39. 
9 Mitchell M F.  Tortolero-Luna G, Wright T, et al. Cervical human papillomaviru s 
infection and intraepithelial neoplasia: a review. J Natl Cancer lnst Monogr 
1 996;1 7-25. 
1 0 Ostor AG. Natural h istory of cervical intraepithelial neopla sia: a critical review. 
lnt J Gynecol Pathol 1 993;1 2 : 1 86-1 92.  
1 1  Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma 
of the uterus. Am J Obstet Gynecol 1 941 ;42:1 93-206. 
1 2  Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a 
tragedy. JAMA 1 989;261 :737-743. 
1 3  Quinn M, Babb P, Jones J, et al .  E. Effect of screening o n  incidence of and 
mortality from cancer of cervix in England: evaluation based on routinely 
collected stati stics. BMJ 1 999;31 8:904-908. 
1 4  B igrigg A, Haffenden OK, Sheehan AL, et al. Efficacy and safety of large-loop 
excision of the transformation zone. Lancet 1 994;343:32-34. 
1 5  Finan MA, De Cesare S, Fiorica JV et al .  Radical hysterectomy for stage 181 vs 
182 carcinoma of the cervix: does the new stagin g  system predict morbidity and 
survival? Gynecol Oncol 1 996;62:1 39-1 47. 
1 6  National I nstitutes of Health Consensu s  Development Conference statement on 
cervical cancer. April 1 -3, 1 996. Gynecol Oncol 1 997;66:351 -361 . 
1 7  Landoni F, Man eo A, Colombo A, et al .  Randomised study of radical surgery 
versu s  radiotherapy for stage lb- l la cervical cancer. Lancet 1 997;350:535-540. 
6 
1 8  Burke TW. Treatment opt ions in stage IB cerv ical cancer: Rad ical hysterectomy 
and rad iotherapy. Sem in Rad iat Oneal 1 994;4:34-40. 
1 9  St itt JA. Use of postoperat ive irrad iat ion for carc inoma of the cerv ix. Sem in 
Rad iat Oncol 1 994;4:41 -45. 
20 Peters WA, I l l, l iu PY, Barrett RJ et al .  Concurrent chemotherapy and pelv ic 
rad iat ion therapy compared w ith pelv ic rad iat ion therapy alone as adjuvant 
therapy after rad ical surgery in h igh-r isk early-stage cancer of the cerv ix. J Cl in 
Oneal 2000; 1 8:1 606-1 613 .  
2 1  Wh itney CW, Sause W, Bundy BN, et  al .  Random ized compar ison of  fluorourac il 
plus c isplat in versus hydroxyurea as an adjunct to rad iat ion therapy in stage l iB­
IVA carc inoma of the cerv ix w ith negat ive para-aort ic lymph nodes: a 
Gynecolog ic Oncology Group and Southwest Oncology Group study. J Cl in Oneal 
1 999;1 7:1 339- 1 348. 
22 Rose PG, Bundy BN, Watk ins EB, et al. Concurrent c isplat in-based rad iotherapy 
and chemotherapy for locally advanced cerv ical cancer. N Engl J Med 
1 999;340:1 1 44-1 1 53. 
23 Morr is M, E ifel PJ, Lu J, et al .  Pelv ic rad iat ion w ith concurrent chemotherapy 
compared w ith pelv ic and para-aort ic rad iat ion for h igh-r isk cerv ical cancer. N 
Engl J Med 1 999;340:1 1 37-1 1 43. 
24 Monk BJ, Cha DS, Walker JL, et al .  Extent of d isease as an ind icat ion for pelv ic 
rad iat ion fol low ing rad ical hysterectomy and b ilateral pelv ic lymph node 
d issect ion in the treatment of stage IB and IIA cerv ical carc inoma. Gynecol 
Oncol 1 994;54:4-9. 
25 Pras E, W illemse PH, Boonstra H, et al. Concurrent chemo- and rad iotherapy in 
pat ients w ith l ocally advanced carc inoma of the cerv ix. Ann Oncol 1 996;7:51 1 -51 6. 
26 Cerv ical cancer. N IH Consens Statement 1 996;1 4:1 -38. 
27 Koss LG. Cerv ical (Pap) smear. New d irect ions. Cancer 1 993;71 :1 406-141 2.  
28 Robertson JH,  Woodend B.  Negat ive cytology preced ing cerv ical cancer: causes 
and prevent ion. J Cl in Pathol 1 993;46:700-702. 
29 Freeman-Wang T, Walker P, L inehan J, et al. Anx iety levels in women attend ing 
colposcopy cl in ics for treatment for cerv ical intraep ithel ial neoplas ia: a 
random ised tr ial of wr itten and v ideo informat ion. BJOG 2001 ;1 08:482-484. 
30 Bekkers RL, van der Dank M, Klaver FM, et al .  Var iables influenc ing anx iety of 
pat ients w ith abnormal cerv ical smears referred for colposcopy. J Psychosom 
Obstet Gynaecol 2002;23:257-261 . 
3 1  van Bal legoo ijen M, Koopmanschap MA, Habbema JD. The management of 
cerv ical intra-ep ithel ial neoplas ia (CIN): extens iveness and costs in The 
Netherlands. Eur J Cancer 1 995;31 A: 1 672-1 676. 
32 Stehman FB, Thomas GM. Prognost ic factors in locally advanced carc inoma of 
the cerv ix treated w ith rad iat ion therapy. Sem in Oncol 1 994;21 :25-29. 
33 Zur Hausen H. Condylomata acum inata and human gen ital cancer. Cancer Res 
1 976;36:794. 
34 Zur Hausen H. [V irus and cancer. The concept of the masked causat ive agent]. 
lmmun lnfekt 1 973; 1 :5-9. 
35 Zur Hausen H. Pap illomav irus infect ions--a ma jor cause of human cancers. 
B ioch im ica et B iophys ica Acta 1 996; 1 288:F55-F7 8. 
36 Burger M P.  Hol lema H, Gouw AS, et al .  C igarette smo king and human 
pap il lomav irus in pat ients w ith reported cerv ical cytolog ical abnormal ity. 
BMJ 1 993;306:749-752. 
37 Steller H. Mechan isms and genes of cel lu lar su ic ide. Sc ience 1 995;267:1 445-
1 449. 
38  Ash kenaz i A .  Target ing death and decoy receptors of the tumour-necros is factor 
superfam ily. Nat Rev Cancer 2002;2:420-430. 
39 Sher idan J P.  Marsters SA, P itt i RM et al. Control of TRAIL- induced apoptos is by a 
fam ily of s ignal ing and decoy receptors. Sc ience 1 997;277: 81 8-82 1 .  
40 Traut BC, Klas C, Peters AM et al. Monoclonal ant ibody-med iated tumor 
regress ion by induct ion of apoptos is. Sc ience 1 989 ;245:301 -305. 
41 Mor imoto H, Yonehara S, Bonav ida B. Overcom ing tumor necros is factor and 
drug res istance of human tumor cell l ines by comb inat ion treatment w ith ant i­
Fas ant ibody and drugs or tox ins. Cancer Res 1 993;53:2591 -2596. 
42 Debat in KM, Goldman CK, Waldman TA, Krammer PH. AP0-1 - induced apoptos is 
of leu kem ia cells from pat ients w ith adult T-cell leu kem ia. Blood 1 993;81 :2972-
2977. 
43 Panay iot id is P. Ganeshaguru K, Foron i L, et al. Express ion and funct ion of the Fas 
ant igen in B chron ic lymphocyt ic leu kem ia and ha iry cell leu kem ia. Leu kem ia 
1 995;9:1 227-1 232. 
44 Le ithauser F, Dhe in J, Mechtershe imer G et al .  Const itut ive and induced 
express ion of AP0-1 , a new member of the nerve growth factor/tumor necros is 
factor receptor superfam ily, in normal and neoplast ic cells. Lab Invest 
1 993;69:41 5-429. 
45 Koornstra JJ, Kle ibeu ker JH, van Geelen CM et al .  Express ion of TRAIL (TNF­
related apoptos is- induc ing l igand) and its receptors in normal colon ic mucosa, 
adenomas, and carc inomas. J Pathol 2003;200:327-335. 
46 Pan G, O 'Rourke K, Ch inna iyan AM et al .  The receptor for the cytotox ic l igand 
TRAI L Sc ience 1 997;276:1 1 1 -1 1 3 .  
47 Pan G, N i  J, We i YF, et al . An antagon ist decoy receptor and a death doma in­
conta in ing receptor for TRAI L Sc ience 1 997;277:81 5-81 8. 
48 K im HS, Sh ira ki K, Par k  SH. Express ion of surv iv in in CIN and invas ive squamous 
cell carc inoma of uter ine cerv ix. Ant icancer Res 2002;22:805-808. 
49 Ryu HS, Chang KH, Chang SJ, et al .  Express ion of TRAIL (TNF-related apoptos is­







World -wide cervical cancer is an important cause of death. Infection with human 
papillomavirus (HPV} plays an important role in cervical carcinogenesis. Current cervical 
cancer screening occurs by morphological assessment of cervical smears, but because 
of high false positive and false negative rates efforts have been made to improve 
cervical cancer screening by the use of HPV DNA testing or by using other new 
molecular mar kers. In this review we wil l summarize data on cervical cancer 
epidemiology and etiology and the current cervical cancer screening approach in short. 
Available data on molecular diagnostic targets such as microsatel lite a lterations, 
telomerase activity and tumor suppressor gene promotor hypermethylation for cervical 
cancer detection wil l be reviewed in more detai l .  
EPIDEMIOLOGY AND ETIOLOGY OF CERVICAL CANCER 
The cumulative l ifetime ris k for a woman to develop cervical cancer varies from 0.4% in 
Israel to 5.3% in Colombia. Cervical cancer represents the third most frequent 
gynecological malignancy among women worldwide, with the highest incidence rates 
in less developed countries.' It is estimated that 1 2,200 new cervical cancer cases will 
be diagnosed in 2003 in the US and that an estimated 4, 1 00 deaths from cervical 
cancer wi ll occur (accounting for 1 .9% of al l  cancers in women and 1 .5% of all cancer 
related deaths in women}.2 In sharp contrast to these relatively low incidence numbers 
of cervical cancer are the high number of surgical treatments each year for 
prema lignant cervical lesions in countries with nation-wide screening programs.3� 
Cervical cancer develops from these premalignant lesions, also called cervical 
intraepithelial neoplasia (CIN}. The mildest form, CIN I, regresses in most cases, while 
20-45% of the CIN II/I I I  lesions wil l progress to cervical cancer when left untreated. It is 
estimated that the progression from CIN to cervical cancer generally ta kes 1 0-1 5 years.6 
Sufficient evidence for a causal role of HPV in cervical carcinogenesis has been 
provided by both epidemiological as well as experimental studies in different parts of 
the world. It has been proposed that HPV infection is the first identified necessary 
cause of cervical cancer, implying that cervical cancer, with very rare exceptions, can not 
develop without HPV infection.7 Over 1 00 HPV types have been identified of which 
more than 35 types can be found in the genital tract and of which 1 8  are associated 
with cervical carcinogenesis.8 For cervical oncogenesis expression of the viral proteins 
E6 and E7 is pivotal because E6 and E7 facil itate increased degradation of respectively 
p53 or pRB proteins, leading to inactivation of two important cel lular regulatory 
proteins. HPV 1 6  accounts for 50-70% of the cervical cancer cases in most countries. 
The second most frequent HPV type is HPV 1 8  (1 0 -1 2%} fol lowed by HPV 31 and 45/·8 
Despite of a l l  the evidence for the important role of HPV in cervical carcinogenesis it is 
clear that additional factors, both viral and host-cell related have to be involved 
because the majority of patients infected with HPV wil l  not develop invasive cervical 
cancer. 9 
CURRENT CERVICAL CANCER SCREENING 
Cytomorphological examination of cervical smears is the most widely applied 
screening-method for cervical cancer and its precursors. In 1 941 it became clear that 
cytomorphological assessment of cervical smears could be used to detect cervical 
cancer and its precursors and many countries started to organize screening programs.1 0 
Cervical smears are classified according to a modified Papanicolaou system (Pap/CISOE-A) 
or the Bethesda classification system. An overview of the different nomenclature used 
in cervical cytomorphology and histomorphology is given in Table 1 .  
Table 1: Cytolomorphological and histolmorphological nomenclature 
Dysplasia CIN Bethesda 
Normal Normal Within normal limits 
Benign atypia Inflammatory atypia Benign cellular changes 
Atypical cells Squamous atypia ASCUS 
Mild dysplasia CIN I Low-grade Sl L 
Moderate dysplasia CIN II High·grade SIL 
Severe dysplasia CIN I l l  High·grade SIL 
Carcinoma in situ CIN Ill High-grade SIL 
(microinvasive) cancer (microinvasive) cancer (microinvasive) cancer 
ASCUS atypical suamous cells of undetermined significance 
CIN cervical intraepitheliat neoplasia 










Although the introduction of nation-wide screening programs have lead to decreasing 
incidences of cervical cancer it has been questioned whether the disadvantages 
counter-balance the relatively low reduction in cervical cancer deaths.11 
Disadvantages include the high numbers of false-positive and false-negative cervical 
smears, leading to an overshoot of diagnostic procedures or even a delay in the 
diagnosis of cervical cance r:·s·12 Up to 1 4 % of a l l  cervical smears are 
cytomorphologically abnormal without the presence of a (pre)malignant cervical 
lesion.13 These false-positive results can cause unnecessary anxiety and invasive 
procedures. False-negative cytology may be found in about 50% of cases when 
previous negative smears are reviewed from the small proportion of screened women 
who develop invasive cancer.14•15 High-grade CIN or microinvasive cervical cancer has 
cure rates close to 1 00% with appropriate treatment. False-negative screening results 
wi l l  leave CIN or cancer undetected. Even when symptoms start to occur, the falsely 
given assurance by a false negative smear may lead to a further delay in the diagnosis 
and treatment of the cancer which will negatively influence curation chances. 
Women can be emabarrassed to undergo a vaginal examination, which leads to low 
attandance rates. Low attandance to the cervical cancer screening pro grams is another 
major drawback of cervical cancer screening. It has been investigated wether self­
sampling can overcome this problem and wether it can be a reliable alternative for 
cervical cancer screening on physician-collected samples, because half of cervical 
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cancer cases arise in women who are not adequately screened.1 6•17 Preference for self­
sampling has been reported.18 •19 However, although feasible, patient-collection seems an 
inferior alternative to physician-collected cervical cytology.18 20 Possibly, for newly 
developed options for cervical cancer screening self-col lected cervico-vaginal samples 
may be less inferior alternatives for physician-collected samples than for cytology­
based-methods. The possible use of self-col lected samples would improve the current 
screening approach. 
TECHNICAL IMPROVEM ENTS FOR MORPHOLOGICAL 
SCREENING 
AUTOMATED PAP- SMEAR AN ALYSIS 
For automated sl ide m icroscopy d ig ital photographs are ta ken of ord inary 
Papanicolaou-sta ined cerv ical smears. The data thus obta ined are documented and 
images can be analyzed by computer systems such as done by the neural-network­
based approach and by the AutoPap system.21 23 These automated methods have the 
potent ial to improve the accuracy of cerv ical cytolog ic exam inations as well as to ma ke 
a pos it ive impact on the product iv ity of cytology laboratory personnel .23 For the 
detect ion of h igh-grade cerv ical neoplas ia (CIN II/I I I  or HSIL and cerv ical cancer) in a 
primary screen ing sett ing, both systems show sl ightly improved spec if ic ity and 
equ ivalent sensit iv ity to the Pap test.21 23 Confort in i et a/. therefore stated that 
compar ison of the AutoPap system and convent ional read ing should focus ma inly on 
cost analys is.22 The current expense of the automated technolog ies in compar ison to 
convent ional screen ing l im it their w idespread implementat ion.24 At present it is not 
clear whether the potent ial benef its of computer ized screen ing relat ive to convent ional 
Pap test are suff ic ient to just ify a poss ible increase in costs.2526 However, in the future 
w idespread implementat ion of automated Pap-smear may become cost-effect ive s ince 
costs of manpower w il l  further increase, whereas automated technolog ies in general 
become less expens ive in t ime. 
LI QUI D BASED CYTOLOGY 
For l iqu id based cytology, also called th in-layer test or Th in Prep Pap test, cerv ical cells 
are collected by scrap ing the cerv ix w ith a sampl ing dev ice after wh ich the sampl ing 
dev ice is transferred d irectly to a v ial of l iqu id preservat ive. Collected cells are 
mechan ically d ispersed into the l iqu id med ium before a representat ive al iquot is 
transferred to the sl ide. Poss ible advantages of th is procedure compared to 
convent ional Pap-smear test ing are: prevention of inadequate a ir dry ing of cells after 
sampl ing; debr is and blood are removed before cell transfer to sl ides and cel lular 
separat ion is enhanced; several slides can be tested from one sample and the res idual 
flu id can be used for a var iety of molecular analyses. 
Two stud ies compared convent ional Pap-smear classif icat ion w ith class if icat ions 
obta ined by l iqu id based cytology and showed 85-87% and 97% correspondence 
w ithin one d iagnost ic category, respect ively.21.2s When 8,636 Costa R ica women were 
tested, specific ity for h istolog ical CIN II or worse was 99% for both convent ional and 
l iqu id based cytology. Sens it iv ity of smears show ing at least moderate dys karyos is for 
h istolog ical CIN II or worse was 64% for convent ional cytology and 69% for l iqu id 
based cytology.29 In a multicentre screen ing study l iqu id based cytology showed a 39% 
reduct ion in unsat isfactory sl ides and a 44% reduct ion in l im ited reports. A random ized 
tr ial in 1 ,999 women showed that the qual ity of convent ional Pap-smear sampled after 
removal of mucus and cel lu lar debris with a cel lu lose swab was better than of l iqu id 










better for 'conventional' Pap-smears than for liquid based cytology. However, most 
studies report that liquid based cytology provides more satisfactory results and has 
s l ightly h igher sensitivity for h igh-grade cervical neoplasia compared to conventional 
Pap-smears.21.2831 37 The use of liquid based cytology is associated with increasin g  costs 
of cervical cancer screening because the average cost of a thin-layer test is $2.4 h igher 
than that of the conventional smear test.38 The higher price of liquid based cytology is 
only justifiable if this screening technique outperforms the conventional method.38 
Current evidence appears to be insufficient to recommend for or against the routine use 
of liquid-based cytology especially because it is unclear whether its use will reduce the 
incidence of and mortal ity from invasive cervical cancer despite the reported increase in 
sensitivity.2s2 6 The American Cancer Society reports in its guideline for the early 
detection of cervical neoplasia and cancer that cervical screening using liquid-based 
cytology may be an alternative to conventional screening.39 In our opinion efforts 
should be made to develop a less expensive way to perform liquid-based cytology by 
comparing  the commercially available cell preservatives with alternative preservatives, 
for example ethanol-carbowax {7% polyethylene-glycol, 50% ethanol). When the 
average costs of a thin-layer test would be comparable to the average costs of a 
conventional Pap-smear test the integration of liquid based cytology in existing 
screening programs would be justifiable. We can then benefit from the better sensitivity 
and improved number of satisfactory results. At the same time the residual fluid can be 
used to further develop and evaluate new screening concepts and technologies based 
on the presence of molecular markers present in cervical cancer. 
Improvement of specificity of cervical cancer screening would lead to the reduction of 
costs associated with false positive results. Improvement of sensitivity could result in a 
h igher detection percentage of premalignant or early stage mali gnant cervical lesions. 
Early detected cervical cancer can be treated more effectively than advanced sta ges of 
disease. In the following parts of this review we describe whether molecular markers 
may be able to improve cervical cancer screening. 
STAINING OF MOLECU LAR MARKERS SUPERI M POSED OVER 
THE CONVENTIONAL PAP-SM EAR 
QUANTITATIVE CYTOCHEMISTRY 
IMMUNOCYTOCHEMICAL STAINING OF MARKERS 
OF CELL PROLIFERATION 
The f irst markers to be d iscussed are the ones that can be used superimposed over the 
convent ional Pap-smear. These markers explo it the advantage of both Pap-smear analysis 
and the molecular ident if ication of dysplastic cells. Dysplastic cells can be recogn ized by 
the ir increased pers istence in cell cycle compared w ith normal ep ithel ial cells that ex it the 
cell cycle dur ing maturation and d ifferent iat ion.4° K i-67 antigen is a prol iferat ion marker, 
which is expressed during late-G1 , S and G2M phases of the cell cycle, but not dur ing 
G0.41 42 Immunoh istochemical stain ing of K i-67 antigen by the MIB1 ant ibody is strongly 
related to the sever ity of cerv ical neoplasia.4345 The same phenomenon was observed for 
immunoh istochemical sta ining of prol iferating cell nuclear ant igen (PCNA} wh ich is a 
prote in essential for the synthes is of DNA during cell prol iferat ion.46 PCNA 
immunocytochem ical sta in ing has not been investigated on Pap-smears. K i-67 sta in ing on 
Pap-smears can be used to distinguish high-grade CIN lesions from atroph ic cerv ical 
ep ithelium.47"50 Furthermore, K i-67 stain ing on cervical cytology was also proposed as a 
tr iage tool for patients with minor abnormal it ies on Pap-smear cytology. 51 However, 
neither Ki-67 nor PCNA sta in ing have been evaluated for a possible use in pr imary 
cerv ical cancer screening. Both K i-67 and PCNA sta ining have been compared with more 
recently identified markers of cell prol iferation.4° Cdc6 and Mcm5 are prote ins assembled 
into a prerepl icat ive complex that is essent ial for the in it iat ion of DNA repl icat ion. H igher 
percentages of dysplast ic cells in h igh and low-grade squamous intraepithelial lesions 
were immunoh istochemically stained by both Mcm5 and Cdc6 compared to K i-67 and 
PCNA sta in ing.40 In the same study sensit iv ity of Mcm5 and Cdc6 immunocytochem ical 
sta in ing on 58 cerv ical smears taken from pat ients attend ing a colposcopy outpat ient 
cl in ic was h igher on d irect compar ison w ith conventional Pap-smear analys is. However, 
these markers of DNA repl ication may also detect immature phases of squamous 
metaplas ia wh ich can lead to false pos it ive results.40 The data on Mcm5 and Cdc6 
immunocytochem istry need to be further evaluated in larger studies compr is ing pre­
cl in ical screen ing populations. 
MARKERS FOR CHROMOSOMAL AND DNA ANEUPLOIDY 
Other markers of dysplasia to be detected in the same smears as used for 
morpholog ical Pap-smear analys is are markers to analyze chromosomal and DNA 
aneuplo idy. In cervical smears and t issue samples, aneuplo idy is found to be related 
w ith the sever ity of neoplas ia using Feulgen-sta ined image analys is. 52 53 Monsonego and 
coworkers found aneuplo idy to be present in 78% of smears taken from pat ients with 
h igh-grade CIN and in 21 % of smears taken from CIN I patients. 
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Both aneuplo idy measurements and immunocytochemistry of Mcm5 and Cdc6 proteins 
should preferable be used super imposed over convent ional Pap-smear analys is, wh ich 
w il l  lead to the development of a labor intens ive and therefore expens ive screen ing 
approach. New PCR-based detect ion techn iques may be used w ithout concurrent 
morpholog ical screen ing and may therefore prov ide a more clear-cut approach. 
DETECTIO N  OF MOLECULAR MARKERS BY PCR-BASED 
TECHNIQU ES 
HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER SCREENING 
HPV plays an important causat ive role in cerv ical carc inogenes is. It is est imated that for 
women the l ifet ime r isk of contract ing a gen ital H PV infect ion is 80%, lead ing to 
gen ital warts in 5%, abnormal cerv ical scrapes in 35%, CIN in 25%, and invas ive 
cerv ical cancer in less than 1 %.5457 HPV can be detected in almost all CIN I l l  les ions and 
cerv ical cancers and can be detected in cerv ical smears. 11 It is therefore suggested that 
the detect ion of h igh-r isk HPV in cerv ical smears may well improve cerv ical cancer 
screen ing because of h igh sens it iv ity. sg,6D Over 1 00 stud ies were undertaken to proof th is 
suggest ion r ight. In general, the sens it iv ity of h igh-r isk HPV test ing by general pr imer 
PCR (GP5+/6+; MY 09/1 1 ;  CP1 /2G; SPF1 0) or Hybr id Capture 2 to detect CIN I l l  and 
cerv ical cancer is more than 90%. However, women w ithout cerv ical dysplas ia can also 
be HPV pos it ive. Therefore, due to low spec if ic ity, HPV test ing alone w ill not suffic iently 
improve cerv ical cancer screen ing. 8 13 St il l ,  HPV test ing may be used in spec if ied pat ient 
groups. The test ing of HPV m ight improve cerv ical cancer screen ing in women w ith 
smears show ing borderl ine abnormal it ies (borderl ine dysplas ia or atyp ical 
squamous/glandular cells of undeterm ined s ign if icance (ASCUS/AGUS)), because it 
could prevent a number of referrals. The women w ith ASCUS who are H PV negat ive do 
not need referral because women w ith ASCUS who are HPV negat ive very rarely w il l  
have CIN I l l  o r  cerv ical cancer. In  women w ith ASCUS, HPV test ing w il l  ident ify more 
patients with high-grade neoplasia compared to repeat cytology. However, a spec if ic ity 
of 59-64% in th is group of pat ients w il l  st il l  lead to more referrals than necessary.61 
HPV test ing may also be used together w ith cytology to def ine a pat ient group in wh ich 
screen ing intervals can be prolonged. HPV negat ive women w ith normal cytology have 
an extremely low r isk to develop cerv ical cancer in 1 0 or more years / Another group of 
pat ients that may benef it from HPV test ing is the group of women aged 35 years or 
older. In these women HPV test ing has a h igher spec if ic ity because HPV infect ions are 
less frequent in th is group and when present, infect ions more often represent HPV 
pers istence.62 In women w ith cytolog ical abnormal it ies HPV pers istence is strongly 
related to the development of CIN I l l  and cerv ical cancer. 63 Resum ing, HPV test ing can 
be used as a d iagnost ic tool for screen ing purposes, but it has a relat ively low 
spec if ic ity due to frequent HPV infect ions w ithout dysplas ia. H PV DNA test ing can best 
be restr icted to a subset of females in wh ich spec if ic ity of HPV test ing is h ighe r. 
Currently the def in it ive ev idence of eff icacy from long-term follow -up stud ies and from 
random ized tr ials should best be awa ited before cons ider ing implementat ion of HPV 
DNA test ing in ex ist ing screen ing programs. Tr ials are unde rway that should soon clar ify 
the role of HPV test ing for cerv ical cancer screen ing.2526•64 
The psycholog ical consequence of a pos it ive h igh-r isk HPV test w ithout the presence of 
CIN Il l or cancer can be cons iderable. Regardless of how it is implemented, the 
incorporat ion of HPV DNA test ing into pr imary screen ing w il l  inev itably result in 
inform ing m il l ions of women w ith normal Pap-smears world-w ide that they are at 
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increased r isk for cerv ical cancer. Then, it w il l  be necessary to assure HPV pos it ive 
women that they do not have to feel unduly alarmed or st igmat ized wh ile conv inc ing 
them of the need for proper follow-up in order to ident ify those who w il l  actually 
develop cerv ical cancer.65 In l ight of these cons iderat ions, the use of other markers of 
molecular changes occurr ing in cerv ical carc inogenes is should also be invest igated. 
Most of the markers and assays in the fol low ing parts of th is rev iew have only recently 
been ident if ied or developed. For most of these new techn iques it w il l  be d ifficult to 
already est imate poss ible cost-effect iveness wh ich we w il l  therefore not d iscuss. 
LOSS OF HETEROZYGOSITY, MICROSATELLITE ALTERATIONS 
S ince HPV infect ion not always leads to cerv ical cancer, other genet ic alterat ions must 
also play a role in tumor-development. Oncogenes and tumor suppressor genes are 
genes involved in cell growth and regulat ion. Oncogenes may foster mal ignant 
processes if act ivated, whereas tumor suppressor genes usually w il l  be inact ivated 
dur ing mal ignant transformat ion, necessary because of the ir natural repress ive funct ion 
on mal ignant processes. Poss ible mechan isms to down-regulate a tumor suppressor 
gene are po int mutat ions result ing in aberrant gene products, methylat ion of the 
promotor sequences or delet ions of (parts of the) tumor suppressor genes. To inact ivate 
tumor suppressor genes located on autosomal chromosomes both al leles need to be 
inact ivated, often by comb inat ions of d ifferent mechan isms. For instance, the loss of 
one of the a l leles can be detected qu ite eas ily by the analys is of loss of heterozygos ity 
(LOH). To determ ine LOH, DNA from tumor t issue is compared w ith normal DNA of the 
same ind iv idual after ampl if icat ion us ing PCR based m icrosatell ite analys is. 
M icrosatel l ites are short tandem repeats on chromosomes that can be used as markers 
for a reg ion in wh ich a tumor suppressor gene is suspected. Most m icrosatell ite PCR 
markers are h ighly polymorph ic and can therefore d ist ingu ish both al leles. In case of a 
delet ion, the intens ity of one of the al leles in the tumor sample w il l  decrease, referred 
to as allel ic imbalance and in th is part icular case LOH .  In cerv ical neoplas ia. us ing 
t issue samples, frequent LOH has been found on several chromosome arms, includ ing 
3p, 4p, 4 q, 5p, 6p, 9p, 1 1  p, 1 1  q and 1 7p.66 The frequency of LOH in premal ignant 
les ions increases w ith sever ity. 57 Us ing Pap-smear DNA and 9 markers, m icrosatel l ite 
alterat ions (LOH or m icrosatel l ite instab il ity) were present in 85% of 1 3  smears taken 
from pat ients w ith cerv ical cance �. Due to the necessary compar ison between tumor 
and normal DNA, LOH analys is requ ires large quant it ies of cancer-cell DNA. In most 
cases 50% of the total DNA in the sample has to be tumor-der ived to rel iably detect 
LOH wh ich makes cerv ical scrap ings unsu itable for cerv ical cancer detect ion by LOH 
analys is. 6 9 
The short tandem repeats of m icrosatel ites m ight be prone to alterat ion as the result of 
loss of m ismatch repa ir funct ion. M icrosatel l ite instab il ity (MSI) can be detected when 
several changes in the tandem repeat sequence and length of m icrosatel l ites are 
present. MSI is eas ier to detect than LOH .  Approx imately one m icrosatel l ite instable cell 
among 200 normal cel ls can be deteded.70 Despite the fad that improved techn iques 
have reduced the time required, MSI analysis is stil l  difficult to carry out on a large 
number of clinical samples for a reliable detection of cancer.71 Furthermore, MSI is only 
present in a subset of cervical cancers. Using five markers, MSI was only detected in 
29% of 93 squamous cell cervical cancer samples.72 Although LOH and MSI analyses are 
not suitable as high-through-put techniques yet, these analyses are useful to identify 
future markers of cervical cancer with diagnostic and prognostic value. 
TELOMERASE ACTIVITY 
Telomerase is a nuclear enzyme that is able to synthesize the short stretches of repeat 
nucleotides that are lost from telomeric ends of chromosomes with each round of 
replication. Studies in cancer cell l ines, as well as in human tumors showed that, in 
contrast to normal somatic cells, the vast majority of malignant cells (>90%) are 
characterized by increased telomerase activity.73•74 Therefore, determination of 
telomerase activity was suggested for early cancer detection. Telomerase activity is 
associated with severity of cervical neoplasia /5.79 The percentage of telomerase activity 
in cervical cancer tissue varies from 86% to 97% /4•75'7 9•80 However, in cervical scrapings 
positivity for telomerase activity was found in only 31 % of cervical cancer patients.75 
For CIN lesions percentages of telomerase activity are reported between 0 and 
68%.74•75•80-92 Ngan et a/. reported that telomerase activity assessment was unable to 
improve the detection of high-grade CIN in a study population comprising 86 women 
with normal cytology and 1 1 4  women with abnormal cervical smears.n Testing for both 
telomerase activity and the telomerase components hTR and hTERT in cervical 
scrapings led to the conclusion that detection of telomerase activity and components 
are not suitable for the detection of CIN II or more severe lesions in women with 
cytological borderline, mild or moderate dyskaryosis. Furthermore, the combined 
sensitivity and specificity of these tests were too poor to suggest a role in primary 
screening. 92 
DNA METHYLATION 
Some 30 years ago it became clear that, as a 'fifth base', methylcytosine is formed 
postreplicatively in DNA by addition of a methyl group to a cytosine already 
incorporated into previously synthesized DNA.94 Methylation forms a modification of 
DNA and is referred to as an epigenetic change since it does not alter the primary DNA 
sequence. The function of DNA methylation may be a contribution to overal l  genetic 
stability and maintenance of chromosomal integrity and to facilitate organization of the 
genome into active and inactive regions with respect to gene transcription.•s.ss 
Genes with promoter region CpG islands are virtually always unmethylated in normal 
tissues. Exceptions are inactivated genes on the female X-chromosome and the 
inactivated al lele for selected imprinted genes on autosomal chromosomes. For the past 
1 5  to 20 years, abnormal patterns of DNA methylation have been recognized as 
molecular changes in neoplasia. Areas of hypermethylation involve CpG islands in 5' 
regulatory regions of genes and these represent 'epimutations' in which genes are 
silenced. Hypermethylation of tumor suppressor genes contributes to an immortalized 
29 
30 
phenotype by silencing expression of genes responsible for control of normal cell 
differentiation and/or inhibition of cell growth. 
It has been shown that promotor hypermethylation of at least one of the genes p 1 6, 
DAPK, MGMT, APC, H/C- 1, and E-cadherin was present in 79% of 53 cervical 
cancer tissues and in none of 24 normal cervical tissues.87 Furthermore, aberrant 
methylation of at least one of the genes p 1 6, RARB, FHIT, GSTP1, MGMT and 
hMLH 1 was detected in 1 4  of 1 9  cervical cancer tissue samples; in 1 2  of 1 7  high-grade 
CIN samples; in 1 1  of 37 women with no dysplasia or with CIN I and in none of 22 
negative controls.88 All these experiments were carried out using conventional 
methylation specific PCR (MSP) which takes advantage of the sequence differences 
resulting from bisulfite modification by designing PCR primers in CpG islands to 
distinguish methylated from unmethylated DNA. An advancement of conventional MSP 
is real-time quantitative methylation specific PCR (QMSP) which permits reliable 
quantification of methylated DNA after adjusting for DNA input. QMSP is more 
sensitive than conventional PCR and can therefore detect aberrant methylation patterns 
in human samples with substantial (1 :1 0.000) contamination of normal DNA, 89 which is 
important for the use of cervical scrapings. Moreover, QMSP is amenable to high­
throughput techniques al lowing the analysis of close to 400 samples in less than 2 
hours without requirement for gel-electrophoresis, which can facil itate the 
implementation of QMSP in nation-wide screening programs. It has been demonstrated 
by QMSP analysis that cervical scrapings can reflect the hypermethylation status of the 
underlying cervical epithelium well and 32 of 48 (67%) cervical cancer patients could 
be identified by analyzing cervical scrapings for APC, DAPK, GSTP1  and MGMT 
hypermethylation.90 However, a lot of developmental work has yet to be performed. 
First, it wil l be necessary to identify other genes more specifically methylated in 
(cervical) cancer to compose a sensitive and specific cervical cancer hypermethylation 
panel. The candidate tumor suppressor gene 'tumor suppressor in lung cancer 1 '  
(TSLC1) and the TRAIL decoy receptor DcR 1 may be interesting candidates. TSLC1 
hypermethylation was present in 59% of 49 cancer tissues, 35% of 20 high-grade CIN 
lesions and in none of 1 1  low-grade CIN lesions.91 Hypermethylation of DcR1 was 
present in 1 00% of 50 cervical cancer tissue samples of unknown tumor stage and in 2 
of 1 1 2  normal tissues of different origin.92 As soon as a cervical cancer sensitive and 
specific panel has been identified, the use of QMSP on cervical scrapings has to be 
establ ished in a large preclinical population. 
CONCLUSION AN D FUTURE PERSPECTIVES 
Current morphology based cervical cancer screening is associated with significant false 
positive and false negative results. In this review we show that to date no other 
diagnostic tools are available with proven cost-effectiveness to replace or augment 
current Pap-smear screening. HPV DNA detection stands closest to implementation in 
nation-wide screening programs of al l  markers reviewed. However, low specificity for 
(progressive) high-grade CIN and cervical cancer and negative psychologic effects of 
knowledge of HPV positivity are important drawbacks. Even when the trials that are 
underway would show cost-effectiveness of implementing HPV DNA testing in cervical 
cancer screening new markers and technologies could theoretically sti l l  lead to major 
improvements. Implementation of liquid based cytology would by itself slightly improve 
Pap-smear screening. Perhaps more importantly it would aid the development of new 
technologies which can be tested in residual fluid and the results thus obtained can be 
compared with the paired cytologic classification. 
In our opinion, of the molecular markers and molecular-changes-based technologies, 
two techniques especially shoul be further evaluated. Immunocytochemical staining of 
cervical smears by Cdc6 and Mcm5 will be the fastest option. Apart from further 
evaluation, QMSP wil l  also need further development. In comparsion to morphology 
based Pap-smear analysis and immunocytochemical staining QMSP has three major 
theoretical advantages: 1 )  clear-cut results after the definition of cervical cancer cut-off 
levels; 2) QMSP is amenable to high-throughput analysis, resulting in cost-effectiveness 
and 3) promise of high sensitivity combined with high specificity. 
Primary prevention of cervical cancer by effective prophylactic HPV vaccines may be 
possible in the near future which will further challenge cervical cancer screening.� If 
implemented, HPV vaccination will lower the prevalence of cervical cancer and its 
precursor lesions. Positive screening results will thereby be more l ikely to represent 
false positives. Whenever HPV vaccination will be implemented nation-wide it wi l l  be 
only acceptable to screen for residual cervical cancer if we have highly specific 
screening tools at our disposal. Morphology based Pap-smear analysis does not meet 
those criteria. It therefore seems to be of eminent importance that the search for and 
development of new cervical cancer screening approaches are continued at present, 
now that cervical cancer prevalence is still high. 
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Cervical cancer is an important cause of death in women world wide, which develops 
from cervical intraepithelial neoplasia (CIN).' A CIN-Iesion can either regress, persist or 
progress towards (micro)invasive carcinoma. Most of the low grade CIN lesions (CIN I) 
will regress, while in the long term 1 2% to 40% of high grade CIN lesions (CIN I I/I I I) 
wil l progress to squamous cell carcinoma.2•3 Because no markers exist that identify 
those lesions that wil l progress, clinicians have felt compelled to treat at least a l l  CIN 
1 1/ 1 1 1  lesions. 
Cytomorphologic examination of cervical smears is the most widely applied screening­
method for cervical cancer and its precursors. Disadvantages are high numbers of false­
negative and false-positive cervical smears. Cervical cytology alone is a good predictor 
for the presence of CIN 1 111 1 1  when it shows severe dyskaryosis or carcinoma in situ. In 
women with these severely abnormal smears CIN 1 111 1 1  or cancer was found in 89-93% 
of womenY In contrast, 51 -58% of women with cytological mild or moderate 
dyskaryosis is diagnosed with CIN 11/11 1 .5•6 All of the women with cytological mi ld or 
moderate dyskaryosis are subjected to colposcopic evaluation, implying an overshoot of 
diagnostic procedures.7•8 Therefore parameters in cervical scrapings are needed which 
more accurately predict the presence of CIN I I/I I I  or cancer in women with borderline, 
mild or moderate dyskaryotic smears. 
Although it has been suggested that high risk HPV testing may well improve cervical 
cancer screening/·'0 its role in the triage of women with cytological borderline, mild or 
moderate dysplasia is less clear. 
Another possible parameter that is reported on is telomerase activity assessment by 
PCR-based telomere repeat amplification protocol (TRAP) assay.1 1 12 Telomerase is an 
enzyme that replenishes short stretches of repeat nucleotides lost from telomeric ends 
of chromosomes with each round of replication. Studies in tumour cell lines, as well as 
in human tumor specimens have shown that, in contrast to normal somatic cells, the 
vast majority of malignant cells (>90%) are characterized by increased telomerase 
activity. 11·" Therefore determination of telomerase activity has been suggested for early 
cancer detection. In a previous study of our group it was shown that although 
telomerase activity was associated with severity of cervical neoplasia, it was only 
detected in 27% of scrapings from women with CIN 1 111 1 1  and cervical cancer.•• In 
contrast, Reddy et al. detected telomerase activity in 96.5% of cervical cancer samples 
and in 68.7% of premalignant cervical scrapings. 1 1 In a previous study of our group and 
in the study of Reddy et a/. telomerase activity was detected by a non-commercial ly 
available TRAP-assay. 
Low sensitivity has been found for telomerase activity assessment in urine and 
screening for bladder cancer. However, when detection of the human telomerase RNA 
component (hTR), was performed, sensitivity for detecting bladder cancer increased.'5 
In another study hTR detected by in situ hybridization in frozen cervix samples was 
related to grade of CIN.16 We therefore speculate that detection of hTR in cervical 
scrapings might be a more sensitive alternative than telomerase activity assessment in 
screening for CIN 1 1/1 1 1 .  Another option could be the detection of human telomerase 
reverse transcriptase mRNA (hTERT) in cervical scrapings. hTERT is the catalytic subunit 
of telomerase which is thought to be the rate-limiting component in the formation of 
functional telomerase.17 20 
Aim of the present study was to examine whether the detection of telomerase activity 
hTR, hTERT and HPV in cervical scrapings has clinical value in the triage of women 
referred because of cytological borderline, mild or moderate dyskaryosis. 
41 
42 
PATIENTS AND M ETHODS 
PATIENTS 
Patients were recruited from the outpatient clinic of the Department of Gynecology, 
University Hospital Groningen. Eligible for participation in the study were al l  patients 
referred by their general practitioner in the period May 1 999 - August 2000 because of 
a cervical cytology report showing two times a borderline or mild dyskaryosis or with a 
single moderately dyskaryotic smear. In the Netherlands cervical smears are classified 
according to a modified Papanicolaou system in which no ASCUS diagnosis exists.2' 
Instead a cervical smear can be classified as borderline dyskaryotic, but the two terms 
do not necessarily describe identical abnormal ities. Exclusion criteria were previous 
colposcopic examination because of an abnormal cervical cytology report and 
pregnancy at the time of the diagnostic or therapeutic procedure. 
All patients were asked to participate in the study during their initial visit to the 
outpatient clinic. All specimens used for the study were collected during the initial visit, 
before diagnostic procedures. All patients underwent colposcopically directed biopsies. 
CIN was diagnosed and graded according to international criteria.22 Only if CIN II or I l l  
was diagnosed, the transformation zone was excised 4 to 6 weeks later by diathermic 
loop excision. Cervical neoplasia was classified according to the most severe lesion 
found on histological examination of biopsy and loop excision specimen and 
categorized in low grade lesions for no dysplasia (CIN 0) and CIN I and high grade 
lesions for CIN I I  and I l l .  This categorization corresponds well with the classification of 
low grade and high grade squamous intraepithelial lesions, which is also widely used. 
The study-protocol was approved by the medical ethical committee of the University 
Hospital Groningen. Al l patients gave informed consent. 
CERVICAL SCRAPINGS 
The cervix of al l  eligible women was scraped with the blunt or pointed end of an Ayre's 
spatula and with an endocervical brush. The scraped cells were suspended in 5 mL ice­
cold phosphate buffered saline (PBS: 6.4 mM Na2HP04; 1 .5 mM KH2P04; 0 . 14 M NaCI; 
2.7 mM KCI (pH 7.2)) and kept on ice until further processing. Of this cell suspension 4 
mL was centrifuged and washed with wash buffer (1 0 mM HEPES-KOH (pH=7.5); 1 .5 
mM MgCI2; 1 0  mM KCI; 1 mM dithiothreitol) (as described previously), '4 after which 
half of the pel let was snap frozen in liquid nitrogen and then stored at -80 •c until 
further use for telomerase activity assessment with TRAP assay. The other half of the 
pellet was suspended in 500 IJL guanidine isothiocyanate (GT) buffer, quickly frozen in 
liquid nitrogen and stored at -80 •c until further use for rt-PCR. 
TRAP ASSAY 
The TRAP assay was performed with TRAPeze XL Telomerase Detection Kit (lntergen 
Company, Purchase NY. USA) in accordance with the manufacturers' directions for use. 
Lysis of the pellet was performed as described previously.'6 All samples were tested in 
dupl icate and average results were categorized as positive when peaks represented 
;?: 1 0  GLC4 (a human small-cell lung cancer cell line) cell equivalents (quantification 
comparable to the normalized fluorescence of 1 0  GLC4 cell equivalents is 1 0  U/IJg 
protein) . 
HPV ANAlYSIS 
DNA was prepared from the pellets of scrapings, obtained after extraction of proteins 
with TRAP lysis buffer using the GT-diatom procedure and dissolved in 1 00 IJL of 1 0 
mM tris/HCI, 1 mM EDTA (pH 7 .0). This procedure did not affect the HPV-PCR results of 
cervical carcinoma cell lines with known HPV-status: Hela 53; Caski; SiHa and C33a 
(results not further shown). The GP5+/6+ PCR enzyme immunoassay for high risk HPV 
detection was performed as described previously.23 
REVERSE TRANSCRIPTASE PCR FOR HTR AND HTERT 
Isolation of RNA and rt-PCR was performed as described previously by Wisman et a/. 16 
PCR was performed separately for hTERT mRNA (35 cycles), hTR (35 cycles) and a 
housekeeping mRNA, glyceraldehyde-3-phosphatase dehydrogenase (GAPDH)(30 
cycles). GAPDH, hTR and hTERT levels in 1 IJg total RNA of GLC4 cells were set at 
1 00%. Expression levels in the cervical samples were relatively expressed to the 
expression levels in GLC4, after which the expression levels were normalized to the 
house-keeping gene GAPDH.  Expression levels of hTR and hTERT were categorized as 
follows: no expression = negative; expression <1 0% of 1 IJg total GLC4 RNA = very 
low; expression between 1 0% and 75% GLC4 = low; expression between 75% and 
200% GLC4 = moderate and expression between 200% and 1 000% GLC4 = high. 
STATISTICS 
To test for differences in expression levels of hTR and hTERT in women with no 
dysplasia/CIN I and CIN 11/11 1 the Mann-Whitney-U test was used. Independent 
associations of HPV and age with the two diagnostic categories were estimated using a 
multiple logistic regression model. A difference associated with a p-value � 0.05 was 
considered to be significant. Diagnostic-test characteristics were calculated by using the 
proportion of women with CIN 0/1 and CIN 1 1/1 1 1 .  The 95% confidence intervals were 
calculated using the CIA (©Gardner & British Medical Journal. London, GB) software. 
Al l other analyses were performed using the statistical analysis program SPSS (©SPSS 




In the period May 1 999 - August 2000, 50 consecutive patients participated in the 
study. The median age was 37 years (Inter Quartile range (IQ-range) 31 -45). Of the 50 
women 22 {44%) were diagnosed with CIN 0/1 {no dysplasia n=1 1 ,  CIN I n=1 1 )  and 28 
{56%) with CIN I IIII I {CIN I I :  n=1 7, CIN I l l :  n=1 1 ). The median age of women with CIN 
0/1 was 43.5 (IQ-range 34.8 - 48.8) and of women with CIN 1 111 1 1  35.5 (IQ-range 30-
42.5) {p=0.01 ). The association between age and the diagnostic categories remained 
borderline significant {p=0.065) when adjusted for the presence of HPV. Table 1 shows 
the final histological diagnosis in relation to the cytology results of the cervical smear 
at referral .  
Table 1 :  Histological diagnosis related to cytology results of cervical smears a t  referral 
Histology 
Cy1ological dysplasia N CIN 0/1 CIN 11/111 
Borderline 4 4 
Mild 24 1 2 12 
Moderate 22 6 1 6  
Total so 22 28 
In Table 2 the proportion of women with CIN 011 or CIN 1 1/ 1 1 1  positive for telomerase 
components or high risk HPV is shown. All scrapings could be analyzed for the presence 
of telomerase activity and HPV, but the quality of three cervical scrapings was too poor 
to analyse with rt-PCR for hTR and hTERT. 




hTERT mRNA expression 
High risk HPV 
' > 1 OU/�g protein 
CIN 0/1 N=22 
1 (4.5%) 
22 (1 00%) 
4 (1 8%) 
1 1  (SO%) 
' Quality of 3 samples was too poor to analyze 
Histology 





Telomerase activity was only detected once, in a cervical scraping from a woman with 
CIN 0/1. Because hTR was detected in 44 of 47 scrapings we analyzed whether the 
frequency of low and high hTR expression levels differed between the two diagnostic 
categories. In women with CIN 0/1, hTR expression was negative in none, weak in 1 3  
{59%), moderate in 6 {27%) and high in 3 {1 4%). In women with CIN 1 111 1 1 ,  hTR 
expression was negative in 3 {1 2%), weak in 8 {32%), moderate in 1 1  {44%) and high 
in 3 {1 2%) {p=0.74). For hTERT most samples had very low or low expression, without 
differences between CIN 0/1 and CIN I IIII I. One sample was found to have moderate 
expression and one high expression. Both samples were taken from patients with CIN 11/1 1 1 .  
Of the 6 women diagnosed with CIN 1 111 1 1  who were high risk HPV negative four were 
diagnosed with CIN II and two with CIN I l l .  The 33 HPV positive women were younger 
(median age 35, IQ-range 30 - 43.5) than the 1 7  HPV negative women (median age 44, 
IQ-range 33 .5-49.5) (p=0.01 7). The presence of HPV was independently associated with 
the severity of the histological diagnosis (p=0.023}, after adjusting for age. 
It was analyzed whether detection of one of the telomerase components or HPV 
analysis could be used as a diagnostic test by calculating sensitivity, specificity, positive 
predictive value and negative predictive value for the detection of CIN I I/ I I I  (Table 3). 
For none of the analyzed tests a combination of high (90% or higher) sensitivity and 
high specificity was observed. The 95% confidence intervals excluded a combined 
sensitivity and specificity of at least 90% for any of the evaluated parameters (Table 3). 
Table 3: Test characteristics of telomerase components and HPV when used for the detection of CIN II/III in women referred 
because of cervical cytology reports showing at most moderate dyskaryosis 
Telomerase activity ' 
h TR expression 
hTERT mRNA expression 
High risk HPV 
1 Positive predictive value 
2 Negative predictive value 
3 > 1 OU/Jl!J protein 
Test characteristics in % (95% Confidence Interval) 
Sensitivity Specificity PPV' 
0 (0-12) 95 (77-100) 0 
88 (69-98 ) 0 (0-15) 50 (35-65) 
28 (1 2-49) 78 (60-95) 58 (31 -89) 
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In recent literature it is debated whether low grade cervical lesions should be diagnosed 
and treated.14 Since CIN I is estimated to progress to cervical cancer in approximately 1 %  
of all cases, 1 immediate treatment of these lesions seems rather drastic. A major drawback 
of identifying women with CIN 0/1 during screening is that women may become worried 
that they are at risk for cervical cancer development, when in fact the far majority wil l  
never develop this disease.15 I n  most cervical-screening programs patients are referred for 
colposcopy when cytological atypia or borderline dyskaryosis is found more than once, or 
directly when cytological abnormalities are more severe. Using this policy a significant 
number of women with CIN 0/1 are referred and disturbed with time consuming and 
invasive diagnostic procedures. A diagnostic tool is therefore needed, that can sensitively 
detect CIN 1111 1 1  in women with cytological borderline, mild or moderate dyskaryosis, and 
that also has high specificity so few women are bothered with invasive procedures 
incorrectly. Such a diagnostic test should best be performed on cervical scrapings, as was 
done for al l of the presented parameters in this article. 
In our study CIN 1 11 1 1 1  was diagnosed in 46% of all patients. Others found 4.7-26% in 
comparable groups of women.48·16 The high percentage found in our study probably 
represents the fact that more than half of the patients were referred because of moderate 
dyskaryosis and only four women were referred because of a borderline dyskaryotic smear. 
Furthermore, in the Netherlands women are not referred with a single borderline or mildly 
dyskaryotic smear but only when such an abnormality is found twice, leading to a higher 
percentage of women diagnosed with CIN IIIII I. Lanham et a/. found percentages of 
histological proven CIN II/I I I  in women referred because of moderate dyskaryotic smears 
that correspond well with the percentage in which CIN 11/111 was diagnosed in our 
population.4 
At present TRAP assays are commercially available which makes the clinical use of 
telomerase activity assessment accessible. However. with a commercially available TRAP 
assay we found only one scraping with telomerase activity, indicating a much too low 
sensitivity for the detection of CIN 1 1/1 1 1  to be clinically applied. In a previous study of our 
group a different (home made14) TRAP assay was used, which detected telomerase activity 
more frequently. Even the sensitivity of the more sensitive home made TRAP assay was too 
low, because telomerase activity was found in only 7 cervical scrapings of 48 (1 5%) 
women with cytological borderline, mild or moderate dyskaryosis with histological proven 
CIN 1 1/1 1 1 .  In a review of recent literature Nowak17 showed that studies using cytology 
specimens of more than 1 0 women report telomerase activity detection rates of 0-1 1 %  in 
normal cases; 12-31 % in low grade lesions; 6-66% in high grade lesions and 3 1 -1 00% in 
cervical cancer cases. In the same review detection percentages in frozen tissue samples 
were reported to be between 0 and 92% for normal tissue; 1 7-96% for high grade lesions 
and 82-1 00% for cervical cancer tissue. These widely varying numbers demonstrate that 
telomerase activity assessment has a too high variability and a too low sensitivity and 
specificity for the detection of CIN I I/I I I or cervical cancer to be clinically applied. 
We found low specificities in predicting CIN 11/11 1  for both hTR (1 00% positive in CIN 0/1} 
and hTERT (1 8% positive in CIN Oil) analyses in cervical scrapings. Low specificity of hTR 
assessment for the detection of CIN I IIIII was also found by others.4 Snijders et a/. 28 found 
hTERT mRNA expression in 40% of CIN 0/1 tissue samples, also demonstrating low 
specificity. Lanham et a/.4 used cytology specimens for the detection of hTERT and found 
positivity in only 6 % of CIN 0/1 cases and in none of the 40 women with CIN 1 1/1 1 1 .  
It is known that the prevalence of HPV declines with age.29 Therefore, our finding that HPV 
negative women were older than HPV positive women, was not surprising. However. we 
did not expect the women with CIN 0/1 to be older than the women with CIN IIIII I. This 
difference in age might be explained by the lower percentage of HPV positive women in 
the CIN 0/1 group. The association between age and diagnosis was only borderline 
significant when adjusted for the presence of HPV. Another explanation for the difference 
in age between the two diagnostic categories might be that reactive changes in cervical 
smears, mistaken for cervical dyskaryosis, are more frequent in older women, leading to a 
high percentage of CIN 0/1 in older women. 
HPV studies in women with cervical smears showing more than mild dyskaryosis, as 
presented here, are rare. In a Dutch none intervention studyJ0 high risk HPV was found in 
1 82/297 (61 %) women referred for mild or moderate dyskaryosis. This corresponds well to 
the 66% of positives found in our study population. HPV testing as a screening tool for 
women at risk for CIN II/III has been studied extensively in women with cervical cytology 
showing Atypical Squamous Cells of Undetermined Significance (this corresponds best with 
borderline dyskaryosis) or mild dyskaryosis. The ALTS trial (Randomized Atypical Squamous 
Cells of Undetermined Significance/Low-Grade Squamous lntraepithelial Lesion Triage Study) 
showed that HPV DNA testing represents a promising approach for colposcopy triage of 
atypical squamous cells of undetermined significance, but not for low-grade squamous 
intraepithelial lesions.10 High risk HPV testing in women with cervical cytology showing low­
grade squamous intraepithelial lesions had good sensitivity but low specificty for the 
detection of CIN I l l .  One may think that specificity of high HPV viral load is higher than the 
specificity of HPV presence alone, because viral load is associated with the severity of the 
histological diagnosis.29 However. Sun et a/. reported that specificity remains low because 
high HPV-viral load is also found in 1 2.5% of women without dysplasia and in 25% of 
women with low grade lesions.3' We therefore think that HPV detection is not useful. 
We real ize that the number of patients in our study is low, leading to broad 95% Cl's for 
the calculated test characteristics (Table 3). However. for al l of the presented tests the 
calculated 95% Cl's exclude the possibility for a test to combine 90% sensitivity with 90% 
specificity. This shows that the chance that one of the tests will prove to be of clinical value 
in a larger study is rather low. We therefore conclude that other diagnostic tests are 
needed for the triage of women with cytological borderline, mild or moderate dyskaryosis 
because high risk HPV detection by PCR and detection of telomerase activity and 
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Cervical cancer is an important cancer related cause of death in women worldwide. ' 
Clinical staging of cervical cancer occurs by the criteria of the International Federation 
of Gynecology and Obstetrics (FIGO) for which, during a pelvic examination under 
general anesthesia, tumor-size and involvement of the vagina and parametrium are 
estimated.2 Traditionally, clinical stage is the most prominent prognostic parameter and 
therefore determines the choice of treatment modal ity to a great extent. 
The NIH consensus statement of 1 997 on cervical cancer reported that radical 
hysterectomy (combined with adjuvant radiotherapy when indicated) and primary 
radiotherapy are equally effective treatments for early stage (FIGO 18/IIA) cervical 
cancer.3 This consensus opinion was later confirmed by a randomized trial.• In daily 
practice however, most gynecologic oncologists prefer radical hysterectomy with pelvic 
lymphadenectomy for their relative young and healthy early stage patients because of 
the shorter treatment course, opportunity for ovarian preservation, and presumed better 
post-treatment vaginal function.5 
'Classic' indications for adjuvant radiotherapy such as lymph node metastases; positive 
resection margins and parametrial involvement, are generally accepted in early stage 
cervical cancer after radical hysterectomy. 56 Using these indications, adjuvant 
radiotherapy is given to approximately 30% of stage 18/IIA patients.7 Using both 
'classic' and so-called ' intermediate' indications, approximately 38% stage 181  (tumor 
< 4 em) and 72% stage 182 (tumor > 4 em) patients will be treated with adjuvant 
radiotherapy. 2 
When patients receive adjuvant radiotherapy after surgery, treatment related morbidity 
and costs will increase and benefits of primary surgery alone wil l  disappear.•·• Two­
modality treatment (radical surgery followed by adjuvant radiotherapy) should be 
avoided as much as possible3•5•8 and in some institutions radical surgery is therefore 
already restricted to stage 18 patients with tumors equal to or less than 3 em, thus 
reducing the frequency of adjuvant radiotherapy to approximately 1 2% of the operated 
patients.9 In an editorial on treatment choices in early stage cervical cancer, Morris 
suggested that criteria for selecting patients for radical hysterectomy should be defined 
such that postoperative adjuvant radiotherapy will be given to a maximum of 1 0-20% 
of the patients.• 
Squamous cell cancer antigen (SCC-ag) is a known serum tumor marker for squamous 
cell cervical cancer. Most studies reported that elevated preoperative serum sec -ag is 
associated with pelvic lymph node metastases and independently from lymph node 
metastases with worse survival. '0.16 All these (often too small) studies used different 
single cut-offs for preoperative serum SCC·ag analysis and analyzed predictive values 
for lymph node metastases only, which is just one of the three 'classic' indications for 
radiotherapy. Due to these l imitations, until now not enough nuances were available to 
al low wide spread implementation of pretreatment serum SCC-ag analysis in clinical 
decision making. 
To obtain a better informed choice between primary surgery and primary 
(chemo)radiotherapy in early stage squamous cell cervical cancer patients, we analyzed 
in the present study the predictive value of a continuum of preoperative serum SCC-ag 
levels for either one or a combination of postoperative indications for adjuvant 
radiotherapy and compared the performance of serum SCC-ag analysis to currently 
world-wide used clinical parameters, i.e. FIGO stage and tumor-size. 
53 
54 
PATIENTS AND M ETHODS 
PATIENTS 
We retrospectively analyzed the data of patients primarily treated with radical 
hysterectomy, because of invasive (� 3 mm) squamous cell cervical cancer in the 
University Hospital of Groningen or in the Academic Medical Centre (Amsterdam) in the 
period 1 991 - 2002. Tumors were classified according to the criteria of Kurman et al. 17 
The data of patients who were treated with cold knife exconisation or loop excision 
before serum sampling were excluded from analysis because a study by Maruo et a l .  
showed that 80% of patients with e levated serum SCC-ag seroconverted within 24 
hours after surgical excision of cervical tumors.18 Follow-up data were completed for al l  
patients of both hospitals t i l l  November 2002. 
STAGING , TREATMENT AND FOLLOW-UP 
Pelvic examination under general anesthesia was performed for staging in accordance 
with the FIGO criteria.2 During this procedure lesion size (largest diameter) and tumor 
spread beyond the cervix were estimated routinely. Tumor size was expressed in em. 
Patients with FIGO stages IB and I IA were el igible for surgical treatment which 
consisted of a class I l l  radical hysterectomy with pelvic lymphadenectomy in both 
institutions.19 Exceptions were made for patients with poor general conditions for 
whom surgery determined an unacceptable risk. When primary radical surgery was 
abandoned during operation due to obvious extracervical tumor mass, patients were 
treated with primary radiotherapy. Radiotherapy was combined with chemotherapy (3 
cycles of carboplatin (300 mg/m2, day 1 )  and 5-FU (600 mg/m2 , day 2 -5) and from 1 -1 -
2002 with Cisplatin 40 mg/m2/week for 6 weeks) in the University Hospital of 
Groningen. 
In both hospitals patients received adjuvant radiotherapy when considered to be at 
high risk for locoregional recurrence. 'Classic' high-risk indications were: one or more 
pelvic lymph node metastases; close (<2 mm) or positive resection margins and 
parametrial involvement. Patients considered to be at intermediate risk (with either 
deep stromal infiltration (> 2/3 of the cervical stroma) and/or massive 
capil lary/lymphatic space involvement (at least 3 different tumor localisations in 
capil lary or lymphatic space to be seen outside of the main tumor mass in at least two 
slides using a 1 Ox20 enlargement) only received adjuvant radiotherapy in the University 
Hospital of Groningen. Adjuvant radiotherapy consisted of external radiotherapy (6-1 0 
MV) to the pelvis, using the box-technique, 5 fractions a week of 1 .8 Gy to a total dose 
of 45 Gy. 
FOLLOW-UP 
Standard follow-up surveil lance consisted of a clinical history, physical examination and 
blood analysis starting 6 weeks after treatment, then every 2 months for the first year, 
every 3 months in the second year, then every 6 months until the sixth year and yearly 
thereafter until 1 0 years after treatment. 
SCC-AG ANALYSIS 
During the study period it was clinical practice to use serum SCC-ag analysis for the 
confirmation of complete remission after surgery and for the early detection of 
recurrences. To serve as a reference, a serum sample was routinely taken at the patients 
initial visit. SCC-ag was measured by the IMx SCC-ag microparticle enzyme 
immunoassay (Abbott Laboratories, Abbott Park, IL, USA). Treatment decisions were 
taken independently of the preoperative SCC-ag value. The standard cut-off value used 
for serum SCC-ag was > 1 .9 ng/mL, which is the 99th percentile in a population of 250 
healthy women tested at the University Hospital of Groningen. 
STATISTICAL ANALYSIS 
Differences in the distributions of age, stage and other patient-characteristics were 
analyzed with the X2-test. The ability to preoperatively identify those patients with a 
'classic' indication for adjuvant radiotherapy by serum SCC-ag analysis was compared 
with the performance of tumor-size and FIGO stage by calculating receiver operating 
characteristic (ROC) curves. Multivariate analysis was performed using the COX­
regression model entering serum SCC-ag, tumor-size and stage into the model in a one 
step analysis. For the ROC curves and regression analysis one cut-off level was chosen 
for the three variables used: for SCC-ag 1 .9 ng/mL; for tumor-size > 4 em and stage 18 
versus I IA. For evaluation of serum SCC-ag analysis as a diagnostic tool to 
preoperatively identify those patients who will receive adjuvant radiotherapy for 
'classic' indications, positive and negative predictive values were calculated for the 
SCC-ag cut-off values 1 .0; 2 .0; till 1 0.0 separately. The association between increasing 
levels of SCC-ag and the chance of receiving adjuvant radiotherapy was evaluated with 
the i-test for trend. As most locoregional recurrences of early stage cervical cancer 
occur within 2 years after primary treatment/0•21 analysis of two year recurrence 
percentages was performed, using the X2-test or Fisher-exact test when appropriate. 
Differences associated with a p-value $; 0.05 were considered significant. All these 
analyses were performed using SPSS software( version 1 1 ,  © SPSS Inc. Chicago, I L, 
USA). 95% confidence intervals for proportions of patients with indications for adjuvant 
radiotherapy were calculated using the CIA software (© Gardner & British Medical 





From 1 991 - 2002 a total number of 537 stage 18/IIA squamous cell cervical cancer 
patients was primarily treated with a radical hysterectomy in either of both hospitals. 
The data of 200 women were not included in the final analysis because of the 
following reasons; in 1 84 patients serum samples were drawn after exconisation or 
loop excision; in five patients the data of clinical staging were incomplete and 1 1  
patients were not treated according to protocol (6 patients because tumor-spil l 
occurred during surgery; 2 patients could not be radically operated due to severe 
prolaps and 3 patients were treated with a trachelectomy and laparoscopic 
lymphadenectomy}. The data of the 337 remaining patients were analyzed. 
STUDY GROUP CHARACTERISTICS 
Median age at time of diagnosis was 41 years (lnterquartile-range (IQR} 34 - 50}. FIGO 
stage 18 cervical cancer was diagnosed in 276 (82%} patients (1 98 (72%}stage 181 ; 61 
(1 8%} stage 182} and FIGO stage IIA in 61 (1 8%} patients. Adjuvant radiotherapy was 
given for 'classic' indications in 1 1 0  (33%} patients (presence of pelvic lymph node 
metastases in 80 (73 %}, parametrial involvement in 1 6  (1 5%}, tumor positive resection 
margins in eight (7.3%} and a combination of these three in six (5.5%} patients}. 
In 1 8  patients macroscopic extracervical disease (confirmed by frozen section} was found 
during surgery after which the radical hysterectomy was abandoned and the patients 
were treated with primary (chemo}radiation. For the evaluation of the value of serum 
SCC-ag to predict 'classic' indications for adjuvant radiotherapy, these 1 8  patients were 
categorized as having 'classic' indications for adjuvant radiotherapy, as these patients 
finally received both surgery and radiotherapy (combined with chemotherapy in 4 
patients} . These 1 8  patients were not included for the evaluation of recurrence 
percentages in patients treated with radical hysterectomy and adjuvant radiotherapy. 
Only nine patients received adjuvant radiotherapy because of 'intermediate' -risk. 
Therefore it was decided not to analyze the predictive value of serum SCC-ag levels for 
' intermediate'-risk separately. For the evaluation of the value of serum SCC-ag to 
predict 'classic' indications for adjuvant radiotherapy these nine patients were classified 
as having no 'classic' indication for adjuvant radiotherapy. The data of these nine 
patients were not used in the analyses of recurrence percentages in patients only 
treated with radical hysterectomy. 
The overal l  frequency of indications for adjuvant radiotherapy, including the 27 patients 
who were reclassified, is shown in Table 1 . In stage 182 and I IA patients a comparable 
frequency of indications for adjuvant radiotherapy and of elevated serum SCC-ag was 
observed and therefore both groups were combined for further analysis. There was no 
difference in the distribution of age, stage, frequency of adjuvant radiotherapy for 
'classic' indications, or frequency of recurrence between the two hospitals. 
Table 1: Adjuvant radiotherapy and elevated preoperative sec -ag levels according to FIGO stage 
FIGO stage Adjuvant RT* sec > 1.9 ngtml 
Stage Number of patients Number of patients (%) Number of patients (%) 
181 198 51 (26) 47 (24) 
182 78 43 (55) 48 (62) 
IIA 61 34 (56) 33 (54) 
Total 330 128 (38) 128 (38) 
• 'Classic' indication for adjuvant radiotherapy 
FIGO STAG E ,  TUMOR SIZE AND SERUM SCC-AG IN RELATION TO INDICATIONS FOR 
ADJUVANT RADIOTHERAPY 
Preoperative serum sec -ag levels were elevated (> 1 .9 ng/ml) in 1 28 (38%) patients 
(Table 1 ). Table 2 represents the frequency of elevated serum SCC -ag levels for patients 
without any indication for adjuvant radiotherapy and for the different indications for 
radiotherapy separately. The frequency of elevated serum SCC-ag was highest in 
patients with more than one 'classic' indication for adjuvant radiotherapy . .  
Table 2: Elevated serum sec -ag according to different indications for adjuvant radiotherapy 
lndkatlon for radiotherapy sec > 1 .9 ngtml 
Indication Number of patients Number of patients (%) 
No adjuvant radiotherapy 209 41 (20) 
Positive resection margins only 8 3 (38) 
Known intermediate risk only 9 4 (44) 
Positive lymph nodes only 80 53 (66) 
Parametrial invasion only 1 6  1 1  (69) 
Abortion of surgery 18 14 (78) 

















Figure 1 ,  comprising the ROC curves, represents the identification of patients with a 
'classic' indication for adjuvant radiotherapy by the criteria FIGO stage, tumor-size and 
serum SCC-ag, respectively. The better performance of serum SCC-ag compared to 
tumor-size and stage is expressed by its ROC curve, which is closest to the upper left 
corner of the graph. 
Figure 1: ROC-curve for tumor-size, FIGO stage and serum SCC-ag in predicting a 'classic' indication for adjuvant 
radiotherapy in 330 stage I BillA squamous cell cervical cancer patients 
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Elevated serum SCC-ag was the only independent predictor for indications for adjuvant 
radiotherapy with an odds-ratio of 7.1 in multivariate analysis including tumor-size and 
FIGO stage. 
Table 3: Odds ratios for a 'classic' indication for adjuvant radiotherapy, estimated using multiple logistic regression analysis 





< 4 cm 
> 4 cm 
SCC-ag 
s: 1 .9 ng/ml 
> 1 .9 ng/ml 
• 95% Confidence interval 







Odds ratio (95% Cl)* p 
1 .8 (0.96 - 3.5) 0.07 
1 .7 (0.98 • 3.0) 0.06 
7 1 (4.2 - 12) <0.001 
Figure 2 shows the frequency of adjuvant radiotherapy because of 'classic' indications 
for increasing levels of preoperative serum SCC-ag. The higher the level of preoperative 
serum SCC-ag the higher the frequency of adjuvant radiotherapy (p<0.001 ). 
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Standard deviations can not be given because the observed frequency of indication for adjuvant radiotherapy in one category 
is not independent from the frequencies observed in the other categories. 
Using our classic cut-off value (1 .9 ng/ml), serum SCC-ag analysis al lowed the 
identification of a group of patients at high-risk for adjuvant radiotherapy in both stage 
181 and stage 182/IIA patients. In 27 of 47 (57%) stage 181 patients with elevated 
serum SCC-ag 'classic' indications for adjuvant radiotherapy were present in contrast to 
24 of 1 51 (1 6%) stage 181 patients with normal preoperative serum SCC-ag (Figure 4, 
p<0.001 ). In 60 of 81 (74%) stage 182/IIA patients with elevated serum SCC-ag 'classic' 
indications for adjuvant radiotherapy were present in contrast to 1 7  of 58 (29%) stage 
182/IIA patients with normal preoperative serum SCC-ag (p<0.001 ). 
The predictive value of serum SCC-ag for 'classic' indications for adjuvant radiotherapy 
is shown in figure 3 for a continuum of different cut-off values. This figure allows 
evaluation of the impl ications of choosing a single cut-off value at different levels for 
serum SCC-ag for a l l  early stage cervical cancer patients. When a cut-off value of 2.0 
ng/ml is chosen, the likelihood of having an indication for adjuvant radiotherapy in the 
patients treated with surgery is approximately 1 6% in stage 181 and 22% in stage 
182/IIA patients. Choosing a higher cut-off, for example 4.0 ng/ml, wil l especial ly lead 
to higher positive predictive values. When preoperative serum SCC-ag is higher than 4.0 
ng/ml the l ikelihood of having and indication for adjuvant radiotherapy wil l  be 
approximately 80% for both stage 181 and stage 182/IIA patients. 
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All analyses were also performed for both hospitals individual ly. No differences were 
observed between the data of the two hospitals separately. 
THE ASSOCIATION OF ELEVATED SERUM SCC-AG AND RECURRENCE OF DISEASE 
The median time in follow-up in our population of 337 early stage cervical cancer 
patients was 3.9 years (IQR 1 .4 - 6.2). Twenty-one patients were lost to fol low-up for a 
variety of reasons after a median time in follow-up of 3.3 years (IQR 0.9 - 5.4). Overal l  
54 recurrences were observed and the median time to recurrence was 1 .0 year ( IQR 0.6 
- 1 .8, range 0.3 - 1 0.3 years). Of these 54 recurrences 22 occurred in patients with 
normal and 32 in patients with elevated preoperative serum SCC-ag. At the time of 
recurrence nine (41 %) patients with normal and 1 5  (47%) patients with preoperatively 
elevated SCC-ag levels had distant metastases. 
In the group of 1 98 patients with stage 181 disease 1 44 were not treated with adjuvant 
radiotherapy. In patients with normal preoperative serum SCC-ag two of 1 24 (1 .6%) 
had a recurrence within two years, while in the remaining 20 patients with elevated 
serum SCC-ag three (1 5%) patients had recurrent disease (p=0.02, figure 4). In 49 
stage 181 patients that received adjuvant radiotherapy for 'classic' indications no 
differences in frequency of recurrences were observed between patients with normal (4 
recurrences in 23 patients) and elevated preoperative serum SCC-ag (4 recurrences in 
26 patients) . 
Figure 4: Treatment Flow-Chart 
198 stage 181 patients 




RT + sec normal 
n= 51 n=151 
26% (20-32%) 76% (70-82%) 
RT - RT + 
n=127 n=24 




RT - RT + 
n=20 n=27 
43% (28-58%) 57% (42-72%) 
Based on the data of our cohort of 181 patients two flow charts were constructed of actual treatment that patients received. 
On the left side the frequency of adjuvant radiotherapy when classic preoperative staging is performed and on the right side 
the hypothetical situation when 181 patients would have been divided in two groups based on serum SCC-ag values. The grey 
shaded blocks indicate which patient group would, in the future, receive primary radiotherapy upfront when a preoperative 
serum SCC-ag level of 1 .9 ng/ml or higher would be used as a cut-off for primary therapy. The data of 5 patients were not 
used in the calculation of recurrence percentages because they either received adjuvant radiotherapy for 'intermediate' 
indications or surgery was aborted because of extracervical tumor mass (* Adjuvant Radiotherapy (Rn). 
In stage 182/IIA patients serum SCC-ag levels did not identify patients at higher-risk for 
recurrence, neither in patients only treated with surgery nor in patients treated with 




Our study shows for the first time that in early stage squamous cel l  cervical cancer 
patients prediction of 'classic' indications for adjuvant radiotherapy after radical surgery 
is improved by preoperative serum SCC-ag analysis. Using the exact serum SCC-ag 
value al lows an individualized and refined pre-treatment risk assessment of risk for 
ending-up with combined modal ity treatment, which is associated with increased 
morbidity. 
Patient characteristics of our study population are comparable to the characteristics of 
other early stage cervical cancer populations previously described.l.4.22 The relative high 
percentage of adjuvant radiotherapy in our study can be explained by the exclusion of 
1 84 patients with previous loop excision or exconisation, as these patients particularly 
have small tumors at low risk for adjuvant radiotherapy. 
Discussing treatment choices in early stage cervical cancer, Morris suggested that only 
patients with a preoperative likelihood below 1 0-20% for adjuvant radiotherapy after 
surgery should be eligible for radical hysterectomy. a As a consequence patients with a 
higher likelihood should be treated with primary radiotherapy in order to avoid the 
increased morbidity of two-modality treatment in a significant proportion of patients. 
Our study shows that when knowledge of FIGO stage and SCC-ag levels are combined 
the group of patients with FIGO stage 181 and preoperative serum SCC-ag levels 
between 0 and 1 .5 ng/ml (figure 2) indeed fulfi l ls this criterion. When in stage 181 
patients the 'classic' cut-off for SCC-ag of 1 .9 ng/ml is used, approximately 1 6% of the 
patients will ultimately have an indication for adjuvant radiotherapy (figure 4) which 
also lays within the range, as suggested by Morris. Our study also indicates that in 
stage 182/IIA only patients with serum SCC-ag levels between 0 and 1 .0 ng/ml have a 
frequency of adjuvant radiotherapy close to 1 0-20%. However, these data should be 
used with caution since only a smal l  group of stage 182/IIA patients (n=31 ) had a 
preoperative serum SCC-ag value of 1 .0 ng/ml or lower. Although thoroughly discussed, 
the choice to use a pretreatment likelihood of 1 0-20% for adjuvant radiotherapy as a 
criterion for eligibility for radical surgery is an arbitrary one. One great advantage of 
our present study is, that figure 2 and 3 allow implementation of serum SCC-ag 
analysis in existing clinical guidelines in which, based on figure 2 and 3 different SCC­
ag levels corresponding to different l ikelihoods for two modal ity treatment can be 
chosen as cut-offs in choice between primary surgery and (chemo)radiation. 
An obvious drawback of implementation of preoperative serum SCC-ag as a cut-off in 
choice between primary surgery and primary radiotherapy is the treatment with primary 
radiotherapy of patients who based on 'classic' indications would not have received 
adjuvant radiotherapy after surgery (e.g. 43% of the stage 181 patients with 
preoperative serum SCC-ag > 1 .9 ng/ml, figure 4) and one could argue that treatment 
by primary radiotherapy may cause unnecessary higher long-term morbidity in these 
patients. However, our data suggest that especial ly this group of patients is at higher 
risk for recurrence when treated with radical surgery only. In 1 5% of stage 181 patients 
with elevated serum SCC-ag and no 'classic' indication for adjuvant radiotherapy 
recurrent disease was observed in contrast to 1 .6% recurrent disease in otherwise 
comparable stage 181 patients with normal serum SCC-ag. Preoperative serum SCC-ag 
analysis apparently also al lows identification of patients at greater risk for recurrence 
after radical surgery who would not have been identified otherwise. Especially this 
patient group may benefit from choosing (chemo}radiotherapy as primary treatment as 
prognosis after a recurrence is poor, with most patients dying as a result of 
uncontrolled disease.20 A randomized trial will of course be the only way to really prove 
such a benefit. Radiotherapy as primary treatment can be combined with chemotherapy 
because recent trials (primarily in more advanced stages of disease} show a survival 
benefit for this combined modality treatment in cervical cancer.23 
Until now previous studies on preoperative serum SCC-ag levels have not led to a wide 
implementation of preoperative serum SCC-ag analysis into clinical practice, due to 
small study populations, the lack of including parametrial involvement and positive 
resection margins into a predictive model, and/or inclusion of more advanced staged 
patients into the predictive model. Despite the restrictions mentioned, these studies 
also showed strong associations between elevated preoperative serum sec -ag levels 
and the presence of lymph node metastases, thus underlining the strength of the data 
reported in our present study. ' '·13•15•16•24 
In both our institutions imaging techniques such as magnetic resonance imaging or 
computer tomography are not routinely used in staging patients with cervical cancer 
although it has been reported that these imaging techniques can be used for either 
staging of cervical cancer or for preoperative identification of lymph node metastases.25 
However, it has also been shown that interobserver correlations are rather low with 
Kappa values between 0.28 and 0.62 and that the qual ity of images largely depend on 
the equipment and different techniques used.26•27 In contrast, serum SCC-ag analysis can 
easily be performed everywhere with a relatively cheap, commercially available enzyme 
immunoassay, which is not subject to interobserver variation. Serum SCC-ag analysis 
can be reliably used by every oncologist and therefore our results should be used to 
identify future squamous cell cervical cancer patients at different levels of risk for 
adjuvant radiotherapy after surgery (figure 2}. 
Above each cut-off level one may consider to choose radiotherapy as primary treatment 
in stead of surgery. Radiotherapy as primary treatment can be combined with 
chemotherapy because recent trials (primarily in more advanced stages of disease} 
show a survival benefit for this combined modality treatment in cervical cancer.21 
Another application of preoperative serum SCC-ag analysis is stratification of early 
stage cervical cancer patient in different risk groups when designing future clinical 
trials. In patients with early stage squamous cell cervical cancer clinical trials should not 
only stratify for tumor size and FIGO stage, but also for patients with elevated serum 
SCC-ag levels, because of the clearly different risk profile. Studies on more intensive 
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treatment regimens (such as combining chemotherapy and radiotherapy) could be 
restricted to early stage cervical cancer patients at high risk for recurrence, preventing 
additive morbidity in patients that are adequately treated with surgery. 
In conclusion, our current study shows that serum SCC-ag analysis al lows more refined 
and individualized preoperative risk assessment for adjuvant radiotherapy than 
currently used clinical parameters. Preoperative serum SCC-ag analysis deserves 
implementation in existing treatment guidelines for early stage cervical cancer. 
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Cervical intraepithelial neoplasia (CIN) is a morphologically defined lesion associated 
with the development of cervical cancer. In the conventional morphogenetic model, CIN 
is separated into three grades according to the degree of cel lular atypia and 
disturbance of the epithelial architecture.1 
The proliferation rate of the lesion increases with increasing CIN grade.23 Risk factors 
for cervical neoplasia are smoking and l ifetime number of sexual partners.• Human 
papil lomavirus (HPV) is strongly associated with CIN, and the frequency depends on the 
CIN grade. In women with cytologic abnormalities, cervical H PV was found in 27% of 
those without neoplasia, 37% with CIN I, 43% with CIN I I, and 68% with CIN 1 1 1 . 5 
Epidemiological ly, the risk factors for cervical HPV infection are similar to those for 
cervical neoplasia.6 Bacterial vaginosis is defined as replacement of the lactobacilli of 
the vagina by characteristic groups of bacteria accompanied by changed properties of 
the vaginal fluid. It is a polymicrobial condition, and the micro-organisms most often 
found are Gardnerel/a vagina/is, Prevotella species, anaerobic gram-positive cocci, 
Mycoplasma hominis and Mobiluneus species 7. The clinical features of bacterial 
vaginosis are, 1 )  a thin, homogenenous vaginal discharge; 2) a vaginal pH of more than 
4.5; 3) vaginal epithelial cells heavily coated with bacilli (clue cells); and 4) release of 
fishy odor from the vaginal discharge on alkal inization with 1 0% potassium hydroxide 
(KOH).8 
It has been reported that bacterial vaginosis occurs significantly more often in patients 
with the colposcopic or cytologic suspicion of pre-cancerous changes or early cervical 
carcinoma than in women with normal cervical findings.9 Pavic hypothesized that the 
local production of nitrosamines in patients with bacterial vaginosis may act 
synergistically with other agents in the development of cervical neoplasia.10 In the 
present study, we explored the possible importance of bacterial vaginosis in the 
etiology of cervical neoplasia. We analyzed whether the occurrence of bacterial 
vaginosis is determined by the same features as the occurrence of cervical HPV 
infection in women with documented cervical cytologic abnormalities. More specifical ly, 
we analyzed 1 )  the prevalence of bacterial vaginosis, 2) the risk factors for bacterial 
vaginosis; 3) the occurrence of bacterial vaginosis in relation to HPV; and 4) the relation 
between bacterial vaginosis and the severity of histomorphologic changes. 
MATERIALS AND M ETHODS 
PATIENTS 
Patients were recruited from the outpatient clinic of the Department of Gynecology, 
University Hospital Groningen. They were referred either by their general practitioner 
because of an abnormal cervical cytology report, or the cervical cytologic abnormality 
was discovered during gynecologic examination. Patients were eligible to participate in 
the study if they had two mildly or moderately dyskaryotic cervical smears, or one 
severely dyskaryotic cervical smear. These cytologic criteria for eligibility correspond 
with the grounds for colposcopy as agreed on by cytopathologists and gynecologists in 
The Netherlands. In the case of mild or moderate dyskaryosis, the interval between the 
two abnormal smears was a maximum of 1 year. Patients were not eligible if they had 
previously undergone a colposcopic examination because of an abnormal cytology 
report or if their cervical smear was taken during pregnancy. 
For the 5-year period, September 1 ,  1 988 to September 1 ,  1 993, 343 consecutive 
patients were eligible for participation in the study. Sixty-three patients were not 
included for the following reasons: two patients did not want to be involved in the 
study; two had insufficient command of Dutch or English; at the enrolment visit, 24 
patients had their menstrual period or bloody vaginal discharge; and 1 6  had an 
insufficient volume of vaginal discharge for examination; four patients were pregnant 
at the time of colposcopy; and 1 5  were not treated in accordance with the study 
protocol. Thus, 280 newly diagnosed patients were included in the study. The age of the 
patients ranged from 20 to 66 years with a mean value of 34.7 years (standard 
deviation, 7.7 years). 
QUESTIONNAIRE 
Using a structured questionnaire, we asked the women to state the mean number of 
cigarettes they were smoking per day, their age at first sexual intercourse, their l ifetime 
number of sexual partners, and whether they had ever had a sexually transmitted 
disease or genital warts. All of the women were told beforehand that the questionnaire 
contained some intimate questions and that they were not obliged to answer. 
MICROBIOLOGICAL ANALYSES 
Some vaginal discharge was taken from the anterior or lateral vaginal vault or the 
proximal side walls of the vagina. Care was taken to avoid contact with the cervical 
mucus. Examination for fishy odour followed after the addition of 1 0% KOH. A small 
drop of discharge was mixed with 0.9% NaCI and examined microscopically for the 
presence of clue cells. Bacterial vaginosis was diagnosed if the vaginal discharge 
produced a fishy odor after the addition of 1 0% KOH and clue celts were seen under 
the microscope. 
Then, an endocervical swab was taken for Chlamydia Trachomatis analysis. Within 4 
hours of collection, this specimen was inoculated on cycloheximide-treated McCoy cell 
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monolayers on cover slips, as described by Ripa and Mardh.1 1  Detection of 
C. trachomatis inclusions was done after 48 hours using fluorescein-conjugated 
monoclonal antibodies (MikroTrak Culture Confirmation; Syva Corp., Palo Alto, CA). 
Finally, the cervix was scraped with the blunt and pointed end of a wooden cervical 
spatula and with an endocervical brush. The scraped cells were suspended in 5 ml of 
phosphate buffered sal ine, pH 7 .2, supplemented with merthiolate 1 :  1 0,000 
volume/volume. The cell suspension was sent to the laboratory and processed the 
following morning. The samples were analyzed for the presence of HPV using a general 
primer-mediated polymerase chain reaction, as described by Snijders et a/.12 The 
laboratory staff were unaware of the histologic diagnoses. 
MORPHOLOGICAL EXAMINATION 
Four weeks after the cervix had been scraped, we took colposcopical ly directed 
biopsies. If CIN was diagnosed from the biopsies, we subsequently excised the whole 
transformation zone by loop electrosection or cold knife conization. Diathermic loop 
excision was used if the squamocolumnar junction could be visualized entirely and did 
not extend up into the canal more than 5 mm from the anatomical os externum. The 
details of the technique have been described in a previous report.13 Cervical neoplasia 
was diagnosed and graded according to the criteria of the World Health Organization. 
In the individual patient, the most severe grade found by histologic examination was 
her diagnosis. 
For counting mitoses, new sections 4 IJm thick were cut from all of the tissue blocks to 
achieve uniform quality of the study material .  These sections were used to identify the 
area with the highest mitotic index. This area could be localized in one of the biopsies 
or in the electrosectioned sl ice or in the cold knife cone. The mitotic index was assessed 
by using a grid to count the number of mitotic figures per 1 ,000 nuclei from basal to 
proximal through the epithelial layer. Mitotic figures were defined as figures without a 
nuclear membrane, indicating that the cell had passed the prophase, and with clear 
hairy extensions of nuclear material .  Pyknotic nuclei or nuclei with basophilic cytoplasm 
were not counted.14 Sixty-one of the 280 women were not included in the morphologic 
part of the study for the following reasons: no neoplasia was found in 37 patients; 
invasive carcinoma was found in 1 1  patients; the tissue specimen was morphologically 
unsatisfactory in five patients; and the specimens were not avai lable for evaluation in 
eight patients. Therefore, this part of the study was performed on 2 19  patients. 
The microscopic examinations were performed with a Leitz dialux 20 EB microscope 
with a x40 npl fluotar Leitz objective (numeric aperture, 0. 70) and a x1 0 wide-field 
periplan ocular piece. 
STATISTICAL ANALYSIS 
To test for a significant difference between two groups of patients regarding qualitative 
or quantitative variables, we used the chi-squared test or the MannWhitney U test, 
respectively. If there were low numbers for a qual itative variable (frequency, <5% in a 
cell of the contingency table), Fishers's exact test was performed. Spearman's rank 
correlation coefficient was used to express the relations between continuous variables. 
These statistical procedures were performed with the SYSTAT software package 
(SYSTAT, Inc. Evanston, ll, USA, 1 990). The 95% confidence interval of Spearman' s rank 
correlation coefficient was obtained with the Confidence Interval Analysis software 
package (BMJ, london, UK, 1 991 ). The logistic regression analysis and the 2xk-table 
analysis were performed using the EGRET software package version 0.26.6 (Statistics 
and Epidemiology Research Corporation, Seattle, USA, 1 992). In the logistic regression 
analysis, the variables were treated as continuous or as unordered categorical variables. 
Contrasting likelihood values revealed that the descriptive power of the univariate 
logistic models did not change if the continuous variables were converted into 
unordered categorical variables. No two-factor interactions were found. P values of less 
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RESULTS 
Fifty-six {20%) of the 280 women had bacterial vaginosis. Table 1 shows the 
distribution of selected factors according to the presence or absence of bacterial 
vaginosis. An association was found between the presence of bacterial vaginosis and 
the number of cigarettes smoked per day, age at first sexual intercourse, lifetime 
number of sexual partners, and current C. trachomatis infection. No association was 
found between bacterial vaginosis and current age, past history of genital warts, past 
history of venereal disease, or current HPV infection. 
Table 1: Distribution of selected factors among patients with abnormal cerv1cal cytology reports, according to the presence 
or absence of bacterial vaginosis 
Bacterial Vaginosis 




Number of cigarettes 
smoked per day (total population) 
Median 
lnterquartile range 




Lifetime number of partners* 
Median 
lnterquartile range 
Past history of venereal disease n(%) 
Past history of genital warts n(%) 
Human papillomavirus present n(%) 
Chlamydia Trachomatis present n(%) 
*Mann-Whitney U test. 
tData missing for three cases. 
*Data missing for seven cases. 
35 
29-39 







1 9  (8.5) 
1 57 (70. 1 )  
3 (1 .3) 
§chi-squared test for two groups with Yates' correction. 





1 7  
1 5-18 
6 
4-1 5  
1 0  (17.9) 
6 ( 10.7) 
42 (75) 










We used 2xk-table analysis and logistic regression analysis to appraise the relations 
between bacterial vaginosis and smoking behavior, age at first sexual intercourse, and 
lifetime number of sexual partners. Chlamydia Trachomat1s infection was not 
included in this part of the study because of the low numbers. Table 2 shows the results 
of the analysis. The proportion of women with bacterial vaginosis increased significantly 
as the number of cigarettes smoked a day increased {chi-squared = 5.86, degrees of 
freedom = 1 ,  P = 0.02; test for trend). Compared with women who did not smoke, the 
point estimate of the odds ratio increased to 1 .44 in women who smoked more than 20 
cigarettes a day. Each cigarette produced a 3% increase in risk (odds ratio, 1 .03 with 
1 .01 and 1 .06 as the limits of the 95% confidence interval) for bacterial vaginosis when 
the number of cigarettes a day was analyzed as a continuous variable. 
The proportion of women with bacterial vaginosis increased significantly as the lifetime 
number of sexual partners increased (chi-squared = 6.91 , degrees of freedom = 1 ,  P = 
0.009; test for trend). Compared with women who have had one to two partners in 
their lifetime, the point estimate of the odds ratio increased to 3.24 in women who 
have had more than 1 0 sexual partners. Each additional partner conferred a 2% 
increase in the risk for bacterial vaginosis when the lifetime number of sexual partners 
was analyzed as a continuous variable. 
Age at first sexual intercourse was inversely associated with the occurrence of bacterial 
vaginosis (chi squared = 5. 72, degrees of freedom = 1 ,  P = 0.02; test for trend). 
Compared with women who had their first intercourse before 1 6  years old, the point 
estimate of the odds ratio decreased to 0.29 for women who first had sexual 
intercourse after 20 years of age. 
The number of cigarettes smoked per day, the lifetime number of sexual partners, and 
the age at first sexual intercourse were interrelated variables. Spearman's rank 
correlation coefficient between the number of cigarettes smoked per day and the age 
at first sexual intercourse was -0.29 (95% confidence limits, -0.40 to -0. 1 8), and 
between the number of cigarettes smoked per day and the l ifetime number of sexual 
partners was 0. 1 8  (95% confidence limits, 0.07 to 0.30). Spearman's rank correlation 
coefficient between the age at first sexual intercourse and the lifetime number of 
sexual partners was -0.37 with 95% confidence interval l imits -0.46 to -0.26. Because 
of these interrelations, we performed a multivariate logistic regression analysis. We 
showed that the relationship between bacterial vaginosis and the number of cigarettes 
smoked per day and lifetime number of partners was largely unaltered (Table 2). No 
relation was found between bacterial vaginosis and the age at first sexual intercourse 
when the analysis was adjusted for smoking behavior and number of partners. We 
concluded that smoking behavior and lifetime number of partners are independent risk 
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Table 2: Odds Ratios for bacterial vaginosis, by number of cigarettes smoked per day, lifetime number of sexual partners, and 
age at first sexual mtercourse in patients with reported cervical cytological abnormalities 
Odds RatiO (95% Confidence Interval) for Bacterial Vaginosis 
Variable Number (%) with Crude Adjusted• 
Bacterial Vagmosis 
No. of cigarettes 
smoked per day 
0 1 6/104 (1 5.4) 1 (reference) 1 (reference) 
1 -1 0  6/47 (12.8) 0.81 (0.29-2.21 ) 0.92 (0.33-2.57) 
1 1 -20 1 8177 (23.4) 1 .68 (0. 79-3.55) 1 .44 (0.64-3.23) 
:<: 21 1 6/52 (30.8) 2.44 (1 .1 1 -5.41) 2.39 (1 .03-5.53) 
Trend per cigarette 1 .03 (1 .01 -1 .06) 1 .03 (1 .00-1 .06) 
(P=0.01) (P=0.03) 
Lifetime number of 
sexual partners t 
1 -2 8172 (1 1 1 ) 1 (reference) 1 (reference) 
3-4 12/70 (17.1) 1 .66 (0.63-4.33) 1 .39 (0.52-3.72) 
5-1 0  1 8/79 (22.8) 2.36 (0.96-5.83) 1 .90 (0. 75-4.81) 
:<:1 1 1 5/52 (28.8) 3.24 (1 .26-8.38) 2.46 (0.90-6.72) 
Trend per partner 1 .02 (1 .00-1 .04) 1 .02 (1 .00-1 .04) 
(P=0.03) (P=0.06) 
Age at first sexual 
intercourse* 
1 5  14/50 (28.0) 1 (reference) 1 (reference) 
1 6-17 22/97 (22.7) 0.75 (0.35-1 .64) 1 .1 0  (0.47-2.55) 
1 8-19 14/81 (1 7.3) 0.54 (0.23-1.25) 0.89 (0.35-2.25) 
>20 5/49 (1 0.2) 0.29 (0.1 0-0.89) 0.52 (0.16-1 .70) 
Trend per year 0.87 (0.77-0.99) 0.94 (0.83-1.07) 
(P=0.03) (P=0.35) 
•The estimates were adjusted for both other factors through logistic regression by treating these other factors as 
continuous variables. 
toata missing for seven cases. 
*Data missing for three cases. 
Table 3 shows the histologic diagnosis according to the presence or absence of 
bacterial vaginosis. We dichotomized the spectrum of histologic diagnoses between CIN 
I and CIN I I .  No difference was found regarding the presence of bacterial vaginosis 
between minor lesions {no neoplasia or CIN I) and major lesions {CIN II or a more 
severe lesion; 1 5  out of 68 versus 41 out of 2 1 2, P = 0.75, chi-squared test). 
Analysis of the mitotic index was performed only on patients with CIN. The median 
values {range of values) of the mitotic index in the patients with CIN I, CIN I I, and CIN 
I l l  were 3 {0-8), 4 {1 -1 2), and 7 {0-51 ), respectively. In the group of patients with 
bacterial vaginosis and in the group without bacteria l  vaginosis, the median values of 
the mitotic index were 6 {0-28) and 5 {0-51 ), respectively. No relation was found 
between the presence of bacterial vaginosis and the mitotic index {P = 0.27, Mann­
Whitney U test). 
Table 3: Presence of bacterial vaginosis in patients with abnormal cervical cytology reports in relation to the final histologic 
diagnosis 
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It may seem peculiar to study the epidemiologic features and possible morphologic 
sequelae of bacterial vaginosis using a scientific design with one sample of women 
with cytologic abnormalities of the uterine cervix. However, cytologic abnormalities 
result from a spectrum of changes with diverse etiologies and clinical outcomes.'5 
Therefore, the composition of any sample of patients with cytologic abnormalities is 
heterogeneous. An investigation on bacterial vaginosis and cervical neoplasia is not 
possible in patients with invasive carcinoma because the vaginal environment is 
disturbed by blood and tumor necrosis. A regular case-control study with CIN patients is 
difficult to perform because the prevalence of bacterial vaginosis in both groups, 
patients and control subjects, will not differ very much. Thus, very large groups of 
patients and control subjects would be needed. 
We defined bacterial vaginosis as vaginal discharge that released a fishy odor after 
being mixed with a drop of 1 0% KOH and that showed the presence of clue cells in the 
wet smear during microscopic examination. These two criteria are the most relevant for 
diagnosing bacterial vaginosis and permit a correct diagnosis of bacterial vaginosis to 
be made in almost al l  cases.'6.18 An elevated pH value of the vaginal fluid is the least 
specific indicator for the diagnosis of bacterial vaginosis'7 and is a physiologic 
phenomenon in post-menopausal years. Assessing whether the discharge has a thin, 
homogeneous appearance is a subjective process and is less reliable for clinical 
purposes.'6 
In our series, bacterial vaginosis was found in 56 (20%) of the 280 women. This 
prevalence seems comparable with the prevalence normally found in samples of 
patients attending gynecology outpatient clinics. The prevalence of bacterial vaginosis, 
as reported by other investigators, depends on the characteristics of the patient 
population. In one study, bacterial vaginosis was diagnosed in six (1 2%) of 52 virginal 
post-menarchal girls.'9 In populations of outpatients at gynecology clinics, bacterial 
vaginosis was found in 1 9  (1 5%) of 1 26 patients who came for a routine annual or 
contraceptive examination and did not have symptoms of vaginitis (i.e., vaginal 
discharge, vaginal odor, and/or vulvovaginal irritation or itching), a in 32 (29%) of 1 1 1  
patients who presented with symptoms of vaginitis, a and in 1 42 (20.9%) of 680 ferti le 
nonpregnant women who visited the clinic for various reasons.'8 At clinics for sexually 
transmitted diseases, one group of investigators diagnosed bacterial vaginosis in 21 0 
(33%) of 640 women they examined/0 while other researchers diagnosed 364 (36%) 
cases in their group of 455 patients.'6 The reported prevalences indicate that the 
occurrence of bacterial vaginosis is partly determined by sexual behavior. 
In the univariate analyses, we found that bacterial vaginosis was associated with age at 
first intercourse, lifetime number of sexual partners and current C. Trachomatis 
infection. These associations corroborate the relation between the presence of clue cells 
reported, Papanicolaou smears and lifetime number of sexual partners and age at first 
intercourse.1G In women who attended a sexually transmitted disease clinic, the 
presence of bacterial vaginosis was associated with the number of sexual partners 
during the 30 days before examination.1' The associations discussed also indicate that 
sexual behavior influences the risk of contracting bacterial vaginosis. 
We found that bacterial vaginosis is significantly associated with being a smoker. Other 
investigators have reported an association between the presence of clue cells in 
Papanicolaou smears and smoking.2G A question that arises is whether smoking is an 
independent risk factor for bacterial vaginosis or simply a covariable of sexual behavior. 
An association between smoking and the l ifetime number of male sexual partners has 
been demonstrated in a study on women attending a university health services clinic22 
and in a study on women attending a sexually transmitted disease clinic.23 An 
association between smoking and a comparatively young age at first intercourse has 
been demonstrated in studies of healthy young women attending medical 
contraception clinics2425 and in a study of junior high school students.26 In the present 
study, we too demonstrated a relation between smoking and sexual behavior. The 
findings indicate that sexual behavior could be a confounder in studies on the relation 
between smoking and the presence of bacterial vaginosis. In the multivariate analysis, 
we demonstrated that the number of cigarettes smoked per day and the l ifetime 
number of sexual partners are independent risk factors for bacterial vaginosis. Other 
investigators found that both of these factors also have an independent effect on the 
occurrence of the cervical HPV infection.6 Hence, there was a similarity between the 
epidemiologic characteristics of bacterial vaginosis and the cervical HPV infection. 
We did not find a relation between the presence of bacterial vaginosis and current age. 
Other investigators who have reported on patients attending an outpatient gynecology 
clinic also were unable to find such a relation.8·'8 
There was no relation between bacterial vaginosis and cervical HPV infection; nor was 
there a relationship between bacterial vaginosis and the severity of the 
histomorphologic changes. In the latter analysis, we combined "no neoplasia" and "CIN 
I "  into one category of "minor lesions." All of the patients had cytologic abnormal ities, 
and discriminating between benign reactive changes and CIN I is a subjective process.27 
The number of mitoses in the lesions classified as CIN was counted to obtain a mitotic 
index and we confirmed that the mitotic index increased with increasing CIN grade) 
The mitotic index is estimated quantitatively and its use provides increased statistical 
power to detect a relation between bacterial vaginosis and morphologic changes. The 
presence of bacterial vaginosis did not have a demonstrable effect on the mitotic index, 
which supports the conclusion that bacterial vaginosis does not influence the severity 
of the morphologic changes. This contrasts with the reports on HPV that stated the 
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Human papi llomavirus {HPV) plays an important role in the development of cervical 
intraepithelial neoplasia {CIN) and cervical carcinoma. However, compared to the high 
rates of HPV infections in women without cervical neoplasia, the occurrence of CIN and 
cervical cancer is rare.' The search for risk-factors for cervical neoplasia, other than HPV, 
is therefore sti l l  going on. A candidate risk-factor is Chlamydia trachomatis. Case­
control studies have reported that serum antibodies against C. trachomatis are 
relatively more frequent in women with CIN or cervical carcinoma compared to 
controls. 2-7 
In the present study we explored the hypothesis that the presence of C. trachomatis 
antibodies is associated with the severity of neoplastic lesions using a cross-sectional 
study design. An {unexpected) high prevalence of antichlamydial antibodies in women 
with {micro) invasive carcinoma {{M)IC) was found. This high prevalence of 
antichlamydial antibodies in women with {M)IC and a higher prevalence in women with 
{M)IC than in women with CIN I l l  was not reported previously.2•7 Therefore a second 
study population was selected in an attempt to confirm our results. 
PATIENTS AND M ETHODS 
PATIENTS 
Two groups of women referred for an abnormal Pap smear to the gynecological­
outpatient clinic of the University Hospital Groningen, the Netherlands, were recruited 
for this study. Group A comprised 296 women referred between September 1 988 and 
September 1 9938 and group B comprised 331 women referred between November 1 995 
and June 1 999. For both groups separately, the study was approved by the ethical 
review board of the hospital . 
QUESTIONNAIRE 
Using a structured questionnaire, women were asked about their smoking habits and 
their lifetime number of sexual partners. 
DETECTION OF SERUM ANTIBODIES AGAINST CHLAMYDIA TRACHOMA TIS 
Blood samples were taken at the enrolment visit of al l  women. Periodate treated 
Enzyme lmmuno Assays (EIA) were carried out as described previously.9•10 Treatment 
with sodium periodate results in enhanced specificity of the assay compared to the 
native EIA.9 1° For both groups of patients, the same reference serum was used ensuring 
comparability of the results. 
MORPHOLOGICAL EXAMINATION 
Colposcopically directed biopsies were taken and graded according to the criteria of the 
World Health Organisation.11 If CIN was diagnosed, except for CIN I in group B, the 
whole transformation zone was subsequently excised by loop electrosection (LETZ) or 
cold knife conization. Cervical neoplasia was classified according to the most severe 




In group A 1 1 4 (39%) of 296 women tested positive for serum antibodies against C. 
trachomatis. The prevalence of antichlamydial antibodies did not increase significantly 
with increasing severity of CIN. However, the prevalence of C. trachomatis-antibodies 
was significantly higher in the group of women with (M)IC than in women with CIN (table 1 ). 
Table 1: Ant1bod1es agamst C. trachoma tis and the grade of neoplasia 
No (%} of positives for antibodies against C trachomatis, and the 95% Cl 
Grade of neoplasia 
None CIN I CIN II CIN Ill (M)IC 
Group A 1 6/40 (40) 8/34 (24) 1 4/43(33) 63/165 (38) 1 3/14 (93)* 
25-57 1 0·41 1 9-49 31 -46 66-100 
Group 8 8/1 9 (42) 26/50 (52) 41182 (SO) 74/1 53 (48) 1 5127(55) 
20-67 37-66 39-61 40-56 35-75 
* X'-test, p < 0.001 
X'-test for trend was not significant for both groups 
Patient characteristics in group B met the characteristics of group A apart from the 
proportion of women diagnosed with no dysplasia or CIN II, for which the 95% 
confidence intervals did not overlap (table 2). 
Table 2: Patient-characteristiCS for group A and 8 
Group A Group B 
Age (median, interquart1le range) 35 29-39 35 31 -42 
Life time number of sexual partners 
(median, interquartile range) 4 2-10  4 2-8 
Sexarche :s; 1 7  years (%, 95%CI) 52 46-57 49 43-54 
Smoker (%, 95%CI) 65 59-70 69 64-75 
No dysplasia (%, 95%CI) 14  9.6-1 7 5.7 3.5-8.8 
CIN I (%, 95%CI) 1 2  7.9-1 5 1 5  1 1 -1 9 
CIN II {%, 95%CI) 1 5  1 1 -1 9  2 5  20-29 
CIN Ill (%, 95%CI) 56 50-61 46 41 52 
(M)IC (%, 95%CI) 4.7 2.6-7.8 8.2 5.5-1 1 .7 
Serum antibodies against C. trachomatis were found in 1 64 (50%) of 331 women in 
group B. No increasing trend was observed for the proportion of women positive for 
antichlamydial antibodies with increasing severity of CIN (table 1 ). The prevalence of C. 
trachoma tis-antibodies in women with (M)IC was not significantly higher than in 
women with CIN. 
DISCUSSION 
Differences between group A and B might occur because of systematic differences 
between the two groups or due to chance. Effort was made to reduce systematic 
differences: periodate treated EIA was performed for both groups separately, but the 
same reference serum was used. Criteria for eligibi lity for group A and group B 
corresponded. We therefore have no other explanation than that the difference in the 
proportion of women with no dysplasia and CIN II is due to chance. The reported 
differences appeared to have no implication for our results. 
Overal l  prevalences of antichlamydial antibodies were comparable for group A and B. 
However, 93% of the women with (M)IC in group A had antichlamydial antibodies 
compared to 54% in group B. Prevalences reported by others are comparable to the 
prevalence found in group B.2 7 The number of women with (M)IC in group A is low. The 
95%CI of the prevalence is very wide in this group and overlaps the 95%CI of the 
proportion observed in the same category of group B (table 2). Chance has a great 
effect on small study populations.12 Considering what is discussed above we conclude 
that the high prevalence in the (M)IC group of A is due to chance. 
The role of C. trachomatis in the etiology of cervical neoplasia is hard to interpret. 
Many studies reported antichlamydial antibodies to be more frequent in women with 
cervical neoplasia than in controls.H This might indicate that C. trachomatis plays a 
causal role in cervical carcinogenesis. Our results suggest that C. trachomatis does 
not favor the progression from CIN to invasive disease. However, it should be kept in 
mind that these serological data can not exclude the possible involvement of local 
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Human papi llomavirus (HPV) has been the subject of a lot of research since 1 976 when 
zur Hausen published on a possible role for HPV in the etiology of cervical cancer.1 HPV 
is now considered to be the most important factor in the multi-step process leading to 
cervical cancer. HPV is a smal l  (7,9kB) double stranded epithel iotropic virus of which 
more than 90 types are known.2 These types can be divided into a mucosal and 
cutaneous group. Part of the mucosal HPV types are considered to be high-risk or 
oncogenic because they are found in cervical carcinomas. Among these are HPV types 
1 6, 1 8, 3 1 ,  33, 35, 39, 45, 5 1 ,  52, 56, 58, 59, 66, 68 and 69.1 With PCR based methods 
HPV is found in nearly al l  cervical carcinomas.l' 
In the past we reported the prevalence of HPV in women with cervical dyskaryosis to 
be higher with increasing histological severity of neoplasia, more cigarettes smoked per 
day and higher l ifetime number of sexual partners.s 1  In these studies we used the 
GP5/6 PCR for detection of HPV. Other investigators, using the MY 09/1 1 PCR for HPV 
detection, have reported similar associations in various populations.1 1� 
Recently a new and highly sensitive broad-spectrum HPV-PCR, the SPF1 0 PCR, was 
developed.16•17 With the Line Probe Assay (LiP A) typing method 25 different HPV types 
can be identified simultaneously. 17 In this report, we challenge our previously reported 
findings by re-analyzing the data with the test results from the SPF1 0/LiPA system. 
Because 25 HPV types can be identified in one test, we considered the mere presence 
of oncogenic HPV, the five most prevalent HPV types separately and the presence of 
multiple oncogenic types. 
PATI ENTS AND M ETHODS 
PATIENTS 
Between September 1 988 and September 1 993 a total of 343 consecutive patients with 
cervical dyskaryosis were seen in the outpatients colposcopy clinic of the Department of 
Gynecology, University Hospital Groningen, as described previously.7 Briefly, patients 
had had either two cervical smears showing mild or moderate dyskaryosis, or one 
smear with severe dyskaryosis. These cytological criteria for eligibility correspond with 
the grounds for colposcopy as agreed on by the cytopathologists and gynecologists in 
the Netherlands at that time. A total of 39 patients were not included in the present 
study: two of them did not want to be involved in the study; 1 5  patients were not 
treated in accordance with the study protocol, 2 patients had insufficient command of 
Dutch or English, 4 patients were pregnant at the time of colposcopy and the cervical 
scrapes of 1 6  patients were not available for re-testing on HPV with the SPF1 0/liPA 
system. The data of the remaining 304 patients are presented here. The mean age was 
35.0 years (SD 8.0; range 1 9-67 years}. The study was approved by the ethical 
committee of the hospital. 
QUEST IONNAIRE 
Using a structured questionnaire, women were asked about their smoking habits and to 
state the lifetime number of sexual partners. All the women were told beforehand that 
the questionnaire comprised some intimate questions they were not obliged to answer. 
MORPHOLOGICAL EXAMINATION 
Approximately four weeks after the cervix had been scraped for virological analysis, 
colposcopically directed biopsies were taken. Cervical neoplasia was diagnosed and 
graded according to the criteria of the World Health Organisation.'8 If CIN (either CIN I, 
CIN I I  or CIN I l l} was diagnosed, the whole transformation zone was subsequently 
excised by loop electrosection (LETZ} or cold knife conization. LETZ was performed if 
the squamocolomnar junction could be visualized entirely and did not extend up into 
the cervical canal more than 5 mm from the anatomical external os. The tissue was 
examined histological ly. The cervical neoplasia was classified according to the most 
severe lesion found on histological examination. 
CERVICAL SCRAPES AND HPV DETECTION 
At the enrolment visit, the cervix was scraped with an Ayre's spatula and with an 
endocervical brush. The scraped cells were suspended in 5 ml phosphate-buffered 
saline, pH 7 .2, supplemented by merthiolate 1 :1 0 000 v/v. Part of the cell suspension 
was stored at -80 °( until analysis with the SPF1 0/liPA system.17 After ampl ification, 
PCR products were analyzed by 3% agarose gel electrophoresis and the HPV DEIA, a 
microtiter-plate based assay for general detection of SPF amplimers. Typing of the SPF 
amplimers was performed with reverse hybridization in the line Probe Assay (the lnno­
liPA HPV prototype research assay}. By liPA low risk HPV types 6, 1 1 ,  34, 40, 42, 43, 
44, 53, 54, 59, 70 and 74 can be identified, as well as the high risk types 1 6, 1 8, 3 1 ,  
93 
94 
33, 35, 39, 45, 5 1 ,  52, 56, 58, 66 and 68.16 The high risk types as a group are denoted 
as oncogenic HPV. SPF amplimers not identified by LiPA are designated as type X. 
Isolated DNA was control led by the B-globin primers PC03 and PC04.19 
STATISTICAL ANALYSIS 
In the analysis, we considered al l  oncogenic HPV types as a group, the five most 
prevalent HPV types separately, and the presence of multiple oncogenic HPV types. The 
five most prevalent HPV types could be analyzed separately because combinations 
between these types did not occur more frequently than expected by chance alone (as 
determined with the X2-test; see Results section). The severity of the cervical lesion was 
divided into five diagnostic categories. The l ifetime number of sexual partners and the 
number of cigarettes smoked a day were divided into four categories according to the 
calculated quartiles. In the analysis of the association between HPV and these variables, 
the i-test for trend was used. P-values of 0.05 or less were considered to be 
statistically significant. 
To compare the prevalence of specific HPV types, as determined with SPF1 0/LiPA, 
between the GP5/6 positive and negative group, we used the X2-test. To correct for 
multiple testing according to Bonferroni, P-values of 0.005 or less were considered to 
be statistical ly significant. The SPSS software package was used for the statistical 
analysis. 
RESULTS 
SPF1 0/LIPA RESULTS 
A total of 299 women (98%) tested positive for one or more HPV types. Oncogenic HPV 
was detected in 288 women (95%). The five most prevalent HPV types were HPV 1 6  
(50%), HPV 1 8  (1 6%), HPV 31 (21 %), HPV 33 (1 2 %) and HPV 56 (9.9%) (Table 1 ) . In 
86 (30%) of the 288 women infections with more than one oncogenic HPV types were 
identified: 68 women disclosed 2 types, 1 5  disclosed 3 types, 1 disclosed 4 types and 2 
women disclosed 5 oncogenic HPV types. 
Table 1: HPV types detected with SPF/LiPA in 304 women with cervical dyskaryosis* 
HPV N (%) 
Negative 5 (1 .6) 
6 9 (3.0) 
1 1  1 6  (5.3) 
1 6  1 52 (SO) 
18  49 (16) 
31 65 (21) 
33 35 (12) 
























HPV N (%) 
53 (0.7) 
54 (0.3) 
56 30 (9.9) 
58 14  (4.6) 
66 3 (1 .0) 
68 (0.3) 
Type X 7 (2.2) 
HPV 1 6  was present in 50% and HPV 1 8  in 1 6% of the women in the study population. 
If these two HPV types were to occur independently, HPV 1 6  would be found together 
with HPV 1 8  in 8% of the women. Instead, their conjoint presence was actually found in 
only 4% (p<0.001 ;  xz test) (Table 2). Likewise, the combinations of HPV 1 6  with HPV 
31 and HPV 1 6  with HPV 33 were also seen significantly less frequently than expected 
by chance alone (p<0.001 and p=0.002, respectively; XZ test) (Table 2). Similar 
differences were not observed for the combinations of the HPV types 1 8, 3 1 ,  33 and 56. 
Table 2: Combinations between HPV 16 and the other four most prevalent HPV types 
no (%) of combinations 
HPV types expected observed 
1 6  and 18  24 (7.9) 1 2  (3.9)* 
1 6  and 31 33 (1 1 )  16  (5.3)' 
16 and 33 1 8  (5.9) 9 (3.0)$ 
16 and 56 1 5  (4.9) 1 1  (3.6)* 
<0.001 , x'·test 
s p=0.002, x'-test 
HPV AND GRADE OF CERVICAL NEOPLASIA 
The overall occurrence of oncogenic HPV was significantly related to the histological 







When the five most prevalent HPV types were analyzed separately, H PV 1 6  was the 
only HPV type for which a significant association with the grade of the neoplastic 
lesion could be observed (Table 3, p < 0.001 , l for trend). When all oncogenic HPV 
types other than HPV 1 6  were analyzed together, no association with the grade of 
neoplasia could be observed. No association was found between the presence of 
multiple oncogenic HPV types and the grade of the neoplastic lesion. 
Table 3:  HPV and the grade of cervical neoplasia 
grade of neoplasaa 
no dyspl. N=40 CIN I N=35 CIN II N=44 CIN Ill N=1 72 (M)IC N=13 
HPV n (%) n (%) n (%) n (%) n (%) 
Oncogenic HPV 34 (85) 31 (89) 41 (93) 1 70 (99) 12 (92)* 
HPV 1 6  10  (25) 10 (29) 1 5  (34) 1 08 (63) 9 (69)* 
HPV 1 8  6 (15) 11 (31) 10 (23) 20 (12) 2 (1 5) 
HPV 31 10 (25) 1 1  (31) 1 2  (27) 30 (1 7) 2 (15) 
HPV 33 3 (7.5) 6 (17) 3 (6.8) 22 (13) 1 (7.7) 
HPV 56 7 (18) 4 (1 1 )  8 (18) 10 (5.8) 1 (7.7) 
Number of oncogenic types 
25 (63) 1 7  (49) 27 (61) 1 24 (72) 9 (69) 
:2: 2 9 (23) 14 (40) 1 4  (32) 46 (27) 3 (21 )  
p < 0.001, x' for trend 
HPV AND EPIDEMIOLOGICAL RISK FACTORS 
The lifetime number of sexual partners was categorized according to the calculated 
quartiles into 1 ,  2-3, 4-9 and �1 0. No association was found between the l ifetime 
number of sexual partners and oncogenic HPV. the five most prevalent HPV types and 
the presence of multiple oncogenic types (Table 4). 
Table 4: HPV and the lifetime number of sexual partners 
l.Jfebme number of sexual partners 
2-3 4-9 :<: 10 
N=48 N=73 N=78 N=94 
HPV n (%) n (%) n(%) n(%) 
Oncogenic HPV 44 (92) 65 (89) 76 (97) 91 (98) 
HPV 1 6  2 0  (42) 33 (45) 42 (54) 51 (54) 
HPV 1 8  4 (8.3) 18 (25) 8 (10) 1 6  (17) 
HPV 31 9 (19) 7 (9.6) 19 (24) 26 (28) 
HPV 33 5 (10) 5 (6.8) 9 (12) 15 (16) 
HPV 56 6 (13) 5 (6.8) 7 (9.0) 9 (1 1 )  
Number of oncogenk types 
35(73) 51 (70) 51 (65) 59 (63) 
> 2  9 (19) 14 (19) 25 (32) 33 (35) 
The number of cigarettes smoked per day was categorized into 0, 1 -1 0, 1 1 -20 and ;:::2 1 . 
Again, no association was found between smoking and oncogenic HPV. the HPV types 
1 6, 1 8, 3 1 ,  33 and 56 separately, and the presence of multiple oncogenic HPV types 
(Table 5). 
Table 5: HPV and lifetime number of cigarettes smoked per day 
number of cigarettes per day 
0 1 -1 0  1 1 ·20 �1 
N=109 N=SO N=ll3 N=62 
HPV n(%) n(%) n(%) n(%} 
Oncogenic HPV 1 00 {92) 49 {98) 78 (94) 61 (98) 
HPV 1 6  47(43) 29(58) 45(54) 31 (50) 
HPV 1 8  1 9(17) 8(16) 1 2(1 5) 1 0(16) 
HPV 31 2 1 (19) 9(18) 22(27) 1 3(21) 
HPV 33 1 5(14) 3(6.0) 9{1 1 )  8{13) 
HPV 56 1 1 (10) 3{6.0) 7{8.4) 9(15) 
Number of oncogenic types 
1 71 (65) 41 (82) 49{59) 41 {66) 
<:: 2 29(27) 8(16) 29(35) 20(32) 
COMPARISON OF TWO HPV PCR SYSTEMS 
In the 304 patients of the present study, a total of 1 87 (73%) women had been tested 
positive with the GP5/6 PCR. It follows that the SPF1 0/LiPA detects significantly more 
women with cervical HPV than the GP5/6 (98% vs. 73%, p<0.001 , McNemar). For al l  
but four types (HPV 43, 54, 62 and 68) additional positives were found with the 
SPF1 0/LiPA (data not shown). Therefore, the higher sensitivity of the SPF1 0/LiPA applies 
to almost all of the tested HPV types. However, the higher sensitivity did not apply 
equally to all types. HPV 1 6  was found significantly less often in GP5/6 negative women 
than in GP5/6 positive women (1 8% vs. 62%, p<0.001 McNemar), whereas the 




We could not confirm previously reported associations between HPV and lifetime 
number of sexual partners and smoking when a new and highly sensitive HPV PCR 
system, the SPF1 0/LiPA, was used for the detection and typing of HPV. However, the 
association between the presence of oncogenic HPV (any type) and the grade of 
neoplasia remained and turned out to be determined by the influence of HPV type 1 6  
alone. 
The SPF1 0/LiPA was performed five years later than the GPS/6. The results do not 
suggest that the quality of cell suspensions diminished due to storage, because the HPV 
detection rate was higher when the SPF1 0/LiPA was used. H igh HPV detection-rates 
using the SPF1 0/LiPA were described previously.16•17 The use of the new test disclosed a 
substantial number (30%) of multiple infections, which enabled us to analyse co­
occurrences of specific HPV types. Although HPV 1 6  was the most prevalent HPV type in 
the presented population, it was detected significantly less often in multiple infections 
than expected. We can only speculate about the origin of this phenomenon. A possible 
explanation is competition in the PCR which can happen when the SPF primers are 
more sensitive for the detection of HPV 1 6  than for other types. Annealing of primers 
could than occur only to HPV 1 6  DNA although DNA of other HPV types is present in 
the same sample. Another reason for competition in the PCR-reaction could be that 
viral loads of HPV 1 6, when present, are higher than that of other HPV types. Then the 
excess of HPV 1 6  DNA can lead to a false negative PCR result for other HPV types 
present, which can result in observing HPV1 6 infections as single type infections. 
Alternatively, HPV 1 6  might be more oncogenic than the other types. HPV 1 6, present as a 
single type infection, might lead to cervical neoplasia more easily than single type 
infections of other HPV types. These other types might need more factors present, for 
example other HPV types, to lead to the same grade of neoplasia. Our data do not 
support the theory that the other types have additive effects in oncogenesis. The presence 
of multiple HPV types was not associated with the histological severity of the neoplastic 
lesion, although an increasing percentage of multiple infections with increasing grade of 
neoplasia was reported previously. A much more speculative explanation is that HPV 1 6  
induces mechanisms which inhibit infections with other HPV types. 
HPV 1 6  was the most common HPV type in this study population and therefore 
determined the association found for the oncogenic HPV as a group to a great extent. 
The fact that HPV 1 6  is the only HPV type significantly associated with the grade of 
neoplasia has been reported by another group of investigators.20 In most 
epidemiological HPV research al l  oncogenic HPV types are taken together, for example 
in determining risk factors for a HPV infection.10 14 1 5 11 12 It will be interesting to analyze 
in other populations whether the strength of risk factors for HPV infections is a type­
dependent phenomenon, although our data revealed no indication for that. 
The GPS/6 is no longer used in epidemiological H PV research. In more recent studies 
the GPS+/6+ and MY 09/1 1 PCR's are the most widely applied. These latter two PCR 
systems have comparable sensitivities.23 As with the GPS/6 PCR, associations between 
HPV and smoking" '2 and number of sexual partners8-10 12 15 have been reported when the 
MY 09/1 1 PCR was used for the detection of HPV. We could not reproduce our findings 
when the SPF1 0/LiPA system was used for detection and typing of HPV. 
The discrepancies between the results with the GPS/6 and SPF1 0/LiPA cannot be 
explained by a difference in the spectrum of HPV types detected by the two systems. 
Only for HPV types 1 6  and 31 the spectra differed. For these two types no association 
was found with the l ifetime number of sexual partners or smoking behaviour. Women 
with one partner, or anyhow a comparatively low number of partners, might have a 
lower viral load of HPV. Whether this is indeed true and what the mechanism of action 
is, needs further investigation. Sexually transmitted agents might play a role in this 
respect. Promiscuity has been reported as a risk factor for the development of cervical 
neoplasia, independent of HPV.13 Furthermore a number of studies reported an 
association between cervical neoplasia and the presence of antibodies against 
Chlamydia trachomatis, 2427 and underlying possible pathogenetic mechanisms have 
been discussed.28 We suggest that the presence of Chlamydia trachomatis might 
contribute to persistence of an HPV infection and/or an increase of the HPV viral load. 
Likewise, smoking might increase viral load by its impact on the immune system. In this 
respect, it is worthwhile mentioning that the number of Langerhans cells is decreased 
in smokers as compared to non-smokers.29•30 The possible impact of risk factors, l ike 
number of partners and smoking, on viral load of HPV was recently also discussed by 
another group of investigators.3' 
The use of a new detection method in this epidemiological study has put associations 
between HPV on the one hand and l ifetime number of sexual partners and smoking on 
the other into a different perspective. We suggest that the number of sexual partners 
and smoking are determinants of a high HPV viral load, rather than determinants for 
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Cervical cancer is an important cause of death in women world wide.1 There is a strong 
association between certain subtypes (high risk) of Human Papil lomavirus (HPV) and 
cervical cancer.2 However, it is clear that other factors are also involved in cervical 
carcinogenesis, because the majority of patients infected with HPV will not develop 
invasive cervical cancer.3 
Cytomorphological examination of cervical smears is the most widely applied 
screening-method for cervical cancer and its precursors. The Pap-smear has false 
negatives rates of 2 - 40% due to a combination of sampling error, processing artifacts 
and the nature of subjective interpretationY·5 False-negative cytology may lead to a 
delay in the diagnosis of cervical cancer and can be found in about 50% of cases when 
previous negative smears are reviewed from the smal l  proportion of screened women 
who develop invasive cancer.5 Moreover, as many as 20% of all Pap-smears are 
interpreted as atypical squamous cells of undetermined significance (ASCUS) or 
borderline dyskaryotic, leading to increased surveillance frequency and more invasive 
tests in many of these patients.4•6 Although it has been suggested that high risk HPV 
testing may well improve cervical cancer screening/·8 the specificity for high grade 
cervical neoplasia of high risk HPV testing is relatively low.9 Therefore, new objective 
diagnostic methods are needed. 
Silencing of tumor suppressor- or other cancer-associated genes by methylation of CpG 
islands, located in the promoter and/or 5'-regions of many genes, is a common feature 
of human cancer.1° CpG island methylation is often associated with a transcriptional 
block and loss of the relevant protein.10 In addition to the functional implications of 
gene inactivation in tumor development, these aberrant methylation patterns represent 
excel lent targets for novel diagnostic approaches based on methylation sensitive PCR 
techniques. 
Recently Dong et at. showed that promoter hypermethylation of at least one of the 
genes P 1 6, DAPK, MGMT, APC, H/C- 1, and E-cadherin occurred in 79% of cervical 
cancer tissues and in none of normal cervical tissues from 24 hysterectomy specimens.11 
Virmani et at. detected aberrant methylation of at least one of the genes P 1 6, RARB, 
FHIT, GSTP1, MGMT and hMLH 1 in 1 4  of 1 9  cervical cancer tissue samples.12 These 
experiments were carried out using conventional methylation specific PCR (MSP). An 
advancement of this technique is real-time quantitative MSP (QMSP) which permits 
reliable quantification of methylated DNA. This method is based on the continuous 
optical monitoring of a fluorogenic PCR. This PCR approach is more sensitive and more 
specific than conventional PCR and can therefore detect aberrant methylation patterns 
in human samples in the presence of normal DNA in a ratio of 1 to 1 0,000.13 
Currently no data are available on whether cervical scrapings reflect the methylation 
status of the underlying cervical epithelium and it is unknown whether QMSP on 
cervical scrapings could be used as a future screening method. In the present study we 
examined the promotor hypermethylation status of the tumor suppressor genes APC 
DAPK, GSTP1  and MGMT in cervical scrapings and paired fresh frozen tissue 
samples obtained from cervical cancer patients and controls. 
1 0� 
1 06 
PATIENTS AND M ETHODS 
PATIENTS 
CERVICAL CANCER PATIENTS 
In the period March 2001 - August 2003 all patients referred because of cervical cancer 
or abnormal cervical cytology were asked to participate in our research program during 
their initial visit to the outpatient clinic of the University Hospital Groningen. In order to 
obtain a homogeneous population we chose for the present study to only analyze those 
patients diagnosed with squamous cell cervical cancer, in whom cervical cancer had not 
been fully removed by exconisation or loop excision before referral .  Gynecologic 
examination under general anesthesia was performed in all cervical cancer patients for 
staging in accordance with the Federation lnternationale de Gynecologie • Obstetrique 
(FIGO) criteria.14 During this procedure lesion size (largest diameter) and tumor spread 
beyond the cervix were estimated routinely. 
All cervical scrapings were collected during the initial visit or before bimanual 
examination under general anesthesia. Al l tissue samples used for the study were 
collected during bimanual examination or at surgery, which was chosen as primary 
treatment for patients with stage 181/I IA (tumor size $; 4 em) cervical cancer. 
CONTROLS 
As controls served patients without a h istory of abnormal Pap-smears, who were 
planned to undergo a hysterectomy because of non·(pre)malignant disease in the same 
study-period. All samples used for the study were collected during surgery. Cervical 
epithelium of all control patients was confirmed to be normal on final histopathologic 
review. 
The study was approved by the medical ethical committee of the University Hospital 
Groningen and all patients gave written informed consent. 
SAMPLE COLLECTION 
CERVICAL SCRAPINGS 
The cervix of both cervical cancer and control patients was scraped with the blunt or 
pointed end of an Ayre's spatula and with an endocervical brush. The scraped cells 
were suspended in 5 ml ice-cold phosphate buffered saline and kept on ice until 
further processing. Of this cell suspension 1 ml was used for cytomorphological 
examination and 4 ml was centrifuged and washed with wash buffer, as described 
previously.'5 Subsequently a quarter of the pel let was snap frozen in liquid nitrogen and 
then stored at -80 °( until further use for DNA extraction. DNA was extracted using 
standard salt-chloroform extraction and ethanol precipitation for high molecular DNA 
and dissolved in 250 !JL TE-4 buffer (1 0 mM Tris; 1 mM EDTA (pH 8.0)) 
TISSUE SAMPLES 
For the present study fresh frozen tissue samples from the diagnostic or therapeutic 
specimens were only taken when the pathologist was convinced it would not interfere 
with the diagnostic process. Fresh frozen tissue samples were snap frozen and then 
stored at -80 oc until further use for DNA extraction. Tumor tissue was selected from an 
area with > 75% malignant cells as determined on a hematoxylin and eosin stained 
sl ide. Normal cervical epithelium was selected from control patients samples by grossly 
dissecting it from underlying stromal tissue. DNA was extracted from 1 0  unstained 1 0  
IJm frozen sections of the tissue samples by standard salt-chloroform extraction and 
ethanol precipitation and subsequently dissolved in 250 IJL TE-4 buffer. 
REAL-TIME QUANTITATIVE METHYLATION SPECIFIC PCR 
QMSP for APC, DAPK, GSTP1 and MGMT was performed after bisulfite treatment on 
denatured genomic DNA'6 as previously reported for APC and GSTP1 .11· '8 As internal 
reference gene the B-actin gene was chosen. The amplicon sizes for the QMSP were 
74bp for APC (position 761 -834, deposited at GenBank as accession no. U02509), 1 01 
bp for DAPK (5-1 02, X761 04), 1 22 bp for MGMT (1 029-1 1 50, X61 657) and 1 40 bp for 
GSTP1 (1 033-1 1 72, M24485). The basis of primer design has been previously 
described. 7 7, 7 9  For primer sequences, see Table 1 .  
Table 1 :  Primer and probe sequences used for the QMSP and reference gene analys1s 
Gene FOiward primer Reve!Se primer TaqMan probe 
(5' - 3') (5' - 3') (6fAM5' - 3'TAMRA) 
methylated APC AACCAAAACGGCCC TTATATGTCGGTTACG CCCGTCGAAAACCCGC 
CAT TGCGffiATAT CCGATTA 
methylated GSTPI GTTGCGCGGCGAm GCCCCAATAGAAATC GGTCGACGTTCGGGGT 
c ACGACG GTAGCG 
methylated MGMT CGAATATAGAAAACA GTAmmCGGGAGC ATCGCGCGATACGCA 
ACCCGCG GAGGC CCGffiACG 
methylated DAPK GGATAGTCGGATCGA CCGCCCAAACGCCG TCGGTAATTCGTAGCG 
GTTAACGTC A GTAGGGffiGG 
8-actm GGTGATGGAGGAGGT AACCAATAAAACGAC ACCACCACCCAACACA 
TTAGTAAGT TCGCCffiAA CAATAACAAACACA 
Amplifications were carried out in 384-wel l  plates. As positive controls serial dilutions 
of in vitro CpG methylated DNA with Sss I (CpG) methylase (New England Biolabs. Inc., 
Beverly, MA) were used by which a calibration curve was constructed for each plate. 
The calibration curve was used to set a plate specific threshold for positivity and to 
determine DNA equivalents for the results obtained. Multiple water blanks were 
included as negative controls. Dilution experiments showed linearity of ampl ification 
down to a di lution of 1 : 1 0,000 for methylated promoter DNA, as well as for 
unmethylated B-actin DNA. All samples were analyzed at least in dupl icate. For quality 
control all amplification curves were visualized and scored without knowledge of the 
clinical data. Per analysis the methylation result was considered positive when the 
QMSP amplification curve crossed the set treshold before 50 cycles. However, 














result of stochastic amplification and the results of such a single analysis was therefore 
disregarded. Samples that were only one time 'positive' or ' negative' in dupl icate 
analyses after quality control were analyzed at least in quadrupl icate. No samples had 
to be disregarded because of stochastic amplification since sufficient analyses were 
performed to obtain reproducable results. In further statistical analysis, for every single 
gene only a sample with sufficient DNA input (at least 225 pg B-actin DNA because in 
samples with DNA input below 225 pg stochastic amplification was too frequent) that 
was positive at least twice after multiple analyses was considered to be 
hypermethylation positive. A sample with sufficient DNA input that was negative at 
least twice and at most one time positive after multiple analyses was considered to be 
negative. 
CYTOMORPHOLOGIC EXAMINATION 
After scraping of the cervix 1 ml of cell suspension was diluted with ethanol-carbowax 
(7% Polyethyleneglycol, 50% ethanol) and after resuspending centrifuged for 1 0 
minutes at 1 000 rpm. The cell-pellet was resuspended in ethanol-carbowax until an 
appropriate cell concentration was obtained. Hettich cytospins (Hettich centrifuge, 
Depex b.v., Veenendaal, the Netherlands) were made on Poly-L-Lysin (Sigma chemical 
c.o., St. Louis, MO) treated sl ides by centrifugation for 1 0 minutes at 1 000 rpm. 
Cytospins were Papanicolaou stained and routinely classified by two independent 
pathologists without knowledge of the clinical data. In the Netherlands cervical smears 
are classified according to a modified Papanicolaou system in which borderline 
dyskaryosis corresponds well with the Bethesda classification ASCUS, mild dyskaryosis 
with low grade squamous intraepithelial lesion (LSIL) and moderate and severe 
dyskaryosis and carcinoma in situ with high grade intraepithelial lesion (HSIL).2"2' 
STATISTICAL ANALYSIS 
QMSP values were adjusted for DNA input by expressing results as ratios between two 
absolute measurements ((average DNA quantity of methylated gene of interest I 
average DNA quantity for internal reference gene B-actin ) x 1 0000) (more detailed 
information was described previously13·'7). The correlation between methylation ratios as 
determined in cervical scrapings and in fresh frozen tissue samples was tested for al l  
genes separately by the Spearman test. Differences in the heights of ratios between 
cancer patients and controls were tested with the Mann-Whitney U test for al l genes. 
To evaluate the clinical value of QMSP in cervical scrapings 'screen positive' cutoff 
values were chosen above the highest ratio observed in controls for al l genes 
separately. 
Observed differences were considered to be significant when associated with p � 0.05. 




In the period March 2001 - August 2003 1 08 patients met our inclusion criteria. Four 
patients refused to participate in the study; in two patients no cervical scraping was 
taken; in three the scraping taken was lost for analysis and one control patient was 
excluded because of complex atypical hyperplasia of the endometrium. The specimens 
of 98 patients, 53 squamous cell cervical cancer patients and 45 controls were used for 
further analysis. FIGO stage lA cervical cancer was diagnosed in 5 (9.4%); stage 181 in 
20 (38%); stage 182 in 3 (5.7%); stage IIA in 5 (9.4%); stage l iB in 14 (26%); stage I l l  
i n  5 ( 1  0%) and stage IV i n  1 (1 .9%) of the 53  cervical cancer patients. Indications for 
hysterectomy were uterine myomas in 20 (44%}, uterine prolapse in 20 (44%), 
menometrorrhagia in 4 (8.9%) and severe dysmenorrhea in 1 (2.2%) of the 45 controls. 
The cervical cancer patients had a median age of 46 years (IQR 37-59}, the controls of 
49 years (IQR 44-60). 
ADEQUACY OF CERVICAl SCRAPINGS TO REPRESENT THE HYPERMETHYLATION STATUS 
OF THE UNDERLYING CERVICAl EPITHELIUM 
In order to assess whether cervical scrapings reflect the hypermethylation status of the 
underlying cervical epithelium we performed QMSP analysis on cervical scrapings and 
paired fresh frozen tissue samples. DNA qual ity was sufficient to perform QMSP in 89 
(48 cervical cancer scrapings and 41 control scrapings) of the 98 available scrapings. 
Paired fresh frozen tissue samples with sufficient DNA qual ity were available of 39 
patients (2 1 cervical cancer and 1 8  control samples); in 23 control cervices the 
epithelial orientation was insufficient to dissect epithelium from surrounding stromal 
tissue; in 21 cervical cancer patients no fresh frozen tissue sample was taken because 
of possible interference in the diagnostic process and in 1 3  an insufficient percentage 
(<75%) of cancer cells was present. The observed ratios between methylated DNA and 
reference DNA of cervical scrapings were compared with the ratios observed in fresh 
frozen tissue samples. In a total number of 1 56 (39 samples x 4 different genes) paired 
QMSP results the QMSP result of scraping and paired tissue corresponded in 1 52 (97%) 
analyzed pairs (Table 2). 
Table 2: Correspondence of QMSP results in cervical scrapings with QMSP results in paired fresh frozen tissue samples 
Gene Number of Number of Number of Number of 
('·Positives (·Negatives NC'- Positives NC -Negatives 
APC 9 27 3 0 
DAPK 1 4  25 0 0 
MGMT 3 35 0 










All three noncorresponding positive scrapings were found in controls and in two of 
these three B-actin DNA was much higher for the scraping than for the corresponding 
tissue sample (25 ng more B-actin DNA in the scraping than in the tissue sample in 
one sample and 1 1  ng more in the other sample). Spearman correlation coefficients 
were calculated for the genes with positive results in the 39 paired samples. High 
correlation coefficients were observed (0.80 (p<0.001 ) for A PC, 0.98 (p <0.001 ) for 
DAPK and 0.83 (p<0.001 ) for MGMT), indicating that high hypermethylation ratios 
were present in scrapings from patients also harboring tumors with high 
hypermethylation ratios as i l lustrated for APC and DAPK in figure 1 .  Comparable 
correlation coefficients were obtained when cervical cancer samples and control 
samples were analyzed separately. It was concluded that the hypermethylation status of 
cervical epithelium is well represented by cervical scrapings. 
Figure 1 A: APC 
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CLINICAL USE OF QMSP IN CERVICAL SCRAPINGS FOR CERVICAL CANCER DETECTION 
In order to assess the possible clinical use of QMSP in cervical scrapings for cervical 
cancer detection, we performed QMSP on cervical scrapings and compared results 
obtained in cancer patients with results obtained in controls. All available 89 scrapings 
with sufficient DNA quality were included in further analysis since cervical scrapings 
represent the hypermethylation status of the underlying epithelium wel l .  Methylated 
APC was detected in 26 (54%), DAPK in 35 (73%), MGMT in 5 (1 0%) and GSTP1 in 
one (2%) of 48 cervical cancer scrapings. In 41 control scrapings methylated APC was 
ampl ified in 1 6  (39%), DAPK in 2 (4.9%, p<0.001 ), MGMT in 6 (1 5%) and GSTP1 in 
none. Methylation ratios are i l lustrated in figure 2 for APC and DAPK. 
The ratio cutoff value for each individual gene to be called 'screen positive' was 
arbitrarily defined to be above the highest ratio observed in controls. APC ratios were 
'screen positive' in 6 ( 13%), DAPK ratios in 26 (54%), MGMT in two (4.2%) patients 
and GSTP1 in one (2.1 %). Three patients were 'screen positive' for more than one 
gene, two for DAPK and APC and one for DAPK and MGMT. Overal l  32 of 48 (67%) 
cervical cancer patients were 'screen positive' for at least one gene. When cutoff values 
for all genes were based on the 95th percentile observed in controls, 5 (1 2%) controls 
would be 'screen positive' for at least one gene and 35 (73%) of the cervical cancer 
patients. When a fixed cutoff value of 1 00 (average DNA quantity of methylated gene 
of interest I average DNA quantity for internal reference gene 8-actin ) x 1 0000=1 00) 
for each gene was chosen, positives were only observed for APC (n=4 (8.3%)) and for 
DAPK (n=1 2 (25%)}, and 1 5  (31 %) patients were 'screen positive' for at least one of 
these two genes. 
M ORPHOLOGIC PAP-SMEAR CLASSIFICATION AND REAL-TIME QMSP 
For comparison with cytomorphological screening we used the cutoff values as defined 
above the highest control, because this appeared to be the optimal balance between 
sensitivity and specificity. 
CONTROLS 
For the 45 controls a morphologic Pap-smear classification was not obtained for nine 
because the cervical scrapings of five controls were not available and another four 
scrapings were inadequate for cytomorphologic assessment. Al l four inadequate 
scrapings had sufficient DNA input to perform QMSP. Although the cervical epithelium 
of all controls was histologically diagnosed to be normal, six scrapings were 
cytomorphologically classified with borderline dyskaryosis (comparable to ASCUS)(Table 
3). In five of these six DNA input was sufficient to perform QMSP and all these 
scrapings were negative (partly due to our definition). Three of the four scrapings with 
insufficient input DNA for QMSP were taken from control patients operated on because 
of prolapse uteri and one was taken from a control patient with myomas. 
Table 3: Morphological Pap-smear classification related to hypermethylation results in cervical scrapings of control patients. 
Morphologic classification Number of patients Sufficient' DNA Screen positive' 
No dyskaryosis 30 27 0 
Borderline dyskaryosis 6 0 
Inadequate 4 4 0 
Not assessed 0 
Total 45 41 0 
a adequate DNA input. defined as 8-actin DNA above 225 pg. 
b 'soeen positive' is hypermethylation status defined as <! 1 of 1he analyzed tumor suppressor genes positive above 1he 
defined cut off value 
CANCER PATIENTS 
In the 53 cancer patients a morphologic Pap-smear classification was not obtained for 
ten because the cervical scrapings of two cancer patients were not available for 
classification and another eight scrapings were inadequate for cytomorphologic 
assessment. Of these eight cervical cancer scrapings seven had sufficient DNA input for 
QMSP of which three showed 'screen positive' ratios for at least one of the four genes 
1 1 . 
1 1 2 
analyzed. Four cervical cancer scrapings yielded insufficient DNA input even though the 
sample was adequate for cytomorphological assessment. In three of these very few 
dysplastic cells were seen and in the other two scrapings many dysplastic cells 
accounted for the dysplastic morphological result. One cervical cancer patient was 
underdiagnosed by cytomorphological assessment which showed only borderline 
dyskaryosis (Table 4). In this borderline dyskaryotic scraping DNA qual ity was sufficient 
for QMSP, however, no 'screenpositive' ratio was observed for one of the four evaluated 
genes, although DAPK amplification was present in the scraping. Of this patient no 
tissue sample was available for analysis. 
Table 4: Morphological Pap-smear class1ficat1on related to FIGO stage and hypermethylaiiOn results in cerv1cal scrapings of 
cervical cancer patients. 
Morphologic classification Number FIGO stage Sufficient Screen 
of patients DNA input ' positive' 
lA IB/IIA IlB-lV 
Borderline dyskaryosis 0 
Severe dyskaryosis/CIS 1 9  4 1 0  1 B  1 1  
Squamous cell cancer 23 1 2  1 1  20 1 7  
Inadequate B 4 3 
Not assessed 2 2 
Total 53 2B 20 48 32 
a adequate DNA input, defined as B-actin DNA above 225 pg. 
b 'screen positive' for hypermethylatlon IS defined as � 1 of the analyzed tumor suppressor genes positive above the 
defined cutoff value 
DISCUSSION 
Important drawbacks of conventional screening for cervical cancer have spurred the 
search for continued improvement of diagnostic accuracy of the Pap test. In this 
feasibil ity study we show that cervical scrapings can be used to detect 
hypermethylation of tumor suppressor genes in cervical cancer because the 
hypermethylation status of the tumor was well represented by cervical scrapings and 
67% of the cervical cancer patients could be identified by QMSP for APC DAPK, 
MGMT and GSTP1 .  
The four tumor suppressor genes analyzed i n  the present study were chosen because 
promoter hypermethylation and transcriptional repression of these genes might 
mediate tumorigenesis as demonstrated in cervical and other squamous cell cancers by 
conventional MSP.1 1 •12•19 MGMT is a DNA repair gene, GSTP1 is a detoxifying gene, 
DAPK is a proapoptotic gene and potentially inhibits metastasis and APC mediates 
prol iferative signals.2226 Analyzing paraffin embedded tissue samples by conventional 
MSP demonstrated hypermethylation of APC DAPK and MGMT in 31 %, 61 % and 
1 0% of squamous cell cervical cancers, respectively.11 These percentages correspond 
well with our observations by analyzing cervical scrapings with QMSP. Adenocarcinoma 
subtypes of cervical cancer have distinct hypermethylation patterns.11 GSTP1 
methylation was detected in 4 of 19  cervical cancer tissues of unknown histological cell 
type, 12 whereas in our series of 48 squamous cell cervical cancer patients GSTP 1  
hypermethylation was demonstrated i n  only one patient. GSTP1 may be  especial ly 
associated with the adenomatous cell type, as GSTP1 is frequently present in prostate 
adenocarcinoma, while it was demonstrated in only 3 of 73 transitional cell carcinoma 
samples of bladder cancer patients.21.28 
Our study shows that cervical scrapings represent the hypermethylation status of 
underlying cervical epithelium well, given the high correlation coefficients between 
hypermethylation ratios of scrapings and tissue samples for al l  genes analyzed. No 
other data are available on a direct comparison between paired cervical scrapings and 
underlying tissue samples. Chan et a/. showed frequent methylation of RARB, DAPK, 
E-cadherin, P 1 6, P 15, GSTP1  and MGMT in urinary bladder cancer and 21 paired 
voided urine samples.28 MSP analysis in voided urine resulted in no noncorresponding 
positives when compared to paraffin embedded tumors. However, noncorresponding 
negative results were frequent (1 7 (1 9%) of 88 paired MSP analyses). Still, MSP 
analysis for 7 genes was more sensitive for detection of bladder cancer than 
morphologic assessment of urine. Jeronimo et a/. analyzed GSTP1 hypermethylation in 
voided urine and frozen or paraffin embedded tissue samples of patients with prostate 
cancer by MSP and QMSP and showed that in urine no noncorresponding positives 
were observed, but noncorresponding negatives were frequent (SO (73%) and 42 (61 %) 
of 69 paired analyses with MSP and QMSP, respectively).27 
1 13 
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In our study on cervical scrapings no noncorresponding negatives were observed for 
APC, DAPK and GSTP1 and only one noncorresponding negative was observed for 
MGMT. Testing cervical scrapings for cancer by molecular changes-based assays wil l 
l ikely continue to give rise to false negatives, especially due to sampling errors. Even 
with sensitive molecular assays, false negatives will occur if no tumor cells are collected 
by scraping the cervix. However, our data show that only a very low number of 
dysplastic cells appears to be necessary for an adequate QMSP since DNA input was 
sufficient for QMSP in seven of eight cervical cancer scrapings that were inadequate for 
cytomorphological assessment while three of these seven were 'screen positive' .  
For DAPK no noncorresponding positives were observed in scrapings. MGMT and 
GSTP1 analysis hardly contributed to the identification of cervical cancer patients by 
QMSP on cervical scrapings and for APC three noncorresponding positives were 
observed. For two of these three the explanation for the conflicting results may be the 
higher (> 1 1  ng more B-adin DNA input) 8-actin DNA levels in the scrapings than in 
the tissue samples. However, the three false positive results could also have been the 
result of technical failure in the tissue samples, meaning that the tissue samples were 
APC hypermethylation positive although not detected by QMSP. Another explanation 
may be that APC hypermethylation was positive in non cervical cancer cells. APC 
methylation has been demonstrated in several non-neoplastic tissues, as has also been 
shown for DAPK.19-31 In the present study DAPK was the gene that was the most 
cervical cancer sensitive and specific gene despite its detection in two controls who 
both had normal cervical epithelium as confirmed by final histopathologic review. 
Cervical scrapings, apart from cervical epithelial cells, may also contain vaginal 
epithelial cells, cells of the endometrium and leukocytes. Although methylation in non­
neoplastic cells may be the reason for some noncorresponding positive results or 
positive results in controls we still expect consequences for the use of QMSP as a 
screening tool to be low. Mal ignant cells usually have significantly higher methylation 
levels when positive than methylated non-malignant cells. By expressing methylation 
results as a ratio with a reference gene QMSP takes advantage of this characteristic.32 
A key issue for molecular diagnosis is the abi lity to detect cancer cells missed by routine 
cytopathology. On direct comparison cytomorphologic assessment underestimated one 
case of stage IB disease in our study, which is not surprising since false-negative rates of 
the conventional Pap-smear are reported to be between 2 and 40%.1 4·5 This 
morphologically false negative smear was not 'screen positive' for QMSP. because the 
DAPK/8-actin ratio was below cutoff and methylation for none of the three other 
genes was detected. However, when more genes would have been avai lable for 
analysis, QMSP might have been able to identify this cervical cancer case, because 
sample adequacy was sufficient for QMSP. 
In our series of cervical cancer patients the frequency of the cytomorphologic results 
'severe dyskaryosis/carcinoma in situ' may seem high (37%) in comparison to other 
studies with conventional Pap-smears. One of the consequences however, of 
manufacturing Pap-smears by cytospin, as was performed in our study, is that mucus 
and debris are largely washed away. In conventional Pap-smears a background of blood 
and tumor debris distinguishes a cancer smear from a carcinoma in situ smear. 
Furthermore, smears classified as severe dyskaryosis/carcinoma in situ were not 
considered by us to be underestimates, because these results lead to immediate referral 
to a gynecologist. 
Apart from the possible identification of cervical cancer patients, missed by cytology, 
QMSP on cervical scrapings may also have the advantage of hardly any false positive 
results in women with normal cervical epithelium. Although a l l  cervical epithelia of 
control patients were confirmed to be normal, 1 3% of the paired cervical smears was 
cytologically classified with borderl ine dyskaryosis. All controls were ' screen negative' 
for QMSP. Because this 1 00% specificty was partly due to the definition we used to set 
cutoff values, future studies are warranted to assess whether the promise of few false­
positives by QMSP in cervical cancer screening wil l  hold, which of course wil l largely 
depend on how cutoff values wil l  be defined. In our setting, analyzing patients already 
referred because of cervical cancer and controls, the choice of a cutoff for all genes 
tested above the highest ratio observed in controls represented the optimal balance 
between sensitivity and specificity. The distributions of the calculated ratios (figure 2) 
show that in the future, the choice for a 'screen positive' cutoff value may best be 
made separately for each gene. APC appears to be less sensitive and specific than 
DAPK, however, high (above 1 00) APC ratios may also be very specific for cancer. 
Defining the cutoff value for APC above 1 00 wil l  improve specificty. However, sensitivity 
wil l  be lower than of DAPK and the use of APC hypermethylation for the detection of 
cervical cancer remains questionable. For future population based screening purposes 
hypermethylation ratios should be determined by comparing large series of healthy 
women with series of cervical intraepithelial neoplasia (CIN) and cervical cancer 
patients and by constructing receiver operating characteristic curves in large preclinical 
populations. 
Theoretically, QMSP appears to be very suitable as a cervical cancer detection technique 
because the PCR reaction is amenable to high-throughput techniques allowing the analysis 
of close to 400 samples in less than 2 hours without requirement for gel-electrophoresis. 
The identification of 67% of cervical cancer patients by QMSP for APC, DAPK. MGMT 
and GSTP1 demonstrates that it wil l  be necessary to identify other genes more specifically 
methylated in (cervical) cancer to compose a both sensitive and specific cervical cancer 
hypermethylation panel. The candidate tumor suppressor gene Tumor suppressor in lung 
cancer 1 (TSLC1) may be such an interesting candidate. Recently Steenbergen et a/. 
showed that methylation of TSLC1 was present in 59% of 49 cancer tissues, 35% of 20 
high grade CIN lesions and in none of 1 1  low grade CIN lesions.33 
QMSP on cervical scrapings is a promising new diagnostic tool for the detection of 
cervical cancer and wil l improve as more genes specifical ly methylated in cervical 
cancer are identified and added to the assay. 
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Cervical cancer represents the third most frequent gynecologic malignancy among 
women worldwide, with the highest incidence rates in less developed countries.' 
Premalignant cervical lesions or cervical intraepithelial neoplasia {CIN) are subdivided 
in low {CIN 1), moderate {CIN I I) or high {CIN I l l) grade lesions, based on morphologic 
criteria. Most CIN I lesions will regress spontaneously, while 20-45% of untreated CIN 
I I/ I I I  lesions wi l l  progress to cervical cancer when left untreated.2 
The primary risk factor for CIN and invasive cervical cancer is infection with oncogenic 
human papil lomavirus {HPV). The oncogenic HPV E6 and E7 proteins are involved in 
cervical carcinogenesis by their potential to inactivate the tumor suppressor gene 
products p53 and pRb, respectively. E6 and E7 thereby prevent cell cycle arrest and 
intrinsic, p53-dependent apoptosis {programmed cell death), thus allowing uncontrolled 
cell-cycle progression, resulting in an imbalance between proliferation and apoptosis 
which indeed has been observed during cervical carcinogenesis.3 Apart from many other 
cellular proteins involved in apoptosis, activation of apoptotic pathways may also occur 
by binding of apoptosis-inducing 'death ligands' such as Fas ligand (Fasl) and tumor 
necrosis factor-related apoptosis-inducing ligand {TRAIL) to their cognate cell-surface 
death receptors, Fas and DR4/DR5, respectively.4 When FasL binds to Fas an intracel lular 
apoptotic cascade is activated.5 The same accounts for TRAIL, but TRAIL can interact 
with four distinct receptors. DR4 {TRAIL-Rl ) and DRS {TRAIL-R2/TRICK2) have 
apoptosis-inducing activity, whereas DcR1 (TRAIL-R3/TRID) and DcR2 (TRAIL­
R4/TRUNDD), the so-called decoy receptors, can bind TRAIL but lack functional death 
domains and thus are unable to induce apoptosis.6 
Expression of FasL, TRAIL and their receptors has been reported in many normal 
(epithelial) cells and neoplastic cells.7 " FasL has been impl icated in immune evasion of 
cancer cells, while the physiological role of Fas extends beyond that exerted on immune 
cells and is involved in the induction of physiological apoptosis in non-immune cells.12 13 
The physiological function of TRAIL or TRAIL-receptors is less well understood. No data 
are available on the expression and localization of FasL, TRAIL and the receptors at 
different stages of cervical carcinogenesis in relation to proliferation and apoptosis. In 
the present study we investigated whether the imbalance between proliferation and 
apoptosis is related to death ligands and death receptors expression, in a series of CIN 
and cervical cancer samples, representing different stages of cervical carcinogenesis. 
PATIENTS AND M ETHODS 
TISSUE COLLECTION 
Stored paraffin embedded tissue samples of patients treated in the University Hospital 
Groningen for cervical neoplasia between 1 988 - 2001 were available for research. 
Eligible for our study were all specimens from patients treated in the University 
Hospital Groningen for an abnormal cervical smear showing at least borderline 
dyskaryosis (which is comparable to ASCUS (atypical squamous cells of undetermined 
significance) in the Bethesda classification system), classified according to a modified 
Papanicolaou system14 and all specimens from patients treated for invasive squamous 
cell cervical cancer. 
Tissue samples of patients with borderline, mild or moderate dyskaryosis were derived 
from either colposcopically directed biopsies or diathermic loop excision of the 
transformation zone following diagnosis of at least CIN I I .  Patients with severe 
dyskaryosis were treated with loop excision without preceding colposcopy taken 
biopsies. Cervical neoplasia was classified according to the most severe lesion found on 
histological examination of biopsy and loop excision specimens according to 
international criteria.15 Patients with lesions of adenomatous or adenosquamous cell 
type were excluded from selection. Tissue samples of patients with squamous cell 
cervical cancer were derived from biopsies taken during gynecological examination 
under general anesthesia for clinical staging or from radical hysterectomy in patients 
with FIGO stage IB/IIA. Clin icopathologic characteristics of the patients from whom 
cervical cancer samples were analyzed, are summarized in Table 1 .  
Table 1: Characteristics of the studied cervical cancers 
FIGO stage Number of Depth of Tumor Poorly lymph node 
samples invasion > 5 em size > 4mm differentiated metastases 
lA 4 0 0 
IB 1 7  10  9 4 5 
IIA 0 2 
liB 
Clinical and histologic data of all patients were prospectively stored in a computerized 
database and from this database specimens from patients of the various groups were 
randomly selected for the present study: 1 1  normal cervices I CIN 0 (despite of an initial 
abnormal cervical smear no dysplasia was detected on histopathologic examination), 
1 5  CIN I, 1 5  CIN I I, 1 3  CIN Ill and 25 (microinvasive) squamous cell cervical cancer 
lesions. 
IMMUNOSTAINING 
For immunostaining 4 �m sections were cut and mounted on APES (amino-propyl­
ethoxy-silan, Sigma-Aldrich, Diesenhofen Germany) coated glass slides and 
deparaffinized by a standard procedure. As a marker for prol iferation Ki-67 expression 
1 23 
1 24 
was determined.16 lmmunostaining for Ki-67, Fas, FasL, DR4, DRS and TRAIL was 
performed as previously described.8•17 In short: antigen retrieval was performed by 
autoclave (Fas, FasL and Ki-67) or microwave (DRS) treatment, while for TRAIL and DR4 
staining no antigen retrieval was performed. All primary antibodies were di luted in PBS 
containing 1 %  BSA and 1 %  AB serum and applied for 1 hour at room temperature. 
Primary antibodies and dilutions were for Ki-67, mouse anti-MIB-1 monoclonal 
antibody (1 :400, lmmunotech, Marseille, France), for Fas mouse anti-Fas monoclonal 
antibody (1 : 1 00, clone CH-1 1 ,  Upstate Biotechnology, Lake Placid, NY), for FasL mouse 
anti-FasL monoclonal antibody (1 : 1 60, Transduction Laboratories, Lexinton, KY), for DR4 
goat anti-DR4 polyclonal antibody (1 :1 00, clone C-20, Santa Cruz Biotechnology, Santa 
Cruz, CA), for DRS rabbit anti-DRS polyclonal antibody (1 : 1 00, Oncogene Research, 
Cambridge, MA), and for TRAIL goat anti-TRAIL polyclonal antibody (1 :2S, clone K1 8, 
Santa Cruz B iotechnology). Sl ides in which the primary antibody was substituted by PBS 
containing 1 %  BSA and 1 %  AB serum served as negative controls. As positive controls 
served normal liver tissue sections for Fas, DR4 and DRS staining, normal testis sections 
for FasL staining and first trimester placenta sections for TRAIL staining. 
SCORING OF IMMUNOSTAINING AND APOPTOSIS 
For FasL, Fas, TRAIL, DR4 and DRS staining intensity was semiquantitatively scored: no 
staining/negative (0), dubious (1 ), weakly positive (2), positive (3) or intense (4). For 
statistical analysis, samples with 0 or 1 staining intensity were regarded to be negative and 
samples with 2, 3, or 4 staining intensity were regarded to be positive. The cellular 
localization (nuclear. membranous or cytoplasmic), tissue localization (in CIN: basal, 
parabasal and superficial layer) and patterns of staining (homogeneous or heterogeneous) 
were also recorded. Cells were regarded positive for Ki-67 if nucleoplasm or nucleoli were 
unequivocally stained, regardless of intensity. Apoptosis was cytomorphologically scored on 
hematoxylin-eosin stained slides, as previously described. 17 In short: morphological 
characteristics included the presence of apoptotic bodies, nuclear condensation, cytoplasmic 
shrinkage and membrane blebbing.1 7•21 Ki-67 positive cells and apoptotic cells were 
evaluated in 1 0  randomly selected high power fields (HPF) at 400x magnification. In case of 
smaller lesions at least S HPFs were evaluated. In CIN lesions full thickness of the epithelial 
layer was counted. For specimens from cancer patients HPFs were counted using an 
eyepiece grid. Per HPF. on ten consecutive horizontal lines, those cells that crossed the grid­
lines were counted. The number of apoptotic and proliferating (Ki-67 positive) cells were 
both expressed as the percentage of the total number of epithelial cells counted. 
STATISTICAl ANALYSIS 
Data analysis was performed using SPSS 1 1 .S software package (SPSS Inc., Chicago, IL). 
Associations between staining positivity, intensity or patterns of staining and the 
severity of cervical neoplasia were evaluated by the Chi-square-test or Fisher's exact 
test, when appropriate. Associations between prol iferation or apoptosis and severity of 
cervical neoplasia were evaluated by the Mann-Whitney-U-test. Differences associated 
with p-values s; O.OS were considered significant. 
RESULTS 
Kl-67 STAINING AND APOPTOSIS IN CERVICAL NEOPLASIA 
Data on Ki-67 positive cells and apoptotic cells are summarized in table 2. In CIN 0 Ki-
67 staining was only observed in the parabasal layer. In CIN 1- 1 1 1  lesions an increasing 
percentage of Ki-67 positive cells was associated with increasing grade of CIN 
(p<0.001 ) .  In  cervical cancer the highest frequency of Ki-67 positive cells was found in 
undifferentiated area's. Overal l, in cervical cancer lesions however there was a trend for 
a lower percentage of Ki-67 positive cells when compared to CIN I l l  (p=0.054). 
Table 2: Frequency of expression of death re<eptors and ligands and apotosis/prollferation in different stages of cervical 
neoplasia 
Staining Evaluable CIN 0 CIN I CIN II CIN Ill cancer 
samples 
n (%) n (%) n (% ) n (%) n (%) 
Fas 78 1 1  (100) 8 (53) 10 (67) 3 (25)' 1 1 2  (48) 
Fasl 79 9 (82) 12 (80) 9 (60) 9 (69) 20 (80) 
DR4 72 8 (89) 10 (71) 10 (83) 10 (83) 24 (96) 
DRS 71 9 (1 00) 1 4  (1 00) 9 (82) 1 1  (92) 25 (100) 
TRAIL 71 8 (89) 1 2  (86) 8 (73) 9 (75) 1 7  (68) 
median median median median median 
Proliferating cells (%) 73 1 6  25 40 48 ' 35 
Apoptotic cells (%) 77 0.4' 1 .8 1 .8 2.0 3.4 ' 
Ratio 71 0.02 0 07 0.04 0.05 0.1' 
X' for trend in CIN lesions, p=0.003 
X' for trend in (IN lesions. p<0.001 
X' for trend in CIN lesions and cervical cancer, p<O.OOl 
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In C IN 1-11 1 and cervical cancer lesions an increasing percentage of apoptotic cells was 
observed with increasing severity of neoplasia (p<0.001 ). However, in all lesions in 
which both apoptosis and proliferation percentages were assessed, the absolute 
number of Ki-67 positive cells far exceeded the number of scored apoptotic cells (fig. 
1 ). Furthermore, figure 1 clearly i l lustrates a growing imbalance between the number of 
proliferating and apoptotic cells in higher grade CIN lesions and cervical cancer. When 
the ratio between apoptosis and proliferation was calculated separately for each of the 
samples, the calculated apoptosis/proliferation ratio was higher in cervical cancer than 
in the CIN lesions (p<0.001 , table 2), indicating that the observed imbalance between 
prol iferation and apoptosis was smallest in the cervical cancer samples. These results 
suggest that higher CIN lesions and cervical cancer have not lost their apoptotic abil ity 
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FAS AND FASL IMMUNOSTAINING IN CERVICAL NEOPLASIA 
Data on Fas and Fasl staining are summarized in table 3. Fas staining was mainly 
cytoplasmatic (fine granules). In CIN 0 and CIN I lesions Fas staining was especially 
localized in the superficial epithelial layer, comprising differentiating epithelial cells, 
while in the parabasal layer only occasionally (n=1 )  weak Fas positive cells were 
observed. Overall, in CIN lesions the mere staining of Fas decreased with increasing 
severity of the lesion (p=0.003). Fas staining was decreased in cervical cancer (48%) vs. 
CIN 0 (1 00 %) lesions (p=0.003), while the higher frequency of Fas staining in cervical 
cancer compared to CIN I l l  lesions was not significant (table 2). 
Table 3: Fas and Fasl expression in the different layers of CIN and cancer 
Staining pattern CIN O CIN I CIN II CIN Il l Cancer 
n=1 1 n=1 5  n=1 5 n=12 n=25 
n (%) n (%) n (%) n (%) n (%) 
Fas 
(Para)basal* 1 (9.1) 0(0) 2(13) 0(0) 3(12) 
Superficial* 8(73) 7(47) 6(40) 0(0) 5(20) ' 
Homogeneous 2(1 8) 1 (6.7) 2(13) 3(25) 4(16) 
FasL 
(Para) basal 9(82) 1 2(80) 9(60) 5(42) 5(20) ' 
Superficial 0(0) 0(0) 0(0) 0(0) 1 (4.0) 
Homogeneous 0(0) 0(0) 0(0) 3(25) 1 4(56) 1 
• in ce!Vical cancer samples (para)basal staining is scored in undifferentiated tumor parts and superficial staining ts scored 
in differentiated tumor parts 
X' for trend in CIN lesions and ce!Vical cancer. p=0.004 
2 X1 for trend in CIN lesions and ceiVical cancer, p=0.001 
3 CIN Ill and cefVical cancer vs. CINO, CIN I and CIN II, p<0.001 
Fasl was detected as a coarse granular cytoplasmatic staining. In C IN Oil lesions Fasl 
staining was only observed in the basal and parabasal layers (see fig. 2 and table 3). In 
Fasl positive samples staining throughout the epithelial layer increased with increasing 
severity. Fasl staining throughout the epithelial layer was observed in none of the CIN 
0/1 and CIN I I  samples, in 44% of CIN I l l  and 70% of Fasl positive cervical cancer 
samples (p<0.001 ). Fas and Fasl were concurrently expressed in 1 7  of the 26 (65%) 
CIN 0 and I samples. In these 1 7  Fas and Fasl positive CIN 0/1 samples Fasl showed a 
basal/ parabasal staining pattern, whereas Fas showed inverse staining with positivity 













DR4 , DRS AND TRAIL IMMUNOSTAINING IN CERVICAL NEOPLASIA 
DR4 (coarse granules) and TRAIL (fine granules) staining was mainly cytoplasmatic. DRS 
(fine granules) staining was also cytoplasmatic but with stronger staining towards the 
nuclear membrane (fig. 3). 
Figure 3 
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DR4 staining was present in 62 of 72 (86%), DRS in 68 of 71 (96%) and TRAIL in 48 of 
71 (6S%) evaluable specimens (Table 2). In CIN Oil lesions DR4, DRS and TRAIL staining 
was associated with undifferentiated cells in the basal and parabasal layer (Table 4). In  
higher grade CIN lesions DR4 positive cells were more frequently observed throughout 
the lesions (p=0.049). There was no association between the percentage of DR4, DRS 
or TRAIL positive lesions and severity of cervical neoplasia (Table 2}, but a 
homogeneous DR4 and DR S staining pattern throughout the lesion was more 
frequently observed in cancer versus CIN lesions (p<0.0001 and p<0.0001 ). TRAIL 
staining was most intense in low grade lesions. In the 20 TRAIL-positive low grade CIN 
samples, intense staining was present in 7 (3S%), whereas 1 of 34 (2.9%) high grade 
samples showed intense staining (p=0.003). 


























CIN I CIN II 
n=1 4  n=1 1 
n(%) n(%) 
9(64) 6(55) 
1 (7) 2(1 8) 
0(0) 1 (9) 
1 1 (79) 7(64) 
0(0) 0(0) 









4(33) 1 6(64)' 
5(42) 4(1 6)' 
0(0) 0(0) 
6(50) 21 (84) . 
4(33) 5(20)' 
0(0) 1 (4) 
5(42) 1 1 (44) 
* in cervical cancer samples (para)basal staining is scored in undifferentiated tumor parts and superficial staining IS scored 
in differentiated tumor parts 
X' for trend in CIN lesions and cervical cancer. p:0.04 
CIN Ill and cervical cancer vs. CIN 0, CIN I and CIN II, p<0.001 
X' for trend in CIN lesions and cervical cancer. p:0.001 
CIN Ill and cervical cancer vs. CIN 0, CIN I and CIN II, p<0.001 
CIN Ill and cervical cancer vs. CIN 0, CIN I and CIN II, p=0.01 
CORRELATION BETWEEN STAINING PATTERNS OF THE VARIOUS PROTEINS 
The staining patterns of FasL, DR4, DRS and TRAIL showed marked similarities. 
Overlapping staining patterns were observed for FasL and DR4 in 66%, for FasL and 
DRS in 7S% for FasL and TRAIL in 63%, for DR4 and DRS in 76% and for DR4,DRS as 
well as TRAIL in 61 % of the 71 evaluable samples. The association between FasL and 
DR4, DRS and TRAIL was also observed in CIN Ill and cervical cancer samples 
separately. 
CORRELATION BETWEEN IMMUNOSTAINING AND APOPTOSIS/PROLIFERATION RATIO 
Neither Fas, FasL, DR4, DRS, nor TRAIL staining were associated with apoptosis 




In  the present study marked changes were observed for Fas, FasL, DR4, DRS and TRAIL 
staining in the different stages of cervical carcinogenesis. In low grade lesions positive 
staining for FasL, DR4, DRS and TRAIL was predominantly observed in a parabasal layer 
and for Fas in the superficial layer comprising differentiated epithelial cells. The 
frequency of homogeneous staining of FasL, DR4 and DRS throughout the epithelial 
layer increased with severity of cervical neoplasia, while Fas expression decreased with 
severity of CIN. Despite the suggested important role of death receptors and their 
ligands in apoptosis no relation was observed. 
Cel l turnover is a rapid process in cervical epithel ium. A lifespan of four to five days is 
estimated for normal cervical epithelial cells and for dysplastic cells the lifespan is 
proposed to be even shorter.22 We observed 3S% prol iferating cells in well to poorly 
differentiated cervical cancer compared to 48% in CIN I l l  which confirms the data of a 
previous report.23 Zanotti et a/. observed higher proliferation in cancer samples 
compared to CIN I l l  lesions, but only undifferentiated tumors were studied/4 In  normal 
human tissue the cell number is held constant by equal rates of cell proliferation and 
elimination. Physiological ly, cells are eliminated by apoptosis which can be induced by 
various stimuli.21 Apoptosis has not been assessed by morphological criteria in cervical 
neoplasia previously, although it is generally considered to be the reference 
standard.'8•20•26•27 Apoptosis percentages were between 1 -4 % in cervical cancer by 
TUNEL staining and 2% in CIN I l l  and 4% in cervical cancer with ISEL staining.1428 
Although we used a distinct technique our results correspond well with these reports. 
In  the present study the proportion of epithelial cells undergoing apoptotic cell death 
increased with increasing severity of neoplasia, which has been previously described for 
cervical epithelium and for epithelium of other origin.8•17 24 26 18•19 The observed higher 
percentage of apoptosis in cervical cancer compared to CIN Ill may reflect an increase 
in DNA damage which makes cells more susceptible for apoptosis. However, the higher 
percentage of apoptosis in cancer may also reflect the absence of anoikis for tissue 
homeostasis. Anoikis is detachment-induced apoptosis which occurs in the top layer of 
epithelium.15 In CIN lesions the percentage of apoptosis may have been underestimated 
because cells dying of anoikis are shed.21 In general, highest proliferation percentages 
were observed in areas with undifferentiated cells. The relatively high proportion of well 
differentiated cancers, together with anoikis, may explain why the imbalance between 
prol iferation and apoptosis seems to be more pronounced in C IN I l l  than in cervical 
cancer samples. 
Both FasL and TRAIL are death ligands that can activate apoptosis by binding to their 
cognate cell-surface death receptors, Fas and DR4/DRS. No associations between the 
mere expression of these proteins, nor with the staining patterns of these proteins and 
apoptosis or proliferation were observed. In other tissue types the expression of 
Fas/FasL or DR4/DRS/TRAIL and the degree of apoptosis was also uncorrelated.8·'7 
Despite the lack of correlation between the expression of death ligands or receptors 
and apoptosis or proliferation, we observed a change in Fas versus FasL staining 
pattern during cervical carcinogenesis. In normal epithelium or CIN I samples Fas and 
FasL showed inverse staining patterns, which was also observed by others in cervical 
lesions and has also been described for epithelium of different origin.30•31 In 
concordance with its more frequent staining in differentiated cells, Fas expression 
decreased with increasing severity of CIN lesions. Interestingly, Fas was more frequently 
expressed in cancer lesions versus CIN I l l .  Again, this last observation may be due to 
the relatively high proportion of well differentiated cancers in our study. By the loss of 
Fas expression in a subset of CIN I l l  and cancer lesions and the high expression of FasL 
some of these lesions may evade induction of apoptosis. The resulting growth 
advantage may be overcome if Fas expression could be upregulated by modulating 
drugs such as interferon-gamma or cytotoxic drugs thereby inducing paracrine or 
autocrine apotosis via interaction with FasL s 
In CIN 0 and CIN I proliferation was observed in the parabasal layer. The constitutive 
expression of FasL in the parabasal layer may therefore protect this layer from 
infiltrating Fas positive T cells and granulocytes as these cells rapidly undergo FasL 
induced apoptosis.5 The increase in homogenous expression of FasL in CIN I l l  and 
cervical cancer may play a functional role in escape from immune surveil lance. FasL was 
more intensely stained in cervical cancer compared to lower grade lesions whereas the 
opposite was true for TRAIL. In light of these results, FasL upregulation seems more 
important for escape from immune surveillance than TRAIL upregulation. FasL is 
thought to be the key death factor in death receptor induced apoptosis in immune 
cells.32 FasL is expressed on activated cytotoxic T cells and NK cells which can kil l virally 
infected cells by activating available Fas receptors.33 If HPV-infected tumor cells 
downregulate their expression of Fas, they may escape immune defence. Conversely, 
expression of FasL on the surface of tumor cells might lead to the kill ing of Fas­
sensitive infiltrating lymphocytes. Studies determining a relation between FasL positivity 
of cervical squamous cell carcinomas and overal l  survival have not been published yet. 
However, patients with FasL expressing cervical adenocarcinomas had a significantly 
reduced survival time as compared to patients with low FasL expressing tumors.34 
Furthermore, all metastatic cervical adenocarcinomas were found to be FasL positive, 
suggesting a role for FasL in immune evasion, progression and metastasizing potential 
in cervical cancer. 
In CIN 0 and CIN I samples expression of DR4, DRS and TRAIL was mainly observed in 
the parabasal layer. Overlapping staining of TRAIL and its death receptors was also 
observed by others in cervical epithel ium and in epithel ium of different origin.8•28 
Several studies have demonstrated that the TRAIUTRAIL receptor system may play an 
important role in the elimination of virus-infected cells, which may implicate persistent 
HPV-infected cervical basal and suprabasal cell layers. Cells infected by human 
immunodeficiency virus or cytomegalovirus revealed increased DR4, DRS and TRAIL 
protein expression levels rendering them more sensitive to TRAIL-induced apoptosis by 
autocrine or T-cell derived TRAIL.3� 36 We found less intense TRAIL staining and a reduced 
1 3 1  
1 32 
percentage of TRAIL-positive specimens with increasing severity of cervical lesions. 
From our results we can not conclude that loss of TRAIL expression plays a role in 
cervical carcinogenesis, but studies using TRAIL-deficient mice have demonstrated that 
TRAIL is important in controlling tumor growth.37 38 The concomitant expression of TRAIL 
and TRAIL-receptors may also suggest that either TRAIL or TRAIL-receptors are not 
expressed on the cell surface or the presence of intrinsic resistance to TRAIL. The 
mechanisms of resistance of normal cells to TRAIL have been shown to vary between 
different cell types.39 The cell kil l ing properties of TRAIL and FasL have made their 
cognate cell-surface death-receptors exciting targets for drug development. For 
treatment of cervical neoplasia, Fas does not seem to be an interesting target because 
it was not expressed in the parabasal layer. DR4 and DRS may be better targets as they 
were expressed in nearly all cervical neoplastic lesions, while the TRAIL decoy receptor 
genes appeared to be at least partially methylated in most cervical cancers.40 
In conclusion, loss of Fas and deregulation of FasL, DR4, DRS and TRAIL in the (IN­
cervical cancer sequence suggest a possible functional role of these death ligands and 
receptors during cervical carcinogenesis. Their observed frequent expression present 
DR4 and DRS as promising targets for innovative therapy modalities in cervical cancer. 
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Cervical cancer is an important cause of death in women worldwide. Infection with 
high-risk human papillomavirus (HPV) has been identified as the main etiologic factor 
in cervical carcinogenesis.1 An estimated number of 370,000 - 470,000 new cases occur 
per year, and 230,000 women die of cervical cancer per year2·• thus being the third to 
second most common cancer in women with large incidence differences between 
developed countries with cervical cancer screening programs and less developed 
countries without such programs. The cumulative lifetime risk for a woman to develop 
cervical cancer varies from 0.4% in Israel to 5.3% in Colombia.5 Cervical cancer 
develops from cervical intraepithelial neoplasia (CIN). A CIN-Iesion can either regress, 
persist or progress towards (micro)invasive carcinoma. Most of the low grade CIN 
lesions (CIN I) wi l l  regress, while in the long-term 1 2% to 40% of high grade CIN 
lesions (CIN 1 1/1 1 1 }  wi l l  progress to squamous cell carcinoma.6 7 Because no markers exist 
that identify those lesions that will progress, clinicians have felt compelled to treat at 
least all CIN I I/I I I  lesions. 
Cytomorphologic examination of cervical smears is the most widely applied screening­
method for cervical cancer and its precursors. Disadvantages are high numbers of false­
negative and false-positive cervical smears. Parameters in cervical scrapings are needed 
which more accurately predict the presence of higher grade CIN or cervical cancer 
lesions to improve cervical cancer screening. 
In Chapter 2 available data on new approaches to cervical cancer screening such as 
quantitative cytochemistry, and detection of HPV DNA, loss of heterozygosity, 
microsatell ite alterations, telomerase activity and DNA methylation were summarized. 
The potential of these approaches to replace or augment current Pap-smear screening 
was discussed. It was concluded that to date no other diagnostic tools are available 
that can cost-effectively replace or augment current Pap-smear screening. However, 
improvements may lay in the future. Implementation of liquid based cytology would aid 
the development of new technologies that can be performed on cervical scrapings. HPV 
DNA detection stands closest to implementation in nation-wide screening programs of 
all markers reviewed, but may also have important drawbacks. An interesting new 
technology that should be further developed is the detection of promoter 
hypermethylation of tumor suppressor genes by quantitative methylation specific PCR 
(see Chapter 7). 
Telomerase is an enzyme that can form new short stretches of repeat nucleotides at the 
telomeric ends of chromosomes that were lost with each round of replication. Studies 
in tumour cell l ines, as well as in human tumour specimens have shown that, in 
contrast to normal somatic cells, the vast majority of malignant cells (>90%) are 
characterized by increased telomerase activity.8•9 Therefore determination of telomerase 
activity has been suggested for early cancer detection. In Chapter 3 we studied 
whether detection of either telomerase and its components, or high risk human 
papil lomavirus (HPV) are of value in predicting the presence of CIN I IIII I in patients 
referred because of cervical cytology reports showing at most moderate dyskaryosis. 
The cervical smears of 50 patients with cytological borderline, mild or moderate 
dyskaryosis were analyzed. Telomerase activity was assessed by a commercially 
avai lable TRAP-assay and its components human telomerase RNA (hTR) and human 
telomerase reverse transcriptase (hTERT) by reverse transcriptase-PCR. HPV was 
detected by GPS+/6+ PCR enzyme immunoassay. Histological findings on colposcopy 
guided biopsies or excised cervical tissue were regarded as pathological final d iagnosis. 
Sensitivity and specificity for detecting CIN I III I I  were calculated. Twenty-eight patients 
(46%) were diagnosed with CIN 1 11 1 1 1 .  In the patients diagnosed with CIN 1 1/ 1 1 1 ,  
telomerase activity was detected in none, hTR in 88%, hTERT in 23% and h igh-risk HPV 
in 79%. As a diagnostic test none of the described analyses combined a sensitivity of at 
least 90% with a specificity of at least 90%. Despite the small numbers, calculation of 
the 95% confidence intervals excluded a combined sensitivity and specificity of at least 
90% for any of the evaluated parameters. Therefore neither detection of telomerase or 
its components, nor detection of high risk HPV seem suitable for the triage of patients 
with borderl ine, mild and moderate cytological dyskaryosis. 
In order to prevent increased morbidity associated with double modality treatment, 
early stage cervical cancer patients should be offered radical surgery only when there is 
a low likelihood for adjuvant radiotherapy. Chapter 4 describes whether serum 
Squamous Cell Carcinoma-antigen (SCC-ag) analysis al lows better preoperative 
identification of a group of patients with a low likelihood for adjuvant radiotherapy 
than currently used clinical parameters. In a historical cohort study, FIGO stage, tumor 
size and preoperative serum SCC-ag levels, as determined by enzyme immunoassay, 
were related to the frequency of postoperative indications for adjuvant radiotherapy in 
337 surgically treated FIGO stage 1 8/IIA squamous cell cervical cancer patients. 
In patients with normal preoperative SCC-ag 1 6% of stage 181  and 29% of stage 
1 82/I IA had postoperative indications for adjuvant radiotherapy, in contrast to 57% of 
stage 181  and 74% of stage 1 82/IIA patients with elevated (> 1 .9 ng/ml) serum SCC-ag 
(p<0.001 ). Serum SCC -ag was the only independent predictor for a postoperative 
indication for radiotherapy (odds ratio 7.1 , 95% 0 4.2-1 2, p<0.001 ) .  Furthermore, in 
stage 181  patients that d id not have indications for adjuvant radiotherapy 1 5% of the 
patients with elevated preoperative serum SCC-ag levels recurred within 2 years in 
contrast to 1 .8% of the patients with normal serum SCC-ag levels (p=0.02). It was 
concluded that determination of serum SCC-ag in early stage cervical cancer patients 
allows more refined preoperative estimation of the likelihood for adjuvant radiotherapy 
than current clinical parameters and simultaneously identifies patients at high-risk for 
recurrence when treated with surgery only. Therefore, preoperative serum SCC-ag 
analysis deserves implementation in clinical decision making. 
Three different infectious agents of which a possible involvement in cervical 
carcinogenesis has been suggested in literature were studied. First, Chapter 5 





bacterial vaginosis in patients with cytological abnormalities of the uterine cervix. 
Therefore 280 patients with dyskaryotic smears (mild, moderate or severe dyskaryosis) 
were asked to participate in the study, using a questionnaire to obtain data on smoking 
habits and sexual history. Bacterial vaginosis was diagnosed if the vaginal discharge 
produced a fishy odor upon alkalin ization and if clue cells were seen in the wet smear. 
Furthermore, cervical scrapes were analyzed for the presence of HPV DNA, and cervical 
tissue specimens were analyzed for the presence and severity of (intraepithelial) 
neoplasia and the proliferation rate (mitotic index) of the lesion. Chlamydia 
trachomatis was identified by culture of an endocervical swab. Bacterial vaginosis was 
found in 56 (20%) of the patients. The presence of bacterial vaginosis was associated 
with the number of cigarettes smoked per day, age at first sexual intercourse, l ifetime 
number of sexual partners, and current Chlamydia trachomatis infection. Number of 
cigarettes currently smoked per day and lifetime number of sexual partners were 
independent risk factors for the presence of bacterial vaginosis. There was no relation 
between the presence of bacterial vaginos1s and HPV infection. Bacterial vaginosis did 
not influence the severity or the mitotic index of the neoplastic lesion found. In 
conclusion, in patients with dyskaryotic cervical smears, the prevalence of bacterial 
vaginosis is not increased, and bacterial vaginosis does not influence histologic 
changes. Bacterial vaginosis is therefore unlikely to be important in the etiology of 
cervical neoplasia, despite the similarity between its epidemiologic features and those 
of cervical HPV infection and cervical neoplasia. 
Chlamydia trachomatis was the second infectious factor possibly involved in cervical 
carcinogenesis that was studied. In Chapter 6 it was explored whether the presence of 
Chlamydia trachomatis antibodies was associated with the severity of neoplastic 
lesions in patients with cervical dyskaryosis. In a cross-sectional study serum samples 
were analyzed for antichlamydial antibodies by enzyme immunoassay. Cervical 
neoplasia was graded histological ly. In 296 eligible patients referred because of cervical 
dyskaryosis between 1 988-1 993 no association was found between increasing grade of 
CIN and the presence of antichlamydial antibodies. The proportion of patients with 
antichlamydial antibodies was higher in patients with (micro)invasive carcinoma (1 3/1 4 
(93%)) than in patients with CIN (1 01 /282 (36%)). As the high prevalence of 
antichlamydial antibodies in patients with cervical carcinoma was not consistent with 
prevalences reported in recent l iterature, a second group of patients was analyzed (331 
eligible patients in the period 1 995-1 999) in which the high prevalence of 
antichlamydial antibodies in patients with cervical carcinoma was not confirmed. These 
results suggest that the presence of circulating antichlamydial antibodies is not 
associated with the severity of neoplastic lesions and it seems unlikely that Chlamydia 
trachomatis has a role in the progression of cervical neoplasia. 
The last and most important infectious parameter studied was HPV. HPV infection is the 
first identified essential step in cervical carcinogenesis, meaning that cervical cancer, 
with very rare exceptions, can not develop without HPV infection. Over 1 00 HPV types 
have been identified of which more than 35 types can be found in the genital tract and 
of which 1 8  are associated with cervical carcinogenesis. Because of the important 
etiologic role of HPV numerous studies have been performed to identify factors 
involved in HPV infection and persistence. Different HPV detection techniques are 
available and might influence the results of epidemiologic studies. 
A previous study comprising 304 patients referred because of abnormal pap smears 
showed that the prevalence of HPV rises with increasing histological severity of 
neoplasia, more cigarettes smoked per day and higher lifetime number of sexual 
partners in patients with cervical dyskaryosis using the GPS/6 primers based HPV PCR. '0 
Data on the lifetime number of sexual partners and smoking behavior were obtained by 
questionnaire. HPV analysis was performed on cervical scrapes obtained at the 
enrolment visit. Some years after that initial epidemiologic study the highly sensitive 
SPF1 0 primers and lnno-LiPA (line probe assay) HPV prototype research assay became 
available for the detection and typing of HPV. In Chapter 7, using the SPF1 0-LiPA 
system, we re-analyzed the stored cervical scrapings of the earlier described study 
population. H igh-risk HPV was present in 288 (95%) patients. A total of 86 (30%) out 
of these 288 patients disclosed multiple types. HPV 1 6  occurred less often in multiple 
infections than was expected on the basis of chance alone. The grade of neoplasia was 
associated with the presence of oncogenic HPV, which depended on the presence of 
HPV type 1 6. No association was found between grade of neoplasia and the presence 
of multiple HPV types. Neither the lifetime number of sexual partners nor smoking were 
associated with high-risk HPV, the five most frequent HPV types separately or the 
presence of multiple types. We conclude that the association between the detection of 
HPV and the epidemiological risk factors, as found with the GPS/6 PCR in the past, 
could not be confirmed when using SPF1 0 PCR primers and LiPA HPV genotyping. We 
suggest that the number of sexual partners and smoking may be determinants of high 
HPV viral load rather than determinants of the presence of high-risk HPV per se. 
It has become increasingly clear that silencing of tumor suppressor- or other cancer­
associated genes by methylation of CpG islands is a common feature of human cancer 
including cervical cancer. In addition to the functional impl ications of gene inactivation 
in tumor development, these aberrant methylation patterns represent interesting 
targets for novel diagnostic approaches based on methylation sensitive PCR techniques 
which we tried to translate to clinical use in cervical cancer detection in Chapter 8. It 
was unknown whether a cervical scraping reflects the methylation status of the 
underlying epithelium. It was therefore unclear whether quantitative hypermethylation 
specific PCR (QMSP) on cervical scrapings could be used as a future screening method 
augmenting the current approach. The use of QMSP on cervical scrapings was explored 
by analyzing cervical scrapings and paired fresh frozen cervical tissue samples obtained 
from 53 cervical cancer patients and 45 controls. All scrapings were morphologically 
scored and analyzed with QMSP for the genes APC, OAPK, MGMT and GSTP1 .  APC 
mediates proliferative signals, DAPK is a proapoptotic gene and potentially inhibits 
metastasis, MGMT is a DNA repair gene and GSTP1 is a detoxifying gene." 1 5 To adjust 




Hypermethylation ratios of paired fresh frozen tissue samples and scrapings of cervical 
cancer patients and controls were strongly related. More cervical cancer patients than 
controls were DAPK positive (p<0.001 ). When 'screen positive' cutoff levels for ratios 
were defined to be above the highest ratio observed in controls, QMSP in cervical 
scrapings identified 32 of 48 (67%) cervical cancer patients. This feasibility study, in 
which cervical scrapings were analyzed for only four genes, demonstrates that QMSP 
holds promise as a new diagnostic tool for cervical cancer. The addition of more genes 
specifically methylated in cervical cancer are necessary to improve the sensitivity of the 
assay. 
Increasing imbalance between prol iferation and apoptosis is thought to be important in 
cervical carcinogenesis. The death ligands FasL and tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) induce apoptosis by binding to their cognate cell­
surface death receptors Fas or death receptor (DR) 4 and DRS. The aim of our study 
described in Chapter 9 was to examine possible changes in expression of these death 
ligands and their receptors at different stages of cervical carcinogenesis. The 
immunohistochemical expression and localization of Fas/FasL and DR4/DRS/TRAIL were 
assessed in 1 1  normal, 1 S  cervical intraepithelial neoplasia (CIN) grade I, 1 S  CIN I I ,  1 3  
CIN I l l  and 2 S  (microinvasive) squamous cell cervical cancers. The number of apoptotic 
cells was determined by the use of morphological criteria and the number of 
proliferating cells by counting Ki-67 positive cells. A marked increase in proliferation as 
well as apoptosis percentage was found with increasing severity of neoplasia. In 
normal cervix and CIN I samples FasL, DR4, DRS and TRAIL staining was mainly 
observed in the basal/parabasal layer, whereas Fas staining was local ized in the 
superficial, more differentiated epithelial layer. Frequency of Fas positive staining 
decreased with increasing severity of CIN. In contrast, homogeneous FasL, DR4, DRS 
and TRAIL expression throughout the lesions was more frequently observed in CIN Il l 
and cervical cancer. FasL, DR4, DRS and TRAIL staining patterns were correlated, 
although TRAIL expression was more intense in low grade lesions. No association was 
found between death receptor or ligand expression with the percentage of apoptosis or 
proliferation. The loss of Fas and the deregulation of FasL, DR4, DRS and TRAIL in the 
CIN-cervical cancer sequence suggest a possible functional role of these death ligands 
and receptors during cervical carcinogenesis. Their observed frequent expression 
present DR4 and DRS as promising targets for innovative therapy modalities in cervical 
cancer. 
FUTURE PERSPECTIVE 
In the Netherlands a population-based cervical cancer screening program exists. 
Women aged 30-60 years are invited to be screened for cervical cancer once every five 
years. Cervical smears are taken by general practitioners. Patients are referred to a 
gynecologist for colposcopic examination if abnormalities are found during screening. 
Current morphology based cervical cancer screening is associated with significant false­
positive and false-negative results. To date no other diagnostic tools are available of 
which is known that they can cost-effectively replace or augment current Pap-smear 
screening. In countries with low prevalence of cervical cancer, as in the Netherlands, it 
is hard to determine whether the decrease in cervical cancer deaths as a results of 
screening counterbalances the negative effects of screening. Cervical cancer screening 
will especially be of benefit in women in countries with high cervical cancer 
prevalences. Pap-smear screening seems the best screening tool currently available. H PV 
DNA detection stands closest to implementation in nation-wide screening programs of 
all currently known 'markers' .  The main advantages of HPV screening would be the 
prolongation of the screening interval for HPV negative women and the possibility of 
triage for women with minor morphological abnormalities. In the next five years the 
results will become available of a Dutch radomized controlled trial that evaluates 
wether implementation of these two main advantages can improve the efficiency of 
cervical cancer screening.16 However, low specificity for (progressive) high-grade CIN 
and cervical cancer as well as negative psychological effects of knowledge of HPV 
positivity are important drawbacks. Even if the trials that are underway will show cost­
effectiveness of implementing HPV DNA testing in cervical cancer screening, new 
markers and technologies could theoretically still lead to major improvements. 
If the high false-positive and false-negative numbers of cervical cancer screening would 
be reduced it will become more beneficial to screen women, even if they live in 
countries with a low cervical cancer prevalence. An interesting new cervical cancer 
detection approach is tumor suppressor gene hypermethylation analysis by QMSP. In  
this thesis we showed that i t  has theoretical advantages over current Pap-smear 
analysis and some other new screening tools based on molecular changes. Our first 
analysis in cervical scrapings was promising. Cervical scrapings reflect the 
hypermethylation status of underlying epithelium very well. Testing for only four genes, 
already 67% of cervical cancer patients were identified by QMSP. In prostate cancer 
GSTP1 is methylated in more than 90% of the tumors and diagnostic tests are now 
being developed.17 In light of these prostate cancer results we expect it to be possible 
that for cervical cancer a panel of genes can be identified, which will cover almost all 
cervical cancer cases. The available data and expectations should spur the search for 
more genes specifically methylated during cervical carcinogenesis. Once a (cervical) 
cancer sensitive and specific hypermethylation panel is composed it will be necessary to 
define 'screen positive' cutoff values for population-based screening purposes. Together 
with sensitivity and specificity of a screening test, the positive and negative predictive 





population. It may therefore be a rational approach to let the QMSP cutoff values 
depend on the prevalence of cervical cancer in a country. Further studies should clarify 
wether QMSP can also be used to identify progressive CIN 1 1/1 1 1  lesions. 
The prevalence of cervical cancer may show a drastic change in the future, because 
primary prevention of cervical cancer by effective prophylactic HPV vaccines may 
become possible.18 When it would be implemented, HPV vaccination is supposed to 
lower the prevalence of cervical cancer and its precursor lesions dramatical ly. If 
sensitivity and specificity of our screening tools will not be changed in that situation, 
positive screen results wil l  thereby be more l ikely to represent false positives. However, 
one may sti l l  want to screen for residual CIN/cervical cancer patients in the hypothetical 
scenario that HPV vaccination is implemented. Reasons for ongoing screening may be 
that immunization will fail in some women, women may refuse to be vaccinated and 
probably only vaccines against HPV 1 6  and 1 8  will be developed. It is hard to estimate 
the prevalence of cervical cancer once HPV 1 6  and 1 8  vaccination is implemented in 
our health care system. Even when this implementation lays in the near future it will 
however take at least decades before it will result in a decrease of cervical cancer 
cases. 
In this thesis we show that it is possible to refine existing treatment protocols for 
cervical cancer by serum detection of SCC-ag. The pretreament level of serum SCC-ag in 
cervical cancer patients was already known to be of prognostic value. Determination of 
serum SCC-ag levels in patients with early stage cervical cancer also allows more 
refined preoperative estimation of the likelihood for adjuvant radiotherapy than current 
clinical parameters and simultaneously identifies patients at high-risk for recurrence 
when treated with surgery only. In our opinion preoperative serum SCC-ag analysis 
should now be implemented in clin ical decision making. 
The etiology of cervical neoplasia starts to be unraveled and new technologies may 
accelerate our understanding of cervical carcinogenesis. It will be an ongoing challenge 
to find ways by which these improvements will help us to refine screening and 
treatment policies for individual patients. 
REFERENCES 
Munoz N.  Bosch FX. de Sanjose S et al .  Epidemiologic classification of human 
papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:51 8-527. 
2 Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major 
cancers in 1 985. Implications for prevention and projections of future burden. lnt J Cancer 
1 993;55:891 -903. 
3 Einstein MH, Goldberg GL. Human papillornavirus and cervical neoplasia. Cancer Invest 
2002;20:1 080-1 085. 
4 Parkin DM, Pisani P. Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 
1 990. lnt J Cancer 1 999;80:827-841 . 
5 lsacson C, Kessis TD, Hedrick L. et al. Both cell proliferation and apoptosis increase with 
lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. 
Cancer Res 1 996;56:669-67 4. 
6 Pinto AP. Crum CP. Natural history of cervical neoplasia: defining progression and its 
consequence. Clin Obstet Gynecol 2000;43:352-362. 
7 Mitchell MF. Tortolero-luna G, Wright T. et al. Cervical human papillomavirus infection and 
intraepithelial neoplasia: a review. J Natl Cancer lnst Monogr 1 996;1 7-25. 
8 Reddy VG, Khanna N, Jain SK, et al. Telomerase-A molecular marker for cervical cancer 
screening. lnt J Gynecol Cancer 2001 ;1 1 :100-106. 
9 Kyo S. Kanaya T. Ishikawa H, et al. Telomerase activity in gynecological tumors. Clin Cancer 
Res 1 996;2:2023-2028. 
1 0 Burger MP. Hollerna H, Gouw AS. et al. Cigarette smoking and human papillomavirus in 
patients with reported cervical cytological abnormality. BMJ (Clinical Research Ed) 1 993; 
306:749-752. 
1 1  Gerson SL Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 
2002;20:2388-2399. 
1 2  McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase I I 
conjugation enzymes and regulatory mechanisms. J Pharmacal Exp Ther 2002;300:361 -366. 
1 3  lnbal B. Bialik S. Sabanay I ,  et al. DAP kinase and DRP-1 mediate membrane blebbing and 
the formation of autophagic vesicles during programmed cell death. J Cell Bioi 
2002;1 57:455-468. 
1 4  Lundberg AS, Hahn WC, Gupta P, et al. Genes involved i n  senescence and immortalization. 
Curr Opin Cell Biol 2000;12:705-709. 
1 5  Sieber OM, Tomlinson I P,  lamlum H .  The adenomatous polyposis coli (APC) tumour 
suppressor-genetics, function and disease. Mol Med Today 2000;6:462-469. 
1 6  Bulkmans NW� Rozendaal L. Snijders PJF. et al. POBASCAM, a population-based 
randomized controlled trial for implementation of high-risk HPV testing in cervical 
screenining: design, methods and baseline data of 44,1 02 women. tnt J Cancer 
2004;1 1 0:94-1 01 . 
1 7  Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hyperrnethylation in bodily 
fluids of patients with prostate cancer. Urology 2002;60:1 1 31 -1 1 35. 
1 8  Koutsky LA. Ault KA. Wheeler CM, et al. A controlled trial of a human papillomavirus type 









SAM ENVATTI NG 
Cervixcarcinoom is wereldwijd gezien een belangrijke doodsoorzaak onder vrouwen. 
lnfectie met hoog risico humaan papil lomavirus (HPV) wordt als de meest belangrijke 
etiologische factor gezien voor cervicale carcinogenese.1 Geschat kent het 
cervixcarcinoom jaarlijks 370,000 - 470,000 nieuwe gevallen en 230,000 doden.2 4 
waarmee het de derde tot tweede meest frequente vorm van kanker onder vrouwen is. 
Er bestaan grote verschillen in incidentie tussen 'westerse' Ianden met nationale 
screeningsprogramma's en ontwikkelingslanden zonder screening. Het cumulatieve 
l ifetime risico voor een vrouw om cervixcarcinoom te krijgen varieert van 0.4% in Israel 
tot 5.3% in Colombia.5 Cervixcarcinoom ontstaan uit voorloper afwijkingen, cervicale 
intraepitheliale neoplasie (CIN). CIN afwijkingen kunnen in regressie gaan, persisteren 
of progressie tot (microinvasief) carcinoom vertonen. De meeste CIN I afwijkingen gaan 
in regressie, terwijl op de lange termijn 1 2% tot 40% van de CIN 1 1/1 1 1 afwijkingen 
plaveiselcelcarcinoom van de cervix zal worden.67 Omdat er geen markers bestaan die 
aan kunnen geven welke premaligne afwijkingen progressief zullen zijn, voelen de 
meeste gynaecologen zich genoodzaakt in ieder geval aile CIN 1 1/1 1 1 afwijkingen te 
behandelen. 
Cytomorfologisch onderzoek van cervix uitstrijkjes wordt het meest gebruikt als 
screeningsmethode voor cervixcarcinoom en CIN. Nadelen hiervan zijn hoge vals 
positieve en negatieve uitslagen. Parameters die de aanwezigheid van progressieve CIN 
of cervixcarcinoom accurater aan kunnen geven en die bepaald kunnen worden in 
cervixschraapsels zijn noodzakelijk om de huidige cervixcarcinoom screening te 
verbeteren. 
In Hoofdstuk 2 werd een overzicht gegeven van de recente literatuur over het gebruik 
van nieuwe methoden om cervixcarcinoom screening te verbeteren, zoals kwantitatieve 
cytochemie, HPV DNA detectie, verlies van heterozygotie, microsatelliet veranderingen, 
telomerase activiteit en DNA methylatie. De mogelijkheden van deze benaderingen om 
de analyse van het huidige Pap-uitstrijkje te verbeteren of te vervangen werden 
bediscussieerd. De conclusie was dat er tot op heden nog geen diagnostische test 
beschikbaar is waarvan bekend is dat deze kosteneffectief ge"implementeerd kan 
worden in bestaande programma's voor cervix carcinoom screening. Verbeteringen 
zouden echter nabij kunnen zijn. De implementatie van liquid based cytology zou de 
verdere ontwikkeling vergemakkelijken van op cervix uitstrijkjes te gebruiken nieuwe 
technieken. Hoewel HPV DNA detectie belangrijke nadelen heeft staat deze techniek 
het dichts bij implementatie in landelijke screening programma's van ai le methoden die 
werden samengevat. Een interessante nieuwe techniek die verder ontwikkeld zou 
moeten worden is de detectie van tumor suppressor gen hypermethylatie door middel 
van kwantitatieve methylatie specifieke PCR (zie Hoofdstuk 7). 
Telomerase is een enzym dat in staat is om aan de uiteinden van telomeren stukjes 
DNA te synthetiseren die verloren waren gegaan tijdens de celvermenigvuldiging. 
Zowel studies in tumorcellijnen als studies in menselijk tumormateriaal hebben Iaten 
zien dat in contrast met normale somatische cellen, de grote meerderheid van 
kwaadaardige cellen (>90%) een toegenomen telomerase activiteit heeft.8·9 Vanwege 
die eigenschap is er voorgesteld om bepaling van telomerase activiteit te gebruiken 
voor de vroege opsporing van cervixcarcinoom. Hoofdstuk 3 had tot doel te 
onderzoeken of het mogelijk was de aanwezigheid van CIN 1 1/1 1 1  te voorspellen bij 
patienten die werden verwezen vanwege een uitstrijkje met atypie of geringe-matige 
dyskaryose. De uitstrijkjes van 50 vrouwen werden onderzocht. Als mogelijke markers 
voor CIN 11/11 1 gebruikten we telomerase activiteit, twee telomerase componenten en 
hoog risico HPV. Telomerase activiteit werd bepaald met behulp van een commercieel 
verkrijgbare TRAP assay. De componenten van telomerase, humaan telomerase RNA 
(hTR) en humaan telomerase reverse transcriptase (hTERT) werden bepaald met behulp 
van reverse transcriptase-PCR. HPV werd gedetecteerd door middel van de GP5+/6+ 
PCR enzymatische immunoassay. De histologische diagnose werd bepaald aan de hand 
van histopathologisch onderzoek van colposcopisch gerichte biopten of van het 
lisexcisiepreparaat. Sensitiviteit en specificiteit voor de detectie van CIN 1 111 1 1  werden 
berekend. 8ij 28 vrouwen (46%) werd CIN 11/1 1 1  gediagnosticeerd. Er werd geen 
telomerase activiteit gevonden bij de vrouwen met CIN 1 1/1 1 1 .  Wei werd hTR bij 88%, 
hTERT bij 23% en hoog risico HPV bij 79% van de vrouwen met CIN II/I I I  gevonden. 
Ondanks de kleine aantallen sloten de berekende 95% betrouwbaarheidsintervallen 
een gecombineerde sensitiviteit en specificiteit van ten minste 90% uit voor aile 
bestudeerde tests. Ondanks het kleine aantal patienten was de conclusie dat noch de 
detectie van telomerase activiteit of de telomerase componenten, noch de detectie van 
hoog risico HPV bruikbaar lijkt voor de triage van vrouwen met atypie, geringe of 
matige dyskaryose in hun uitstrijkje. 
Om bij patienten met een vroeg stadium cervixcarcinoom therapie ge"induceerde 
morbiditeit te voorkomen zouden bij voorkeur aileen de patienten die waarschijnlijk 
geen adjuvante radiotherapie zullen krijgen middels radicale hysterectomie behandeld 
moeten worden. In Hoofdstuk 4 werd geanalyseerd of met behulp van preoperatieve 
serum sec -antigeen bepaling, beter dan met de huidig gebruikte klinische parameters, 
voorspeld kan worden wie een indicatie voor adjuvante radiotherapie zal hebben na 
operatie. Daarvoor werd in een historisch cohort van 337 FIGO stadium 1 8/IIA 
plaveiselcel cervixcarcinoom patienten die een primair chirurgische behandeling 
ondergingen de relatie tussen FIGO stadium, tumor grootte, preoperatieve serum SCC­
ag waarde en de postoperatieve indicatie voor adjuvante radiotherapie bepaald. Van de 
patienten met een norm ale preoperatieve SCC -ag waarde had 1 6% van de stadium 181 
en 29% van de stadium 1 82/IIA patienten een postoperatieve indicatie voor adjuvante 
radiotherapie. 8ij patienten met verhoogd serum sec -ag (> 1 ,9 ng/ml) bleek 57% van 
de stadium 181 en 74% van de stadium 1 82/I IA patienten een indicatie te hebben voor 
adjuvante radiotherapie (p<0,001 ). Serum sec -ag was de enige onafhankelijke 
voorspeller voor een postoperatieve indicatie voor radiotherapie (odds ratio 7, 1 ,  95% 
betrouwbaarheidsinterval 4,2 - 1 2, p<0,001 ). Van de stadium 181 patienten zonder 









preoperatief serum SCC-ag binnen twee jaar een recidief te ontwikkelen. Datzelfde 
gebeurde bij 'slechts' 1 ,8% van de patienten met een normale serum sec -ag waarde 
(p�0,02). De conclusie was dat het preoperatief bepalen van serum SCC-ag een 
scherpere voorspell ing van de noodzaak voor adjuvante radiotherapie mogelijk maakt 
dan dat momenteel kan met behulp van de klassieke FIGO parameters. Tegelijkertijd 
kan serum SCC-ag analyse een groep patienten identificeren met een hoog risico op het 
krijgen van een recidief wanneer zij ai leen operatief zouden worden behandeld. 
Preoperatieve serum SCC-ag analyse verdient daarom implementatie in de klinische 
beleidsbepaling bij patienten met een vroeg stadium plaveiselcel cervixcarcinoom. 
Drie infectieuze (co)factoren die volgens de literatuur mogelijk betrokken zouden zijn 
bij cervicale carcinogenese werden bestudeerd. In Hoofdstuk 5 werd de prevalentie 
van bacteriele vaginose bepaald in 280 patienten die verwezen waren vanwege 
cytologische afwijkingen (geringe, matige of ernstige dyskaryose). We onderzochten 
risico factoren voor het krijgen van bacteriele vaginose en de betekenis voor 
histologische veranderingen. De deelnemende patienten gaven informatie over 
rookgedrag en seksuele voorgeschiedenis door middel van een gestructureerde 
vragenlijst. 
Bacteriele vaginose werd gediagnosticeerd wanneer er in de vaginale afscheiding een 
vissige geur ontstond door toediening van KOH en wanneer clue cells gezien werden in 
een direct preparaat met fysiologisch zout. Verder werden de cervixschraapsels op de 
aanwezigheid van HPV DNA getest en werd de aanwezigheid en ernst van 
(intraepitheliale) neoplasie en de proliferatie graad (mitose index) van de laesie 
bepaald. Chlamydia trachomatis werd ge'identificeerd door kweek van endocervitaal 
afgenomen fluor. Gebruik makende van deze methoden en definities werd bacteriele 
vaginose vastgesteld bij 56 (20%) van de 280 patienten. De aanwezigheid van 
bacteriele vaginose bleek geassocieerd met dagelijkse sigaretten consumptie, aantal 
seksuele partners, sexarche en recente Chlamydia trachomatis infectie. Dagelijkse 
sigaretten consumptie en het aantal verschil lende seksuele partners waren 
onafhankelijke voorspellers voor de aanwezigheid van bacteriele vaginose. Er bestond 
geen associatie tussen de aanwezigheid van bacteriele vaginose en HPV infectie. 
Bacteriele vagi nose had geen invloed op de ernst van de gediagnosticeerde 
neoplastische laesie noch op de mitotische index. De conclusie was dat het 
onwaarschijnlijk is dat bacteriele vaginose een belangrijke etiologische rol speelt bij 
cervicale neoplasie, ondanks de overeenkomsten in de epidemiologische kenmerken van 
bacteriele vaginose en HPV bij vrouwen met een afwijkend uitstrijkje. 
De tweede infectieuze factor die werd bestudeerd is Chlamydia trachomatis. 
Hoofdstuk 6 beschrijft of de aanwezigheid van Chlamydia trachomatis antilichamen 
in serum geassocieerd was met de ernst van neoplastische cervix laesies, 
gediagnosticeerd bij vrouwen die werden verwezen vanwege een afwijkend uitstrijkje. 
In twee onderzoeksperioden analyseerden we serum monsters van vrouwen die werden 
verwezen vanwege een uitstrijkje met geringe, matige of ernstige dysplasie. In die 
serum monsters werd de aanwezigheid van antichlamydia antilichamen bepaald door 
middel van een enzymatische immunoassay. 
Bij 296 patienten, doorverwezen tussen 1 988 en 1 993 bestond geen associatie tussen 
toenemende ernst van CIN en de aanwezigheid van antichlamydia antilichamen. Het 
percentage vrouwen met antichlamydia antilichamen was echter hoger in vrouwen met 
(micro)invasief carcinoom (1 3/1 4 (93%)) dan in de vrouwen met CIN (1 01 /282 (36%)). 
Aangezien deze geobserveerde hoge prevalentie van antichlamydia antilichamen bij 
vrouwen met cervixcarcinoom niet overeenkomt met de in de literatuur gerapporteerde 
prevalenties analyseerden we een tweede groep patienten. Bij 331 patienten, 
doorverwezen tussen 1 995 en 1 999, konden we de hoge prevalentie inderdaad niet 
bevestigen. Deze resultaten suggereren dat de aanwezigheid van circulerende 
antichlamydia antilichamen niet geassocieerd is met de ernst van cervix neoplastische 
laesies en het lijkt onwaarschijnlijk dat Chlamydia trachomatis een rol speelt in de 
progressie van cervicale neoplasie. 
De laatst bestudeerde infectieuze factor in dit proefschrift en de meest belangrijke, is 
HPV. In de literatuur wordt voorgesteld om HPV als de eerst ge'identificeerde 
noodzakel ijke oorzaak van cervix carcinoom aan te merken. Dit houdt in dat men 
aanneemt dat cervixcarcinoom, op zeldzame uitzonderingen na, niet kan ontstaan 
zonder voorafgaande HPV infectie. Meer dan 1 00 verschillende HPV types zijn 
ge'identificeerde, waarvan 35 types in het genitaal kanaal gevonden kunnen worden. 
Van die 35 genitale types zijn er 1 8  geassocieerd met cervixcarcinogenese. Vanwege de 
belangrijke rol binnen de etiologie van het cervixcarcinoom is in vele studies 
geprobeerd factoren te identificeren die van belang zijn bij HPV infectie en persistentie. 
Verschillende HPV detectie technieken zijn beschikbaar, welke mogelijk de uitkomsten 
van epidemiologische studies be'invloeden. 
In een eerdere studie in 304 patienten, verwezen vanwege een afwijkend uitstrijkje 
werd HPV analyse verricht op cervixschraapsels die waren afgenomen bij het eerste 
bezoek aan de polikliniek.10 De op GP5/6 primers gebaseerde HPV PCR werd gebruikt. 
De prevalentie van H PV bleek toe te nemen met de ernst van cervixneoplasie, het 
aantal seksuele partners en de dagelijkse sigaretten consumptie. Een aantal jaren na 
deze epidemiologische stu die kwam de uiterst sensitieve op SPF1 0 primers gebaseerde 
lnno-LIPA (line probe assay) HPV prototype research assay beschikbaar voor de detectie 
en typering van HPV. Gebruik makend van deze nieuwe assay werd in Hoofdstuk 7 
dezelfde onderzoekspopulatie nogmaals geanalyseerd. Hoog risico HPV bleek aanwezig 
bij 288 (95%) patienten. In totaal waren 86 (30%) van deze 288 patienten ge'infecteerd 
met meerdere HPV types tegelijk. HPV 1 6  werd minder vaak gevonden in infecties met 
multipele types dan te verwachten op basis van kans ai leen. De ernst van de 
gediagnosticeerde neoplasie was geassocieerd met de aanwezigheid van hoog risico 
HPV. Deze associatie werd volledig gedragen door de associatie tussen de ernst van 
neoplasie en de aanwezigheid van HPV 1 6. Er werd geen associatie gevonden tussen 
het totale aantal seksuele partners of roken en HPV, noch voor een van de vijf meest 
voorkomende HPV types apart, noch voor de aanwezigheid van multipele types. 
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De conclusie was dat de associatie tussen de detectie van HPV en de epidemiologische 
risico factoren, zoals gevonden met de GPS/6 PCR in het verleden, niet bevestigd 
konden worden met de SPF1 0 PCR primers en LiPA HPV genotypering. Het vermoeden 
bestaat dat het aantal seksuele partners en roken surrogaat determinanten van hoge 
HPV virus belasting zouden kunnen zijn in plaats van determinanten van de 
aanwezigheid van HPV op zich. 
Van epigenetische mutaties, veroorzaakt door de hypermethylatie van promotor 
regionen van tumor suppressor genen, werd het laatste decennium bekend dat ze een 
belangrijke plaats innemen bij het ontstaan van maligne (cervix)afwijkingen. 
Onduidelijk was nog of cervixschraapsels een goede afspiegeling kunnen zijn van de 
hypermethylatie status van onderliggend cervicaal epitheel. Daarom was het ook niet in 
te schatten of QMSP (kwantitatieve methylatie specifieke PCR) op cervixschraapsels in 
de toekomst gebruikt zou kunnen worden ter verbetering van de huidige manier van 
screenen. In Hoofdstuk 8 werd dit verduidelijkt met behulp van cervix schraapsels en 
gepaard vers gevroren cervixepitheel verkregen van 53 cervixcarcinoom patienten en 
van 45 controles. Aile schraapsels werden cytomorfologisch gescoord en geanalyseerd 
met QMSP voor de genen APC DAPK, MGMT en GSTP 1 .  APC medieert 
proliferatieve signalen, DAPK is een proapoptotisch gen en bezit misschien de 
mogelijkheid metastasen te voorkomen, MGMT is een DNA reparatie gen en GSTP1 is 
een detoxificerend gen." '5 Om te corrigeren voor de gebruikte hoeveelheid DNA 
werden de hypermethylatie resultaten uitgedrukt als ratio met een referentie gen. 
Bij cervixcarcinoom patienten en controles waren hypermethylatie ratio's van gepaarde 
cervixweefsels en cervixschraapsels sterk geassocieerd. DAPK was frequenter positief 
in cervixcarcinoom patienten dan in controles (p<0,001 ). Wanneer we afkapwaarden 
voor ratio's definieerden boven de hoogste ratio die werd gevonden in controles, 
konden we met de analyse van slechts vier genen reeds 32 van de 48 (67%) 
cervixcarcinomen identificeren met QMSP op cervix schraapsels. Deze studie laat zien 
dat QMSP bruikbaar is op cervix schraapsels en dat de techniek de potentie heeft om 
een nieuwe screeningstest voor de detectie van cervixcarcinoom te worden. Wei zal het 
noodzakelijk zijn meer genen te identificeren die specifiek gemethyleerd raken tijdens 
cervicale carcinogenese en deze genen dienen toegevoegd te worden aan de test ten 
einde een sensitiviteit en specificiteit van ten minste 90% te bereiken. 
Er wordt gedacht dat een toegenomen dysbalans tussen proliferatie en apoptose 
belangrijk is voor het ontstaan van cervixcarcinoom. De death·liganden Fasl en tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) induceren apoptose door te 
binden aan hun corresponderende death-receptoren: Fas voor Fasl en DR4 en DRS voor 
TRAIL. Het doel van de studie beschreven in Hoofdstuk 9 was om te onderzoeken of er 
veranderingen in de expressie van deze death-liganden en hun receptoren ontstaan 
binnen de verschillende stadia van cervicale carcinogenese. De expressie en localisatie 
van Fas/Fasl en DR4/DR5/TRAIL  werd immunohistochemisch bepaald op coupes van 
cervixepitheel (1 1 keer normaal cervixepitheel, 1 5  keer CIN I, 1 5  keer C IN II, 1 3  keer 
C IN I l l  en 25 keer (microinvasief) plaveiselcel carcinoom). Het aantal apoptotische 
cellen werd op basis van morfologische criteria bepaald en het aantal prolifererende 
cellen werd bepaald door het aantal Ki-67 positieve cellen te tellen. Toegenomen ernst 
van de neoplasie ging gepaard met een duidelijke toename in zowel proliferatie als 
apoptose. In normaal cervicaal weefsel en in ClN I werd FasL, DR4, DRS en TRAIL 
voornamelijk aangekleurd in de basale en parabasale cellagen, terwijl Fas in dezelfde 
coupes met name werd aangekleurd in de oppervlakkige, meer gedifferentieerde 
cellagen. De frequentie van Fas detectie nam toe met de ernst van de CIN graad. FasL, 
DR4, DRS en TRAIL aankleuring van aile cellagen van het epitheel werd daarentegen 
vaker in ClN I l l  en in cervixcarcinoom geobseveerd. De patronen van aankleuring van 
FasL, DR4, DRS en TRAIL waren gecorreleerd. De intensiteit van TRAIL expressie was 
hoog in laag gradige afwijkingen. Er werd geen associatie gevonden tussen death­
receptor of ligand expressie en het percentage prol iferatie of apoptose. Verlies van Fas 
aankleuring en deregulatie van het aankleuringspatroon van FasL, DR4, DRS en TRAIL 
bij de toename van CIN naar cervixcarcinoom suggereert een mogel ijke functionele rol 
bij cervixcarcinogenese. De geobserveerde frequente expressie van DR4 en DRS maakt 






In Nederland bestaat een landelijk georganiseerd programma voor cervixcarcinoom 
screening. Vrouwen worden in de leeftijd van 30-60 jaar eens in de vijf jaar uitgenodigd 
om zich te Iaten screenen. Het hiervoor noodzakelijke uitstrijkje wordt in principe door 
een huisarts afgenomen. Patienten worden doorverwezen naar een gynaecoloog voor 
colposcopisch onderzoek wanneer tijdens de screening afwijkingen worden gevonden. 
De huidige op morfologie gebaseerde manier van screenen voor cervixcarcinoom, kent 
een belangrijk percentage fout positieve en fout negatieve resultaten. Op dit moment 
zijn er nog geen andere diagnostische tests beschikbaar waarvan bekend is dat ze 
kosten-effectief de Pap smear screening kunnen vervangen of aanvullen. In Ianden met 
een lage prevalentie van cervixcarcinoom, zoals Nederland, kan het moeilijk zijn te 
bepalen of de daling in het aantal cervixcarcinoom doden ten gevolge van de screening 
opweegt tegen de negatieve kanten die deze screening ook heeft. De voordelen zijn 
veel duidelijker voor vrouwen in Ianden (met name ontwikkelingslanden) met een hoge 
prevalentie van cervixcarcinoom. Pap smear screening l ijkt de beste test die op dit 
moment gebruikt kan worden. HPV DNA detedie is van aile bekende 'markers' het 
dichtst bij toepassing binnen cervixcarcinoom screeningsprogramma's. De twee grote 
voordelen van HPV screening zouden kunnen zijn het verlengen van het 
screeningsinterval voor HPV negatieve vrouwen en triage van vrouwen met mi lde 
cytologische afwijkingen. In de komende vijf jaar zullen de resultaten bekend worden 
van een Nederlandse gerandomiseerde studie die evalueert of het implementeren van 
deze twee voordelen van HPV DNA detedie ook zou leiden tot verbeterde efficientie 
van het screeningsprogramma.16 Echter, HPV detedie heeft een relatief lage specificiteit 
voor (progressieve) CIN I I/ I I I  en cervixcarcinoom en er zitten ook belangrijke 
psychologische nadelen aan het invoeren van deze test. Zelfs als de HPV DNA test 
kosten-effedief de cervixcarcinoom screening kan verbeteren, zal er ruimte blijven voor 
vooruitgang. 
Wanneer het hoge aantal fout positieve en negatieve uitslagen van cervixcarcinoom screening 
verminderd kunnen worden zal dat het voordeel van cervixcarcinoom screening vergroten, ook 
voor de vrouwen uit Ianden met een lage prevalentie van cervixcarcinoom. Een interessante 
nieuwe benadering van cervixcarcinoom detedie is de analyse van tumor suppressor gen 
hypermethylatie analyse door middel van QMSP. In dit proefschrift beschreven we de 
theoretische voordelen van QMSP ten opzichte van Pap smear analyse en een aantal andere, 
nieuwe screening methodes, die gebaseerd zijn op moleculaire veranderingen. Onze eerste 
QMSP resultaten in cervix schraapsels waren veelbelovend. Cervix schraapsels gaven een 
goede weerspiegeling van de hypermethylatie status van het onderliggende cervicale epitheel. 
Terwijl de cervixschraapsels voor slechts vier genen werd geanalyseerd werd reeds 67% van 
de cervixcarcinoom patienten ge'identificeerd met behulp van QMSP. In prostaat carcinoom is 
GSTP1 gemethyleerd in meer dan 90% van de tumoren en op basis van deze bevinding 
worden momenteel diagnostische tests ontwikkeld.17 Gezien de resultaten die behaald worden 
bij het prostaat carcinoom verwachten we dat het mogelijk moet zijn om voor 
cervixcarcinoom een panel van genen te identificeren waarvan tenminste een gen 
gehypermethyleerd zal zijn in nagenoeg aile cervixcarcinoom gevailen. De beschikbare 
gegevens en deze uitgesproken verwachtingen zouden het onderzoek naar meer genen die 
specifiek gemethyleerd raken tijdens de cervicale carcinogenese aan moeten sporen. Als er een 
sensitief en specifiek cervixcarcinoom hypermethylatie panel samengesteld zou zijn wordt het 
tijd voor het definieren van de 'screen-positieve' QMSP afkapwaardes voor 
screeningsdoeleinden. Samen met de sensitiviteit en specificteit van een screenings test wordt 
de positief en negatief voorspeilende waarde van een test in een populatie bepaald door de 
prevalentie van de op te sporen ziekte in die populatie. Het zou daarom een verstandige 
aanpak kunnen zijn om de hoogte van de QMSP afkapwaarden per land af te Iaten hangen 
van de cervixcarcinoom prevalentie. Verdere studies zouden moeten verduidelijken of QMSP 
ook gebruikt zou kunnen worden om progressieve CIN 11/lll lesies op te sporen. 
De prevalentie van cervixcarcinoom en CIN zou wei eens drastisch kunnen gaan veranderen 
als in de toekomst primaire preventie van cervixcarcinoom door HPV vaccinatie mogelijk 
wordt.18 Als HPV vaccinatie wordt ingevoerd, mag natuurlijk een belangrijke dating in de 
prevalentie van cervixcarcinoom en voorloper afwijkingen worden verwacht. Wanneer in het 
hypothetische geval van ge"implementeerde HPV vaccinatie de sensitiviteit en specificiteit 
van de gebruikte screeningstechniek niet wordt aangepast, zal een positieve test uitslag 
vaker berusten op een fout positief resultaat. Misschien zal het ook na invoering van HPV 
vaccinatie van voordeel zijn om te blijven screenen op cervixcarcinoom omdat het ontstaan 
van cervixcarcinoom niet voiledig is te voorkomen. lmmunisatie zal soms mislukken, 
vrouwen kunnen weigeren om te worden gevaccineerd en het lijkt waarschijnlijk dat er 
aileen tegen de oncogene HPV types 1 6  en 1 8  zal worden gevaccineerd. 
Het is moeilijk in te schatten hoe hoog de prevalentie van cervixcarcinoom zal blijven als 
HPV vaccinatie ge"implementeerd zou zijn in ons gezondheidszorg systeem. Zelfs als zo'n 
implementatie nabij is zal het zeker decennia duren voor het effect op het aantal nieuwe 
gevallen van cervixcarcinoom zichtbaar wordt. 
Dit proefschrift beschrijft dat het mogelijk is om bestaande behandelingsprotocollen voor 
cervixcarcinoom te verfijnen door gebruik te maken van SCC-ag serum detectie. SCC-ag was 
al bekend als prognostische marker bij cervixcarcinoom. Met het bepalen van sec -ag in 
preoperatief afgenomen serum bij patienten met een vroeg stadium cervixcarcinoom is 
nauwkeuriger dan met de in gebruik zijnde klinische parameters, per patient in te schatten 
wat het risico is op postoperatieve radiotherapie. Tegelijkertijd is met serum SCC-ag analyse 
een groep patienten te identificeren met een hoog risico op het krijgen van een recidief, 
wanneer ze aileen chirurgisch worden behandeld. Naar onze mening zou serum SCC-ag 
analyse nu ingevoerd moeten gaan worden in de klinische beleidsbepaling bij vroeg 
stadium cervixcarcinoom patienten. 
De etiologie van cervix neoplasie wordt steeds duidelijker en nieuw ontwikkelde 
technologieen zullen misschien leiden tot sneile toename van kennis over cervicale 
carcinogenese. Het zal een uitdaging blijven om deze nieuwe inzichten te vertalen naar een 
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In de vierde of vijfde klas van de lagere school besloot ik dat ik een boek zou gaan 
schrijven. Het zou gaan over een walvis en een meisje dat Indira heette. En hoewel ik al 
wei had bedacht dat ik (dieren)arts wilde worden had ik toen nooit kunnen denken dat 
het boekje uiteindelijk over afwijkingen aan de baarmoedermond zou gaan, laat staan 
dat ik het pas in 2004 af zou hebben. Maar goed, at is het! 
lk heb bij het doen en het beschrijven van het onderzoek in dit proefschrift veel hulp 
gehad, van mensen op het werk, maar ook van mensen prive. Omdat mijn werk heel 
divers is geweest en zich op verschillende locaties heeft afgespeeld heb ik met zeer 
veel mensen samengewerkt. Voor die samenwerking wil ik iedereen hartelijk bedanken. 
Omdat ik over het algemeen lang van stof ben zal ik het niet bij dit bedankje Iaten, 
maar in stijl proberen af te sluiten. lk wil een persoonlijk woord richten tot die mensen 
die voor het tot stand brengen van dit proefschrift het meest belangrijk waren. 
Allereerst natuurlijk mijn eerste promotor en directe begeleider. Hooggeleerde Van der 
Zee, beste Ate, ik waardeer je enorme enthousiasme en energie waarmee je de 
wetenschap bedrijft. Het straalt er vanaf dat je het erg leuk vindt om te doen. Door 
jouw onophoudende stroom aan ideeen was er altijd veel te doen. Je wist steeds grote 
tijdsdruk op te bouwen, welke onaangenaam kon zijn, maar die er ook toe leidde dat er 
veel in korte tijd kon worden gepresteerd. Zeker gezien de tijdsdruk was het erg 
plezierig dat je altijd snel manuscripten beoordeelde, tijd maakte voor een afspraak en 
dat het ook zonder afspraak makkelijk was om even binnen te vallen voor een vraag. 
We hadden een plezierige, informele, wat plagerige werkrelatie. Tussen de plagerijen 
door kon je gelukkig ook op een hele waardevolle manier Iaten weten wat je van mij 
en mijn werk vond. lk kijk met een zeer goed gevoel op de laatste vierenhalf jaar terug. 
Hooggeleerde De Vries, beste liesbeth, ik ben blij dat ik een van jou vele promovendi 
mocht zijn. Onvoorstelbaar hoeveel mensen jij tegel ijkertijd onder je hoede kan hebben 
en hoe snel je dan in staat bent versies van manuscripten van gedetailleerd 
commentaar te voorzien. Hoewel de baarmoedermond jouw aandachtsgebied niet is, 
wist je er altijd heel goed voor te zorgen dat de kern van de zaak boven kwam in mijn 
stukken. Zeer geleerde De Jong, beste Steven, bedankt voor je hulp en pogingen om 
van mij een goede laboratorium onderzoeker te maken. Ondanks het feit dat mijn 
onderzoek gaande weg steeds klinischer werd denk ik dat ik veel van jou en ai le 
onderzoekers van de medische oncologie heb geleerd. Het was fijn te kunnen leren van 
de systematische besprekingen van het lab-oncologie. De lage 'vraag'-drempel was 
denk ik het resultaat van de goede, vriendschappelijke steer op het lab. Daarvoor wil ik 
jou, maar ook ai le anderen bedanken. Zeer geleerde Hollema, beste Harry, je hebt me 
veel weten bij te brengen over de histopathologie van de cervix in onze klinische en 
research samenwerking. Als we samen konden scoren of overleggen was dat in 
vriendschappelijke steer en kon ik ook op je rekenen voor goede adviezen. lk had graag 
nog meer onderzoek met je sa men will en doen. Je was regelmatig bereid om me te 
helpen door 'jouw mensen' in te zetten. Bedankt voor die hulp: Henk, lnge, Sicco, 
Tineke, Teus. Ook ontstond er via de pathologie een samenwerking met Ed Schuuring en 
Albert Suurmeijer die plezierig en leerzaam was. Zeer geleerde Boezen, beste Marike, 
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het was erg fijn dat je mijn epidemiologische vraagbaak wilde zijn en het was prettig 
om samen vaak lang achter de computer te zitten, zoekend naar oplossingen voor 
lastige problemen. Hoewel ik me zeker niet zo professioneel voel als jij, heb je me toch 
het vertrouwen gegeven dat ik best een aardige epidemioloog ben geworden. Over 
computers gesproken, ik wil ook zeker even Gerard Kroon bedanken die ik zeer 
regelmatig lastig viel met niet functionerende computers/lap-tops/programma's. Aile 
gynaeco-onco-onderzoekers (Alice, Ageeth, Anne, Baukje-Nynke, Bea, Esther, Evelien, 
Fiona, Gert Jan, Gitte, Harry, Jeroen, Klaske, Marco, Margreet) bedankt voor de 
samenwerking, de collegialiteit en de gezellige donderdagochtend bijeenkomsten. Lieve 
Fiona en Klaske, inhoudelijk hebben we bij een aantal projecten erg nauw 
samengewerkt. Het klikte op werkvlak gelukkig erg goed, maar zeker zo goed op 
persoonlijk vlak en daarom ben ik trots dat jul l ie mij op 20 september bij zullen staan 
als officiele en officieuze paranimf. 
Naast mijn begeleiders en directe research-collega's wil ik op het werkvlak nog een 
aantal andere mensen bedanken. Hooggeleerde Aalders, beste Jan, bedankt voor je 
vertrouwen in mij en het feit dat we contact hi elden in de tijd dat ik in het AMC 
werkte. Jij legde het contact tussen Ate en mij en daar ben ik erg blij mee. Naast de vier 
jaar research in het AZG had ik ook klinische taken. De CIN-poli en de oncologische 
dagbehandeling zorgden elke week weer voor een plezierige afwisseling. Dat ik die 
klinische taken zo heerlijk vond kwam niet ai leen omdat ik in hart en nieren 'een 
gewone dokter' ben, maar zeker ook door de plezierige samenwerking met iedereen 
van het secretariaat, verpleging en door de goede supervisie. Doekla, Gerry, Harry, 
Janny, Trijn, het was fijn om zo duidelijk met elkaar op een lijn te zitten tijdens het 
werk. De dinsdagochtend heeft een warm plekje. Marian, Joanne, Hans, bedankt voor 
a lies wat jul l ie me al leerden en voor het vertrouwen dat jul l ie me gaven. 
Voordat ik promotieonderzoek ging doen in Groningen was ik AIO in het AMC, waar ik 
onderzoek deed met materiaal van Groningse patienten met als onderwerp de 
baarmoedermond. Daardoor kon ik het onderzoek van toen ook voor dit proefschrift 
gebruiken en vallen er uit die periode ook nog wei wat mensen te bedanken. 
Hooggeleerde Burger, beste Matthe, ik wil je bedanken voor het feit dat je me 
motiveerde om promotieonderzoek te gaan doen en dat je me voorstelde de opleiding 
epidemiologie te doen. Met beide ben ik nog altijd erg blij. Zeer geleerde Adriaanse, 
beste Albert, jij bedankt voor de directe begeleiding in mijn AMC tijd. Het was plezierig 
om van je onverstoorbare karakter 'gebruik te kunnen maken'. Zeer geleerde ter 
Schegget, beste Jan, bedankt voor al je enthousiast gebrachte HPV-proza en je geloof in 
mijn kunnen. Naast jou natuurlijk ook al je medewerkers van toen bedankt voor de 
hulp en de gastvrijheid in het lab. Zeer geleerde Quint en Kleter, beste Wim en Bernard, 
de HPV tests kwamen na een tijdje bij jul l ie terecht en daardoor heb ik veel van jul l ie 
kunnen leren over de verschil lende technieken om HPV te detecteren. Het was 
aangenaam om te discussleren over de mogelijke redenen van onverwachte uitslagen. 
Hooggeleerde Bossuyt, beste Patrick, ik heb van jou in korte tijd heel veel kunnen en 
mogen leren. lk  bewonder erg dat je altijd in staat was om al na korte uitleg of een blik 
op een manuscript de vinger op de zere plek te leggen, zowel epidemiologisch als 
anderszins. Je steun in de a lgemene begeleiding vond ik  erg plezierig. lk  had graag nog 
veel meer met je willen overleggen. Gelukkig wilde Marike Boezen als 'verlengde-arm' 
van je optreden toen ik naar Groningen ging en kon ik toch mijn vragen kwijt en mijn 
epidemiologie opleiding afronden. Beste AMC onderzoekers (Judith, Madelon, 
Marianne, Marja, Moira, Neriman, Saskia, Wessel), we waren een heerlijke club en het 
was goed om tijdens lunch en soms thee (onderzoekers) lief en leed te delen. Toen ik  
naar Groningen zou gaan wist ik dat ik dat zou gaan missen. Na mijn werk a l s  arts­
onderzoeker in Groningen wachtte de start van de opleiding gynaecologie in de lsala 
klinieken. Gynaecologen, verpleging en collega's uit Zwol le, dank voor het begrip voor 
mijn 'vermoeide' toestand en voor jul l ie interesse. l k  hoop dat jul l ie de reis naar het 
Noorden zullen wagen. Tja en op het grensvlak van werk en prive wil ik nog noemen de 
twee studenten die hun wetenschappel ijke stage 'bij mij ' kwamen doen en die goede 
vriendinnen werden. Justine, ik hoop (mede uit eigenbelang) dat je ook de opleiding in 
komt en dat je artikel op een goede plek gepubliceerd zal worden. Nynke, dat je mijn 
paranimf bent zegt denk ik wat onze vriendschap voor me betekent. 
Zo, na hopelijk niemand te zijn vergeten bij het bedanken van de inhoudelijk betrokken 
mensen kan ik het natuurlijk niet nalaten om ook de spelers achter de schermen in dit 
dankwoord in het zonnetje te zetten. Aan de basis van mijn ' ik '  staan natuurlijk mijn 
ouders. Lieve pap en mam, bedankt dat jul l ie me 'gezond eigenwijs' in de wereld 
hebben gezet en voor de trots die zo voelbaar aanwezig is. Verder is natuurlijk de hulp 
bij de laatste loodjes helemaal geweldigl Ook mijn schoonouders zijn erg belangrijk 
geweest in de afgelopen periode. ledereen die me een beetje kent weet denk ik hoe 
trots ik ben op ons huis in Niezijl. Lieve Hans en Mariean, de bijdrage die jul l ie aan de 
verbouwing leverden was en is geweldig. Ook als i k  druk aan de slag was in het AZG 
werd het in Niezijl steeds mooier en mooier. Gelukkig ging al dit klussen ook nog eens 
gepaard met de nodige warmte en gezel ligheid. Om professioneel het beste uit jezelf te 
kunnen halen moet het thuis op rolletjes lopen. Harma, dat we zo'n stuk van het 
huishouden en de verzorging van Maite en Jonne aan jou over kunnen Iaten is 
geweldig. De kinderen zijn gek op je, en terecht! Je bent niet aileen de ideale hulp, 
maar ook een goede vriendin. Maite en Jonne, wat zijn jull ie heerlijke ukken en als ik 
naar jul l ie kijk ben ik blij dat er nog een derde komen gaat. Jull ie zorgden ervoor dat ik 
het als een noodzaak voelde om het beste uit mijn werk te halen en er van te genieten. 
Anders zou het 't niet waard zijn om tijd met jul lie te missen. En jongens, nog even 
volhouden, vanaf 5 november zijn we weer meer samen. Lieve, lieve Geer, ik ben zo blij 
dat ik het Ieven sa men met jou leef. Bij jou voel ik me beschermd en geborgen en het 
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